

AE

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70673 A2

(51) International Patent Classification⁷: C07C 237/00

Foulkstone Road, Wilmington, DE 19803 (US). VOSS, Matthew, E.; 106 Westview Drive, Lincoln University, PA 19352 (US). XUE, Chu-Biao; 11 Rivendell Court, Hockessin, DE 19707 (US).

(21) International Application Number: PCT/US01/08334

(22) International Filing Date: 15 March 2001 (15.03.2001)

(25) Filing Language: English

(74) Agent: VANATTEN, Mary, K.; Dupont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(26) Publication Language: English

(30) Priority Data:
60/190,182 17 March 2000 (17.03.2000) US
60/233,373 18 September 2000 (18.09.2000) US
60/255,539 14 December 2000 (14.12.2000) US

(81) Designated States (*national*): AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, HU, IN, JP, KR, LT, LU, LV, MX, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA.

(71) Applicant: DUPONT PHARMACEUTICALS COMPANY [US/US]; Chestnut Run Plaza, 974 Centre Road, Wilmington, DE 19805 (US).

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

— without international search report and to be republished upon receipt of that report


(72) Inventors: DUAN, Jingwu; 17 Springbrook Lane, Newark, DE 19711 (US). OTT, Gregory; 2038 Locust Street, Philadelphia, PA 18193 (US). CHEN, Linhua; 402 Foulk Road, Apartment 2C1, Wilmington, DE 19803 (US). LU, Zhonghui; 3314 Old Capital Trail, Wilmington, DE 19808 (US). MADUSKUIE, Thomas, P., Jr.; 613

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/70673 A2

(54) Title: CYCLIC β -AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF- α



(57) Abstract: The present application describes novel cyclic β -amino acid derivatives of formula (I) or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR^a, and S(O)_p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF- α inhibitors.

TITLE

CYCLIC β -AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX
METALLOPROTEASES AND TNF- α

5

FIELD OF THE INVENTION

This invention relates generally to novel cyclic β -
amino acid derivatives as matrix metalloproteases and TNF- α
inhibitors, pharmaceutical compositions containing the same,
10 and methods of using the same.

BACKGROUND OF THE INVENTION

There is now a body of evidence that metalloproteases
(MP) are important in the uncontrolled breakdown of
15 connective tissue, including proteoglycan and collagen,
leading to resorption of the extracellular matrix. This is
a feature of many pathological conditions, such as
rheumatoid and osteoarthritis, corneal, epidermal or gastric
ulceration; tumor metastasis or invasion; periodontal
20 disease and bone disease. Normally these catabolic enzymes
are tightly regulated at the level of their synthesis as
well as at their level of extracellular activity through the
action of specific inhibitors, such as alpha-2-
macroglobulins and TIMPs (tissue inhibitors of
25 metalloprotease), which form inactive complexes with the
MP's.

Osteo- and Rheumatoid Arthritis (OA and RA
respectively) are destructive diseases of articular
cartilage characterized by localized erosion of the
30 cartilage surface. Findings have shown that articular
cartilage from the femoral heads of patients with OA, for
example, had a reduced incorporation of radiolabeled sulfate
over controls, suggesting that there must be an enhanced
rate of cartilage degradation in OA (Mankin et al. J. Bone
35 Joint Surg. 52A, 1970, 424-434). There are four classes of

protein degradative enzymes in mammalian cells: serine, cysteine, aspartic and metalloproteases. The available evidence supports that it is the metalloproteases which are responsible for the degradation of the extracellular matrix of articular cartilage in OA and RA. Increased activities of collagenases and stromelysin have been found in OA cartilage and the activity correlates with severity of the lesion (Mankin et al. Arthritis Rheum. 21, 1978, 761-766, Woessner et al. Arthritis Rheum. 26, 1983, 63-68 and Ibid. 27, 1984, 305-312). In addition, aggrecanase has been identified as providing the specific cleavage product of proteoglycan found in RA and OA patients (Lohmander L.S. et al. Arthritis Rheum. 36, 1993, 1214-22).


Therefore, metalloproteases (MP) have been implicated as the key enzymes in the destruction of mammalian cartilage and bone. It can be expected that the pathogenesis of such diseases can be modified in a beneficial manner by the administration of MP inhibitors, and many compounds have been suggested for this purpose (see Wahl et al. Ann. Rep. Med. Chem. 25, 175-184, AP, San Diego, 1990).

Tumor necrosis factor (TNF) is a cell-associated cytokine that is processed from a 26kd precursor form to a 17kd active form. TNF has been shown to be a primary mediator in humans and in animals, of inflammation, fever, and acute phase responses, similar to those observed during acute infection and shock. Excess TNF has been shown to be lethal. There is now considerable evidence that blocking the effects of TNF with specific antibodies can be beneficial in a variety of circumstances including autoimmune diseases such as rheumatoid arthritis (Feldman et al, Lancet, 1994, 344, 1105) and non-insulin dependent diabetes melitus. (Lohmander L.S. et al. Arthritis Rheum. 36, 1993, 1214-22) and Crohn's disease (MacDonald T. et al. Clin. Exp. Immunol. 81, 1990, 301).

Compounds which inhibit the production of TNF are therefore of therapeutic importance for the treatment of inflammatory disorders. Recently, TNF- α converting enzyme (TACE), the enzyme responsible for TNF- α release from cells, were purified and sequenced (Black et al Nature 1997, 385, 729; Moss et al Nature 1997, 385, 733). This invention describes molecules that inhibit this enzyme and hence the secretion of active TNF- α from cells. These novel molecules provide a means of mechanism based therapeutic intervention for diseases including but not restricted to septic shock, haemodynamic shock, sepsis syndrome, post ischemic reperfusion injury, malaria, Crohn's disease, inflammatory bowel diseases, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic diseases, cachexia, graft rejection, cancer, diseases involving angiogenesis, autoimmune diseases, skin inflammatory diseases, OA, RA, multiple sclerosis, radiation damage, hyperoxic alveolar injury, periodontal disease, HIV and non-insulin dependent diabetes melitus.

Since excessive TNF production has been noted in several disease conditions also characterized by MMP-mediated tissue degradation, compounds which inhibit both MMPs and TNF production may also have a particular advantage in diseases where both mechanisms are involved.


EP 0,780,286 describes MMP inhibitors of formula A:



A

wherein Y can be NHOH, R¹ and R² can combine to form a cycloalkyl or heterocyclo alkyl group, R³ and R⁴ can be a variety of groups including H, and R⁵ can be substituted aryl.


WO 97/20824 depicts MMP inhibitors of formula B:



B

wherein ring V contains six atoms, Z is O or S, and Ar is an
 5 aryl or heteroaryl group. Ar is preferably a monocyclic
 aryl group with an optional para substituent or an
 unsubstituted monocyclic heteroaryl group.

EP 0,818,442 illustrates MMP inhibitors of formula C:



C

wherein Ar is optionally substituted phenyl or naphthyl, Z
 can be absent and X and Y can be a variety of substituents.
 Compounds of this sort are not considered to be part of the
 15 present invention.

The compounds of the present invention act as
 inhibitors of MPs, in particular TNF- α , MMPs, and/or
 aggrecanase. These novel molecules are provided as anti-
 inflammatory compounds and cartilage protecting
 20 therapeutics. The inhibition of aggrecanase, TNF-C, and
 other metalloproteases by molecules of the present invention
 indicates they are anti-inflammatory and should prevent the
 degradation of cartilage by these enzymes, thereby
 alleviating the pathological conditions of OA and RA.

25

SUMMARY OF THE INVENTION

Accordingly, one object of the present invention is to
 provide novel cyclic hydroxamic acids useful as

metalloprotease inhibitors or pharmaceutically acceptable salts or prodrugs thereof.


It is another object of the present invention to provide pharmaceutical compositions comprising a
5 pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

It is another object of the present invention to
10 provide a method for treating inflammatory disorders, comprising: administering to a host, in need of such treatment, a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.

15 It is another object of the present invention to provide novel compounds of the present invention for use in therapy.

It is another object of the present invention to provide the use of novel compounds of the present invention
20 for the manufacture of a medicament for the treatment of a condition or disease mediated by MMPs, TNF, aggrecanase, or a combination thereof.

These and other objects, which will become apparent during the following detailed description, have been
25 achieved by the inventors' discovery that compounds of formula (I):




I.

or pharmaceutically acceptable salt or prodrug forms
30 thereof, wherein A, B, R¹, R², R^{2a}, R^{2b}, and R³ are defined below, are effective metalloprotease inhibitors.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[1] Thus, in an embodiment, the present invention provides a novel compound of formula I:



5

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from $-\text{COR}^5$, $-\text{CO}_2\text{H}$, $\text{CH}_2\text{CO}_2\text{H}$, $-\text{CO}_2\text{R}^6$, $-\text{CONHOH}$,
 10 $-\text{CONHOR}^5$, $-\text{CONHOR}^6$, $-\text{N}(\text{OH})\text{COR}^5$, $-\text{N}(\text{OH})\text{CHO}$, $-\text{SH}$, $-\text{CH}_2\text{SH}$,
 $-\text{S}(\text{O})(=\text{NH})\text{R}^a$, $-\text{SN}_2\text{H}_2\text{R}^a$, $-\text{PO}(\text{OH})_2$, and $-\text{PO}(\text{OH})\text{NHR}^a$;

ring B is a 3-13 membered non-aromatic carbocyclic or
 heterocyclic ring comprising: carbon atoms, 0-3
 15 carbonyl groups, 0-4 double bonds, and from 0-2 ring
 heteroatoms selected from O, N, NR^2 , and $\text{S}(\text{O})_p$, provided
 that ring B contains other than a S-S, O-O, or S-O
 bond;

20 Z is absent or selected from a C_{3-13} carbocycle substituted
 with 0-5 R^b and a 5-14 membered heterocycle comprising:
 carbon atoms and 1-4 heteroatoms selected from the
 group consisting of N, O, and $\text{S}(\text{O})_p$ and substituted
 with 0-5 R^b ;

25

U^a is absent or is selected from: O, NR^{a1} , $\text{C}(\text{O})$, $\text{C}(\text{O})\text{O}$,
 $\text{OC}(\text{O})$, $\text{C}(\text{O})\text{NR}^{a1}$, $\text{NR}^{a1}\text{C}(\text{O})$, $\text{OC}(\text{O})\text{O}$, $\text{OC}(\text{O})\text{NR}^{a1}$, $\text{NR}^{a1}\text{C}(\text{O})\text{O}$,
 $\text{NR}^{a1}\text{C}(\text{O})\text{NR}^{a1}$, $\text{S}(\text{O})_p$, $\text{S}(\text{O})_p\text{NR}^{a1}$, $\text{NR}^{a1}\text{S}(\text{O})_p$, and $\text{NR}^{a1}\text{SO}_2\text{NR}^{a1}$;

X^a is absent or selected from C₁₋₁₀ alkylene, C₂₋₁₀ alkenylene, and C₂₋₁₀ alkynylene;

Y^a is absent or selected from O, NR^{a1}, S(O)_p, and C(O);

5

Z^a is selected from H, a C₃₋₁₃ carbocycle substituted with 0-5 R^c and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-5 R^c;

10

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

15 R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

R² is selected from Q, Cl, F, C₁₋₁₀ alkylene-Q substituted with 0-3 R^{b1}, C₂₋₁₀ alkenylene-Q substituted with 0-3 R^{b1}, C₂₋₁₀ alkynylene-Q substituted with 0-3 R^{b1},

20

(CR^aRA^{a1})_rO(CR^aRA^{a1})_r-Q, (CR^aRA^{a1})_rNR^a(CR^aRA^{a1})_r-Q,

(CR^aRA^{a1})_rC(O)(CR^aRA^{a1})_r-Q, (CR^aRA^{a1})_rC(O)O(CR^aRA^{a1})_r-Q,

(CR^aRA^{a1})_rC(O)O-C₂₋₅ alkenylene, (CR^aRA^{a1})_rC(O)O-C₂₋₅

alkynylene, (CR^aRA^{a1})_rOC(O)(CR^aRA^{a1})_r-Q,

(CR^aRA^{a1})_rC(O)NR^aRA^{a1}, (CR^aRA^{a1})_rC(O)NR^a(CR^aRA^{a1})_r-Q,

25

(CR^aRA^{a1})_rNR^aC(O)(CR^aRA^{a1})_r-Q, (CR^aRA^{a1})_rOC(O)O(CR^aRA^{a1})_r-Q,

(CR^aRA^{a1})_rOC(O)NR^a(CR^aRA^{a1})_r-Q,

(CR^aRA^{a1})_rNR^aC(O)O(CR^aRA^{a1})_r-Q,

(CR^aRA^{a1})_rNR^aC(O)NR^a(CR^aRA^{a1})_r-Q, (CR^aRA^{a1})_rS(O)_p(CR^aRA^{a1})_r-Q,

(CR^aRA^{a1})_rSO₂NR^a(CR^aRA^{a1})_r-Q, (CR^aRA^{a1})_rNR^aSO₂(CR^aRA^{a1})_r-Q, and

30

(CR^aRA^{a1})_rNR^aSO₂NR^a(CR^aRA^{a1})_r-Q;

R^{2a} is selected from H, C₁₋₆ alkyl, OR^a, NR^aRA^{a1}, and S(O)_pRA^a;

R^{2b} is H or C₁₋₆ alkyl;

Q is selected from H, a C₃₋₁₃ carbocycle substituted with 0-5 R^d and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-5 R^d;

R³ is selected from Q¹, Cl, F, C₁₋₆ alkylene-Q¹, C₂₋₆ alkenylene-Q¹, C₂₋₆ alkynylene-Q¹, (CR^aRA¹)_rO(CR^aRA¹)_r-Q¹, (CR^aRA¹)_rNR^a(CR^aRA¹)_r-Q¹, (CR^aRA¹)_rNR^aC(O)(CR^aRA¹)_r-Q¹, (CR^aRA¹)_rC(O)NR^a(CR^aRA¹)_r-Q¹, (CR^aRA¹)_rC(O)(CR^aRA¹)_r-Q¹, (CR^aRA¹)_rC(O)O(CR^aRA¹)_r-Q¹, (CR^aRA¹)₂rS(O)_p(CR^aRA¹)_r-Q¹, and (CR^aRA¹)_rSO₂NR^a(CR^aRA¹)_r-Q¹;

Q¹ is selected from H, phenyl substituted with 0-3 R^d, naphthyl substituted with 0-3 R^d and a 5-10 membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^d;

R^a, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

R^{a1}, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

alternatively, R^a and R^{a1} when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)_p;

R^{a2} , at each occurrence, is independently selected from C_{1-4} alkyl, phenyl and benzyl;

5 R^b , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , NR^aR^{a1} , $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a1}$, $R^aNC(O)NR^aR^{a1}$, $OC(O)NR^aR^{a1}$, $R^aNC(O)O$, $S(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $NR^aS(O)_2NR^aR^{a1}$, $OS(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $S(O)_pR^{a2}$, CF_3 , and CF_2CF_3 ;

10

R^{b1} , at each occurrence, is independently selected from OR^a , Cl, F, Br, I, =O, -CN, NO_2 , and NR^aR^{a1} ;

15 R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , NR^aR^{a1} , $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a1}$, $R^aNC(O)NR^aR^{a1}$, $OC(O)NR^aR^{a1}$, $R^aNC(O)O$, $S(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $NR^aS(O)_2NR^aR^{a1}$, $OS(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $S(O)_pR^{a2}$, CF_3 , CF_2CF_3 , C_{3-10} carbocycle substituted with 0-3 R^{c1} and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-3 R^{c1} ;

20

R^{c1} , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , NR^aR^{a1} , $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a1}$, $R^aNC(O)NR^aR^{a1}$, $OC(O)NR^aR^{a1}$, $R^aNC(O)O$, $S(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $NR^aS(O)_2NR^aR^{a1}$, $OS(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $S(O)_pR^{a2}$, CF_3 , and CF_2CF_3 ;

25

30 R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , NR^aR^{a1} , $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a1}$, $R^aNC(O)NR^aR^{a1}$, $OC(O)NR^aR^{a1}$, $R^aNC(O)O$,

$S(O)_2NR^aRa^1$, $NR^aS(O)_2Ra^2$, $NR^aS(O)_2NR^aRa^1$, $OS(O)_2NR^aRa^1$,
 $NR^aS(O)_2Ra^2$, $S(O)_pRa^2$, CF_3 , CF_2CF_3 , C_{3-10} carbocycle and a
 5 5-14 membered heterocycle comprising: carbon atoms and
 1-4 heteroatoms selected from the group consisting of
 N, O, and $S(O)_p$;

10 R^5 , at each occurrence, is selected from C_{1-10} alkyl
 substituted with 0-2 R^b , and C_{1-8} alkyl substituted with
 0-2 R^e ;

R^e , at each occurrence, is selected from phenyl substituted
 with 0-2 R^b and biphenyl substituted with 0-2 R^b ;

15 R^6 , at each occurrence, is selected from phenyl, naphthyl,
 C_{1-10} alkyl-phenyl- C_{1-6} alkyl-, C_{3-11} cycloalkyl, C_{1-6}
 alkylcarbonyloxy- C_{1-3} alkyl-, C_{1-6} alkoxy carbonyloxy- C_{1-3}
 alkyl-, C_{2-10} alkoxy carbonyl, C_{3-6}
 cycloalkylcarbonyloxy- C_{1-3} alkyl-, C_{3-6}
 cycloalkoxy carbonyloxy- C_{1-3} alkyl-, C_{3-6}
 20 cycloalkoxy carbonyl, phenoxycarbonyl,
 phenyloxy carbonyloxy- C_{1-3} alkyl-, phenylcarbonyloxy- C_{1-3}
 alkyl-, C_{1-6} alkoxy- C_{1-6} alkylcarbonyloxy- C_{1-3} alkyl-,
 [5-(C_{1-5} alkyl)-1,3-dioxo-cyclopenten-2-one-yl]methyl,
 [5-(R^a)-1,3-dioxo-cyclopenten-2-one-yl]methyl,
 25 (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyl, - C_{1-10}
 alkyl- NR^7R^{7a} , - $CH(R^8)OC(=O)R^9$, and - $CH(R^8)OC(=O)OR^9$;

R^7 is selected from H and C_{1-10} alkyl, C_{2-6} alkenyl, C_{3-6}
 cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;

30 R^{7a} is selected from H and C_{1-10} alkyl, C_{2-6} alkenyl, C_{3-6}
 cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;

R⁸ is selected from H and C₁₋₄ linear alkyl;

R⁹ is selected from H, C₁₋₈ alkyl substituted with 1-2 R^f,
C₃₋₈ cycloalkyl substituted with 1-2 R^f, and phenyl
5 substituted with 0-2 R^b;


R^f, at each occurrence, is selected from C₁₋₄ alkyl, C₃₋₈
cycloalkyl, C₁₋₅ alkoxy, and phenyl substituted with 0-2
R^b;

10 p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4;
and,

15 r¹, at each occurrence, is selected from 0, 1, 2, 3, and 4.

[2] In a preferred embodiment, the present invention
20 provides a novel compound of formula II:



II

or a stereoisomer or pharmaceutically acceptable salt form
thereof, wherein;

25

A is selected from -CO₂H, CH₂CO₂H, -CONHOH, -CONHOR⁵,
-CONHOR⁶, -N(OH)COR⁵, -N(OH)CHO, -SH, and -CH₂SH;

ring B is a 4-7 membered non-aromatic carbocyclic or
30 heterocyclic ring comprising: carbon atoms, 0-1
carbonyl groups, 0-1 double bonds, and from 0-2 ring

heteroatoms selected from O, N, and NR^2 , provided that ring B contains other than a O-O bond;

5 Z is absent or selected from a C_{3-11} carbocycle substituted with 0-4 R^b and a 5-11 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^b ;

10 U^a is absent or is selected from: O, NR^{a1} , C(O) , C(O)O , C(O)NR^{a1} , $\text{NR}^{a1}\text{C(O)}$, S(O)_p , and $\text{S(O)}_p\text{NR}^{a1}$;

X^a is absent or selected from C_{1-4} alkylene, C_{2-4} alkenylene, and C_{2-4} alkynylene;

15

Y^a is absent or selected from O and NR^{a1} ;

Z^a is selected from H, a C_{3-10} carbocycle substituted with 0-5 R^c and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-5 R^c ;

20

provided that Z, U^a , Y^a , and Z^a do not combine to form a N-N, N-O, O-N, O-O, $\text{S(O)}_p\text{-O}$, O-S(O)_p or $\text{S(O)}_p\text{-S(O)}_p$ group;

25

R^1 is selected from H, C_{1-4} alkyl, phenyl, and benzyl;

R^2 is selected from Q, C_{1-6} alkylene-Q, C_{2-6} alkenylene-Q, C_{2-6} alkynylene-Q, $(\text{CR}^a\text{R}^{a1})_r\text{O}(\text{CR}^a\text{R}^{a1})_r\text{-Q}$, $(\text{CR}^a\text{R}^{a1})_r\text{NR}^a(\text{CR}^a\text{R}^{a1})_r\text{-Q}$, $(\text{CR}^a\text{R}^{a1})_r\text{C(O)}(\text{CR}^a\text{R}^{a1})_r\text{-Q}$, $(\text{CR}^a\text{R}^{a1})_r\text{C(O)O}(\text{CR}^a\text{R}^{a1})_r\text{-Q}$, $(\text{CR}^a\text{R}^{a1})_r\text{C(O)NR}^a\text{R}^{a1}$,

30

$(\text{CR}^a\text{Ra}^1)_r\text{C}(\text{O})\text{NR}^a(\text{CR}^a\text{Ra}^1)_r\text{-Q}$, $(\text{CR}^a\text{Ra}^1)_r\text{S}(\text{O})_p(\text{CR}^a\text{Ra}^1)_r\text{-Q}$,
and $(\text{CR}^a\text{Ra}^1)_r\text{SO}_2\text{NR}^a(\text{CR}^a\text{Ra}^1)_r\text{-Q}$;

Q is selected from H, a C₃₋₆ carbocycle substituted with 0-5
5 R^d, and a 5-10 membered heterocycle comprising: carbon
atoms and 1-4 heteroatoms selected from the group
consisting of N, O, and S(O)_p and substituted with 0-5
R^d;

10 R^a, at each occurrence, is independently selected from H,
C₁₋₄ alkyl, phenyl and benzyl;

R^{a1}, at each occurrence, is independently selected from H and
C₁₋₄ alkyl;

15

alternatively, R^a and R^{a1} when attached to a nitrogen are
taken together with the nitrogen to which they are
attached to form a 5 or 6 membered ring comprising
carbon atoms and from 0-1 additional heteroatoms
20 selected from the group consisting of N, O, and S(O)_p;

R^{a2}, at each occurrence, is independently selected from C₁₋₄
alkyl, phenyl and benzyl;

25 R^b, at each occurrence, is independently selected from C₁₋₆
alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^{a1}, C(O)R^a, C(O)OR^a,
C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

R^c, at each occurrence, is independently selected from C₁₋₆
30 alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^{a1}, C(O)R^a, C(O)OR^a,
C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, CF₃, C₃₋₆ carbocycle
and a 5-6 membered heterocycle comprising: carbon

atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p;

- R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, CF₃, C₃₋₆ carbocycle and a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p;
- 10 R⁵, at each occurrence, is selected from C₁₋₆ alkyl substituted with 0-2 R^b, and C₁₋₄ alkyl substituted with 0-2 R^e;
- 15 R^e, at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b;
- R⁶, at each occurrence, is selected from phenyl, naphthyl, C₁₋₁₀ alkyl-phenyl-C₁₋₆ alkyl-, C₃₋₁₁ cycloalkyl, C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy carbonyloxy-C₁₋₃ alkyl-, C₂₋₁₀ alkoxy carbonyl, C₃₋₆ cycloalkylcarbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxy carbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxy carbonyl, phenoxycarbonyl, phenyloxy carbonyloxy-C₁₋₃ alkyl-, phenylcarbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy-C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, [5-(C₁₋₅ alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl, [5-(R^a)-1,3-dioxa-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, -C₁₋₁₀ alkyl-NR⁷R^{7a}, -CH(R⁸)OC(=O)R⁹, and -CH(R⁸)OC(=O)OR⁹;
- 20
25
30

R⁷ is selected from H and C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl-, and phenyl-C₁₋₆ alkyl-;

R^{7a} is selected from H and C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;

5 R^8 is selected from H and C_{1-4} linear alkyl;

R^9 is selected from H, C_{1-6} alkyl substituted with 1-2 R^f , C_{3-6} cycloalkyl substituted with 1-2 R^f , and phenyl substituted with 0-2 R^b ;

10


R^f , at each occurrence, is selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-5} alkoxy, and phenyl substituted with 0-2 R^b ;

15 p , at each occurrence, is selected from 0, 1, and 2;


r , at each occurrence, is selected from 0, 1, 2, 3, and 4;
and,

20 r^1 , at each occurrence, is selected from 0, 1, 2, 3, and 4.

[3] In a more preferred embodiment, the present invention provides a novel compound of formula IIIa or IIIb:



IIIa



IIIb

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

30 A is selected from $-CO_2H$, CH_2CO_2H , $-CONHOH$, $-CONHOR^5$, $-N(OH)CHO$, and $-N(OH)COR^5$;

5 Z is absent or selected from a C₅₋₆ carbocycle substituted with 0-3 R^b and a 5-6 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^b;

10 U^a is absent or is selected from: O, NR^{a1}, C(O), C(O)NR^{a1}, S(O)_p, and S(O)_pNR^{a1};

X^a is absent or selected from C₁₋₄ alkylene, C₂₋₄ alkenylene, and C₂₋₄ alkynylene

15 Y^a is absent or selected from O and NR^{a1};

20 Z^a is selected from H, a C₅₋₆ carbocycle substituted with 0-3 R^c and a 5-10 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^c;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

25 R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

30 R² is selected from Q, C₁₋₆ alkylene-Q, C₂₋₆ alkenylene-Q, C₂₋₆ alkynylene-Q, (CR^aRA^{a1})_rC(O)(CR^aRA^{a1})_r-Q, (CR^aRA^{a1})_rC(O)O(CR^aRA^{a1})_r-Q, (CR^aRA^{a2})_rC(O)NR^aRA^{a1}, (CR^aRA^{a2})_rC(O)NR^a(CR^aRA^{a1})_r-Q, and (CR^aRA^{a1})_rS(O)_p(CR^aRA^{a1})_r-Q;

Q is selected from H, a C₃₋₆ carbocycle substituted with 0-3 R^d and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^d;

R^a, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

R^{a1}, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

R^{a2}, at each occurrence, is independently selected from C₁₋₄ alkyl, phenyl, and benzyl;

R^b, at each occurrence, is independently selected from C₁₋₄ alkyl, OR^a, Cl, F, =O, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a1}, C(O)R^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a1}, C(O)R^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, CF₃, and phenyl;

R⁵, at each occurrence, is selected from C₁₋₄ alkyl substituted with 0-2 R^b, and C₁₋₄ alkyl substituted with 0-2 R^e;

R^e, at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4;


5

r^1 , at each occurrence, is selected from 0, 1, 2, 3, and 4;
and,


s and s^1 combine to total 2, 3, or 4.

10

[4] In a further preferred embodiment, the present invention provides a novel compound of formula IVa or IVb:



IVa



IVb

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

20 Z is absent or selected from phenyl substituted with 0-3 R^b and pyridyl substituted with 0-3 R^b ;

U^a is absent or is O;

25 X^a is absent or is CH_2 or CH_2CH_2 ;

Y^a is absent or is O;

Z^a is selected from H, phenyl substituted with 0-3 R^c ,
30 pyridyl substituted with 0-3 R^c , and quinolinyl substituted with 0-3 R^c ;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, or O-O group;

R¹ is selected from H, CH₃, and CH₂CH₃;

5

R² is selected from Q, C₁₋₆ alkylene-Q, C₂₋₆ alkynylene-Q, C(O)(CR^aR^{a1})_r-Q, C(O)O(CR^aR^{a1})_r-Q, C(O)NR^a(CR^aR^{a1})_r-Q, and S(O)_p(CR^aR^{a1})_r-Q;

10 Q is selected from H, cyclopropyl substituted with 0-1 R^d, cyclobutyl substituted with 0-1 R^d, cyclopentyl substituted with 0-1 R^d, cyclohexyl substituted with 0-1 R^d, phenyl substituted with 0-2 R^d and a heteroaryl substituted with 0-3 R^d, wherein the heteroaryl is
15 selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl;

R^a, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

20

R^{a1}, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

25 R^{a2}, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

R^b, at each occurrence, is independently selected from C₁₋₄ alkyl, OR^a, Cl, F, =O, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

30

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a1}, C(O)R^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, NR^aR^{a1} , $C(O)R^a$, $C(O)NR^aR^{a1}$, $S(O)_2NR^aR^{a1}$, $S(O)_pR^{a2}$, CF_3 and phenyl;

5

p , at each occurrence, is selected from 0, 1, and 2;

r , at each occurrence, is selected from 0, 1, 2, and 3;

10 r^1 , at each occurrence, is selected from 0, 1, 2, and 3; and,

s and s^1 combine to total 2, 3, or 4.

15 [5] In another more preferred embodiment, the present invention provides a novel compound of formula II, wherein;

A is selected from $-CO_2H$, CH_2CO_2H , $-CONHOH$, $-CONHOR^5$,
20 $-N(OH)CHO$, and $-N(OH)COR^5$;

ring B is a 4-7 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring
25 heteroatoms selected from O, N, and NR^2 , provided that ring B contains other than a O-O bond;

Z is absent or selected from a C_{5-6} carbocycle substituted with 0-3 R^b and a 5-6 membered heteroaryl comprising
30 carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-3 R^b ;

U^a is absent or is selected from: O, NR^{a1}, C(O), C(O)NR^{a1},
S(O)_p, and S(O)_pNR^{a1};

X^a is absent or selected from C₁₋₂ alkylene, C₂₋₄ alkenylene,
5 and C₂₋₄ alkynylene

Y^a is absent or selected from O and NR^{a1};

Z^a is selected from H, a C₅₋₆ carbocycle substituted with 0-3
10 R^c and a 5-10 membered heteroaryl comprising carbon
atoms and from 1-4 heteroatoms selected from the group
consisting of N, O, and S(O)_p and substituted with 0-3
R^c;

15 provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N,
N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

20 R² is (CR^aRA¹)_rO(CR^aRA¹)_r-Q or (CR^aRA¹)_rNR^a(CR^aRA¹)_r-Q;

Q is selected from H, a C₃₋₆ carbocycle substituted with 0-3
R^d and a 5-10 membered heterocycle comprising: carbon
atoms and 1-4 heteroatoms selected from the group
25 consisting of N, O, and S(O)_p and substituted with 0-3
R^d;

R^a, at each occurrence, is independently selected from H,
C₁₋₄ alkyl, phenyl and benzyl;

30

RA¹, at each occurrence, is independently selected from H and
C₁₋₄ alkyl;

R^{a^2} , at each occurrence, is independently selected from C_{1-4} alkyl, phenyl and benzyl;

5 R^b , at each occurrence, is independently selected from C_{1-4} alkyl, OR^a , Cl, F, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;

10 R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;

15 R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, CF_3 and phenyl;

R^5 , at each occurrence, is selected from C_{1-4} alkyl substituted with 0-2 R^b , and C_{1-4} alkyl substituted with 0-2 R^e ;

20 R^e , at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b ;

p , at each occurrence, is selected from 0, 1, and 2;

25 r , at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

r^1 , at each occurrence, is selected from 0, 1, 2, 3, and 4.

30

[6] In another further preferred embodiment, the present invention provides a novel compound of formula II, wherein;

A is $-\text{CONHOH}$;

ring B is a 5-6 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1
5 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, and NR^2 , provided that ring B contains other than a O-O bond;

Z is absent or selected from phenyl substituted with 0-3 R^b
10 and pyridyl substituted with 0-3 R^b ;

U^a is absent or is O;

X^a is absent or is CH_2 or CH_2CH_2 ;

15

Y^a is absent or is O;

Z^a is selected from H, phenyl substituted with 0-3 R^c ,
pyridyl substituted with 0-3 R^c , and quinolinyl
20 substituted with 0-3 R^c ;

provided that Z, U^a , Y^a , and Z^a do not combine to form a N-N,
N-O, O-N, or O-O group;

25 R^1 is selected from H, CH_3 , and CH_2CH_3 ;

R^2 is $(\text{CR}^a\text{R}^a)^1_{\text{r}}\text{O}(\text{CR}^a\text{R}^a)^1_{\text{r}}\text{Q}$ or $(\text{CR}^a\text{R}^a)^1_{\text{r}}\text{NR}^a(\text{CR}^a\text{R}^a)^1_{\text{r}}\text{Q}$;

Q is selected from H, cyclopropyl substituted with 0-1 R^d ,
30 cyclobutyl substituted with 0-1 R^d , cyclopentyl substituted with 0-1 R^d , cyclohexyl substituted with 0-1 R^d , phenyl substituted with 0-2 R^d , and a heteroaryl substituted with 0-3 R^d , wherein the heteroaryl is

selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl;

5 R^a , at each occurrence, is independently selected from H, CH_3 , and CH_2CH_3 ;

R^{a1} , at each occurrence, is independently selected from H, CH_3 , and CH_2CH_3 ;

10 R^{a2} , at each occurrence, is independently selected from H, CH_3 , and CH_2CH_3 ;

R^b , at each occurrence, is independently selected from C_{1-4} alkyl, OR^a , Cl, F, =O, NR^aR^{a1} , $C(O)R^a$, $C(O)OR^a$,
15 $C(O)NR^aR^{a1}$, $S(O)_2NR^aR^{a1}$, $S(O)_pR^{a2}$, and CF_3 ;

R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, NR^aR^{a1} , $C(O)R^a$, $C(O)NR^aR^{a1}$,
20 $S(O)_2NR^aR^{a1}$, $S(O)_pR^{a2}$, and CF_3 ;

R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, NR^aR^{a1} , $C(O)R^a$, $C(O)NR^aR^{a1}$,
25 $S(O)_2NR^aR^{a1}$, $S(O)_pR^{a2}$, CF_3 and phenyl;

p , at each occurrence, is selected from 0, 1, and 2;

r , at each occurrence, is selected from 0, 1, 2, and 3; and,

r^1 , at each occurrence, is selected from 0, 1, 2, and 3.

30

[7] In another preferred embodiment, the present invention provides a compound selected from the group:

- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-
(trifluoromethyl)[1,1'-biphenyl]-4-carboxamide
- 5 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[2-
(trifluoromethyl)phenoxy]benzamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(3-
methyl-2-pyridinyl)benzamide
- 10 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}[1,1'-
biphenyl]-4-carboxamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-
phenoxybenzamide
- 15 4-(benzyloxy)-*N*-{(1*R*,2*S*)-2-
[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- 20 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-
methoxy[1,1'-biphenyl]-4-carboxamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-
methyl[1,1'-biphenyl]-4-carboxamide
- 25 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(2-
methoxyphenoxy)benzamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(2-
methylphenoxy)benzamide
- 30 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(3-
methylphenoxy)benzamide
- 35 4-(5,8-dihydro-4-quinolinyl)-*N*-{(1*R*,2*S*)-2-
[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-3',5'-
dimethyl[1,1'-biphenyl]-4-carboxamide
- 40 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-6-(2-
methylphenyl)nicotinamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-6-(2-
methoxyphenyl)nicotinamide
- 45 (3*S*,4*S*)-*N*-hydroxy-1-isopropyl-4-({4-[(2-methyl-4-
quinolinyl)methoxy]benzoyl}amino)-3-
pyrrolidinecarboxamide
- 50 (3*S*,4*S*)-1-(2,2-dimethylpropanoyl)-*N*-hydroxy-4-({4-[(2-
methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-
pyrrolidinecarboxamide

- (3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(methylsulfonyl)-3-pyrrolidinecarboxamide
5
- (3*S*,4*S*)-*N*-hydroxy-1-methyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 10 *tert*-butyl (3*S*,4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- (3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
15
- tert*-butyl 4-[cis-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)pyrrolidinyl]-1-piperidinecarboxylate
20
- cis-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(4-piperidinyl)-3-pyrrolidinecarboxamide
25
- cis-1-[3-[(1,1-dimethylethoxy)carbonyl]pyrrolidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
30
- cis-*N*-hydroxy-1-[3-pyrrolidinyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
35
- tert*-butyl (3*R*,4*R*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 40 *tert*-butyl (3*S*,4*R*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- (3*S*,4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
45
- tert*-butyl (3*R*,4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
50

- (3*R*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 5 *N*-{(1*R*, 2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(4-pyridinyl)benzamide
- (3*S*, 4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 10
- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-3-pyrrolidinecarboxamide
- 15
- (3*S*, 4*S*)-1-allyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 20
- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propyl-3-pyrrolidinecarboxamide
- 25
- (3*S*, 4*S*)-*N*-hydroxy-1-(2-methyl-2-propenyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 30
- (3*S*, 4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 35
- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-3-pyrrolidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-1-isopentyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 40
- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-neopentyl-3-pyrrolidinecarboxamide
- 45
- (3*S*, 4*S*)-1-butyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 50
- (3*S*, 4*S*)-1-(3-butenyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

- (3S,4S)-1-(2-butynyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 5 (3S,4S)-1-(2-furylmethyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 10 (3S,4S)-N-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 15 (3R,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-furancarboxamide
- 20 (3S,4R)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-furancarboxamide
- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(1,3-thiazol-2-ylmethyl)-3-pyrrolidinecarboxamide
- 25 (3S,4S)-1-acetyl-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 30 (3S,4S)-N-hydroxy-1-isobutyryl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3S,4S)-N-hydroxy-1-(3-methylbutanoyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 35 (3S,4S)-1-(cyclopropylcarbonyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 40 (3S,4S)-1-(cyclobutylcarbonyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 45 (3S,4S)-N-hydroxy-1-(methoxyacetyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 50 (3S,4S)-1-(2-furoyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-thienylcarbonyl)-3-pyrrolidinecarboxamide
- 5 (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propionyl-3-pyrrolidinecarboxamide
- 10 (3R,4S)-4-{{4-(2-butynyloxy)benzoyl}amino}-N-hydroxy-tetrahydro-3-furancarboxamide
- N-{{(1R,2S)-2-[(hydroxyamino)carbonyl]-4-oxocyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 15 N-{{(1R,2S,4R)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 20 N-{{(1R,2S,4S)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 25 (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-tetrahydro-2H-pyran-4-yl-3-pyrrolidinecarboxamide
- 30 methyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- ethyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 35 propyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 40 allyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 45 isopropyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 50 2-propynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 2-butynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate

- 3-butenyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 5 benzyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 10 N-[(1R,2S)-4-(dimethylamino)-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 15 (3S,4S)-4-({4-(2-butynyloxy)benzoyl}amino)-N-hydroxy-1-isopropyl-3-pyrrolidinecarboxamide
- N-[(1R,2S)-4,4-difluoro-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 20 (3S,4S)-N-hydroxy-1-isopropyl-4-({4-(2-methylphenoxy)benzoyl}amino)-3-pyrrolidinecarboxamide
- 25 *cis*-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- trans*-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- 30 (1S,2R)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- 35 (1R,2S)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- 40 *cis*-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclohexanecarboxamide
- 45 *trans*-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclohexanecarboxamide
- trans*-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 50

- trans-N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 5 *cis*-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 10 *cis-N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 15 (3*S*,4*R*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 20 (3*S*,4*S*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 25 (3*S*,4*S*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 30 (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3*S*,4*R*)-1-[(butoxy)carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 35 (3*S*,4*R*)-*N*-hydroxy-1-[[[(1-methylethyl)oxy]carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 40 (3*S*,4*R*)-*N*-hydroxy-1-(methylsulfonyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 45 (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-3-piperidinecarboxamide
- (3*S*,4*R*)-1-acetyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 50

- (3*S*, 4*R*)-1-benzoyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 5 (3*S*, 4*R*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 10 (3*S*, 4*R*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 15 (3*S*, 4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-3-piperidinecarboxamide
- 20 (3*S*, 4*R*)-1-(dimethylcarbamyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3*S*, 4*R*)-*N*-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 25 (3*S*, 4*R*)-1-ethyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 30 (3*S*, 4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-3-piperidinecarboxamide
- 35 (3*S*, 4*R*)-*N*-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 40 (3*S*, 4*R*)-1-(cyclopropylmethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3*S*, 4*R*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 45 (3*S*, 4*R*)-1-benzyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 50 (3*S*, 4*R*)-1-(2-thiazolylmethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

- (3*S*, 4*S*)-1-[[(1,1-dimethylethyl) oxy] carbonyl]-*N*-hydroxy-3-
[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 5 (3*R*, 4*S*)-1-[[(1,1-dimethylethyl) oxy] carbonyl]-*N*-hydroxy-3-
[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 10 (3*R*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-1-[[(2-methylpropyl) oxy] carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-1-(methoxycarbonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-1-[(1-methylethoxy) carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-1-(methylsulfonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 35 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-1-
(phenylsulfonyl)-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- (3*S*, 4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 45 (3*S*, 4*S*)-1-benzoyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl] carbonyl] amino]-4-
piperidinecarboxamide
- 50

- (3*S*, 4*S*)-1-[(pyridin-3-yl)carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiophenecarbonyl)-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[2-(2-thienyl)ethyl]carbamyl]-4-piperidinecarboxamide
- (3*S*, 4*S*)-1-[(1,1-dimethylethyl)carbamyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-1-ethyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-1-cyclobutyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-1-butyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-methylpropyl)-4-piperidinecarboxamide

- (3*S*, 4*S*)-1-(cyclopropylmethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-cyclopentyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropyranyl)-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-1-benzyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiazolylmethyl)-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-pyridinylmethyl)-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-pyridinylmethyl)-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-pyridinylmethyl)-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*trans*-3-phenyl-2-propenyl)-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-phenyl-4-piperidinecarboxamide
- 45 (3*R*, 4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*R*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-methyl-4-piperidinecarboxamide

- (3*R*,4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*,4*S*)-1-hexyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*,4*S*)-1-(2-fluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*,4*S*)-1-(2,2-difluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*S*,4*S*)-*N*-hydroxy-1-(1-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*,4*S*)-1-(1-ethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 30 (3*S*,4*S*)-1-[1-[(1,1-dimethylethyl)oxy]carbonyl]-4-tetrahydropiperidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropiperidinyl)-4-piperidinecarboxamide
- 35 (3*S*,4*S*)-1-[1-[(1,1-dimethylethyl)oxy]carbonyl]-3-tetrahydropyrrolidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-tetrahydropyrrolidinyl)-4-piperidinecarboxamide
- 45 (3*S*,4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-thiophenylmethyl)-4-piperidinecarboxamide

- (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-1-[2-(*N,N*-dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-1-(benzenesulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-1-(*t*-butylsulfinyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-*N*-hydroxy-1-(2-hydroxyethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-1-[2-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*S*, 4*S*)-1-(2-aminoethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

- (3*S*, 4*S*)-1-[2-(*N,N*-dimethylamino)ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-1-[(2*S*)-2-aminopropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-[(2*R*)-2-amino-3-hydroxypropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[(2*R*)-2-pyrrolidinyl)methyl]-4-piperidinecarboxamide
- 20 (3*S*, 4*R*)-*N*-hydroxy-1-(2-hydroxyethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3*S*, 4*R*)-1-(2-aminoethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 25 (3*S*, 4*R*)-1-cyclobutyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 30 (3*R*, 4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-2*H*-pyran-3-carboxamide
- 35 (3*S*, 4*S*)-1-*tert*-butyl-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 40 *tert*-butyl 2-[(3*S*, 4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate
- 2-[(3*S*, 4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoic acid
- 45 methyl 2-[(3*S*, 4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate

- (3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-1-[2-(dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-1-allyl-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-1-(1-methyl-2-propynyl)-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 35 *N*-{(1*R*, 2*S*)-4,5-dihydroxy-2-[(hydroxyamino)carbonyl]cyclohexyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 40 (5*S*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-3-({4-(2-butynyloxy)benzoyl}amino)-*N*-hydroxy-1-isopropyl-4-piperidinecarboxamide

- (3*S*,4*S*)-3-([4-(2-butynyloxy)benzoyl]amino)-*N*-hydroxy-4-piperidinecarboxamide
- 5 *tert*-butyl (3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-1-piperidinecarboxylate
- 10 (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 15 *tert*-butyl (3*S*,4*S*)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-4-[(hydroxyamino)carbonyl]-1-piperidinecarboxylate
- 20 (3*S*,4*S*)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-*N*-hydroxy-4-piperidinecarboxamide
- 25 (*cis*,*cis*)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 30 (*cis*,*cis*)-3-Methylamino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 35 (*cis*,*cis*)-3-Dimethylmino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*N*-hydroxy)cyclohexylcarboxamide
- 40 (*cis*,*trans*)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*N*-hydroxy)cyclohexylcarboxamide
- 45 (*cis*,*trans*)-3-Dimethylmino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 40 (*cis*,*trans*)-3-(1-Methyl-1-ethylmino)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 45 (*cis*,*trans*)-3-Methylamino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide

- (*cis,cis*)-3-Hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide
- 5 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[[2-methyl-4-quinolinyl)methyl]amino}benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-{methyl[(2-methyl-4-quinolinyl)methyl]amino}benzamide
- 10 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-(3-phenyl-4,5-dihydro-5-isoxazolyl)benzamide
- 15 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(3-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 20 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(2-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-quinolinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 25 4-[3-(2,6-Dimethyl-4-pyridinyl)-4,5-dihydro-5-isoxazolyl]-*N*-{*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-3-methoxy-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 30 3-Hydroxy-*N*-{*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 35 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(2-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(4-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide
- 40 *N*-{4-[(hydroxyamino)carbonyl]-3-pyrrolidinyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide
- N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide
- 45 *N*-hydroxy-3-[(6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthoyl)amino]-4-piperidinecarboxamide
- 50 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthamide

- N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-2-naphthamide
- 5 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-1,2,3,4-tetrahydro-1-isoquinolinecarboxamide
- 10 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-benzimidazole-5-carboxamide
- N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-4-carboxamide
- 15 (±)-*cis-N*-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide
- 20 (±)-*trans-N*-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide
- 25 (4*S*,5*R*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxohexahydro-1*H*-azepine-4-carboxamide
- (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-4-carboxamide
- 30 (3*S*,4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-3-carboxamide
- 35 (4*S*,5*R*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-4-carboxamide
- 40 (2*S*,3*R*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide
- (2*R*,3*R*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide, and
- 45 *tert*-butyl (2*S*,3*R*)-2-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 50 or a pharmaceutically acceptable salt form thereof.

In another embodiment, the present invention provides a novel pharmaceutical composition, comprising: a
5 pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt form thereof.

10 In another embodiment, the present invention provides a novel method for treating or preventing an inflammatory disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt
15 form thereof.

In another embodiment, the present invention provides a novel method of treating a condition or disease mediated by
20 MMPs, TNF, aggrecanase, or a combination thereof in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt form thereof.

25

In another-embodiment, the present invention provides a novel method of treating, wherein the disease or condition is referred to as acute infection, acute phase response, age
30 related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary disease, coagulation,
35 congestive heart failure, corneal ulceration, Crohn's

disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, HIV infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pyoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases, spondylitis, stroke, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis.

20

In another embodiment, the present invention provides novel compounds of the present invention for use in therapy.

25

In another embodiment, the present invention provides the use of novel compounds of the present invention for the manufacture of a medicament for the treatment of a condition or disease mediated by MMPs, TNF, aggrecanase, or a combination thereof.

30

DEFINITIONS

The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically

active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Geometric isomers of double bonds such as

5 olefins and C=N double bonds can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or

10 as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds of the present invention and

15 intermediates made therein are considered to be part of the present invention.

The term "substituted," as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the

20 designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced. Keto substituents are not present on aromatic moieties. When a ring system (e.g., carbocyclic or

25 heterocyclic) is said to be substituted with a carbonyl group or a double bond, it is intended that the carbonyl group or double bond be part (i.e., within) of the ring.

The present invention is intended to include all isotopes of atoms occurring in the present compounds.

30 Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

When any variable (e.g., R^b) occurs more than one time

35 in any constituent or formula for a compound, its definition

at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R^6 , then said group may optionally be substituted with up to two R^6 groups and R^6 at each occurrence is selected independently from the definition of R^6 . Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

As used herein, "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. C_{1-10} alkyl (or alkylene), is intended to include C_1 , C_2 , C_3 , C_4 , C_5 , C_6 , C_7 , C_8 , C_9 , and C_{10} alkyl groups. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example $-C_vF_w$ where $v=1$ to 3 and $w=1$ to $(2v+1)$). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. C_{1-10} alkoxy, is intended to include C_1 , C_2 , C_3 , C_4 , C_5 , C_6 , C_7 , C_8 , C_9 , and C_{10} alkoxy groups. Examples of

alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. C₃₋₇ cycloalkyl, is intended to include C₃, C₄, C₅, C₆, and C₇ cycloalkyl groups. "Alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl. C₂₋₁₀ alkenyl (or alkenylene), is intended to include C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, and C₁₀ alkenyl groups. "Alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl. C₂₋₁₀ alkynyl (or alkynylene), is intended to include C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉, and C₁₀ alkynyl groups.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.

As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl.

As used herein, the term "heterocycle" or "heterocyclic group" is intended to mean a stable 5, 6, or 7-membered

monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined). The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic group" or "heteroaryl" is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1, 2, 3, or 4 heterotams independently selected from the group consisting of N, O and S. It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1.

Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazoliny, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl,

furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indoliziny, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoliziny, quinoxaliny, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; and alkali or organic salts of acidic residues such as carboxylic acids. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington's Pharmaceutical Sciences*, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility,

bioavailability, manufacturing, etc...) the compounds of the present invention may be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same, and compositions containing the same. "Prodrugs" are intended to include any covalently bonded carriers which release an active parent drug of the present invention *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.

"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

"Therapeutically effective amount" is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit a desired metalloprotease in a host. The combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, *Adv. Enzyme Regul.* 22:27-55 (1984), occurs when the effect (in this case, inhibition of the desired target) of the compounds when administered in combination is greater

than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of lower

5 cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components.

SYNTHESIS


10 The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of
15 synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference.

20 The novel compounds of this invention may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description
25 of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work up procedures, are chosen to be the conditions standard for
30 that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the
35 substituents which are compatible with the reaction

conditions will be readily apparent to one skilled in the art and alternate methods must then be used.


A variety of compounds of formula (I) wherein A is hydroxamic acid group are prepared from the corresponding esters via several routes known in the literature (Scheme 1). The methyl ester of 1 ($R^{11}=\text{Me}$) is directly converted to hydroxamic acid 2 by treatment with hydroxylamine under basic conditions such as KOH or NaOMe in solvents such as methanol. The methyl ester of 1 ($R^{11}=\text{Me}$) can also be converted to O-benzyl protected hydroxamic acid with O-benzylhydroxylamine under similar conditions or using Weinreb's trimethylalluminum conditions (Levin, J. I.; Turos, E.; Weinreb, S. M. *Syn. Commun.* **1982**, 12, 989) or Roskamp's bis[bis(trimethylsilyl)amido]tin reagent (Wang, W.-B.; Roskamp, E. J. *J. Org. Chem.* **1992**, 57, 6101). The benzyl ether is removed by methods well known in the literature such as hydrogenation using palladium on barium sulfate in hydrogen, to give compound 2. Alternatively, 2 can be prepared through the carboxylic intermediate 3. Carboxylic acid 3 is converted to 2 via coupling with hydroxylamine, or O-benzylhydroxylamine followed by deprotection.

Scheme 1




5 The β -amino acid moiety in formula (I) can be
 synthesized following a variety of literature routes as
 reviewed in "Enantioselective Synthesis of β -Amino Acids"
 (E. Juaristi, Ed. Wiley-VCH, 1997). One representative
 approach using Davies protocol is summarized in Scheme 2 (*J.*
 10 *Chem. Soc. Perkin Trans I*, 1994, 1411). Michael addition of
 lithium amide 5 to 4 gives cis product 6. The stereochemical
 configuration of 6 is governed by the chirality of 5. De-
 benzylation of 6 provides cis- β -amino acid 7. The trans- β -
 amino acid 9 can be prepared by epimerization of 6 followed
 15 by de-benzylation. Since both amine enantiomers of 5 are
 commercially available, this approach provides ready access
 to both cis and trans isomers (7 and 9), as well as their
 antipodes.

Scheme 2




5 Alternatively, these β -amino acids can be prepared from
the corresponding dicarboxylate derivatives (Scheme 3). The
dicarboxylate derivatives can be de-symmetrized through
enzymatic resolution (for an example with lipase, see Gais,
H.-J. et al, *J. Am. Chem. Soc.* **1989**, 54, 5115), or through
10 chemical resolution (for an example with TADOLates, see
Seebach, D. et al, *Angew Chem Int. Ed. Engl.* **1995**, 34,
2395). The optically pure mono-ester **11** is converted to Cbz
protected β -amino acid ester **12** through Curtius
rearrangement (for a related example, see Kobayashi, S. et
15 al, *Tetrahedron Lett.* **1984**, 25, 2557). Removal of Cbz
protecting group provides cis amino acid ester **13**. The
corresponding trans analogue of **13** can be prepared from the
ester of trans di-carboxylic acid of **10** following same
sequence.

Scheme 3



5 A series of compounds of formula (I) wherein ring B is
 pyrrolidine are prepared following the sequence outlined in
 Scheme 4. Pyrrolidine **15** is prepared following a dipolar
 addition procedure documented in the literature (Joucla, M.;
 Mortier, J., *J. Chem. Commun.* **1985**, 1566). Protecting group
 10 manipulations and Curtius rearrangement (for a related
 example, see Kobayashi, S. et al, *Tetrahedron Lett.* **1984**,
 25, 2557) give intermediate **17**. Hydrogenolysis gives amino
 acid ester **18**. **18** is coupled with acid **20** to provide **21** with
 R¹ as H. To prepare analogues of **21** when R¹ is not a
 15 hydrogen, **18** is first converted to **19** by alkylation or
 reductive amination, then coupled with **20**. The pyrrolidine
 nitrogen in **21** is unmasked and functionalized to various
 tertiary amines, amides, carbamides, ureas, sulfonamides and
 sulfonyl ureas following procedures well known in the
 20 literature. Ester **23** is converted to hydroxamic acid
 following sequence outlined in Scheme 1. Following the same
 sequence, the cis isomer of **23** can be prepared using benzyl
 methyl maleate as the starting material.


Scheme 4



- 5 A series of compounds of formula (I) wherein ring B is piperidine are prepared following the sequence outlined in Scheme 5. The β -amino acid moiety is prepared by reduction of enamine 27. Optically pure α -methylbenzylamine (26) is used to induce diastereoselectivity in the reduction
- 10 (Cimarelli, C. et. al, *J. Org. Chem.* **1996**, 61, 5557). Hydrogenolysis gives amino acid ester 29. 29 is coupled with acid 20 to provide 31 with R^1 as H. To prepare analogues of 31 when R^1 is not a hydrogen, 29 is first converted to 30 by alkylation or reductive amination, then coupled with 20. The

piperidine nitrogen in **31** is unmasked and functionalized to various tertiary amines, amides, carbamides, ureas, sulfonamides and sulfonyl ureas following procedures well known in the literature. Ester **33** is converted to hydroxamic acid following sequence outlined in Scheme 1. Regio-isomers of **33** with piperidine nitrogen transposed to other positions are prepared following a similar sequence. The antipode of **33** can be prepared using the *S* enantiomer of **26**. The trans-isomer of **33** is prepared by epimerization of **31** or **33** under basic conditions (e.g., DBU, PhMe, at reflux).

Scheme 5




A series of compounds of formula (I) wherein ring B is piperidine and R^{2a} is hydroxy are prepared following the sequence outlined in Scheme 6. Ketone **34** is converted to enol triflate **35** following McMurry triflimide conditions

5 (McMurry, J. E.; Scott, W. J. *Tetrahedron Lett.* **1983**, 24, 979). Palladium-catalyzed carbonylation in methanol provides methyl ester **36**. Epoxidation, epoxide opening with NaN₃ and hydrogenation give intermediate **39** with amino and ester groups in cis relationship. The isomer with trans

10 stereochemistry (**43**) is prepared using Sharpless asymmetric aminohydroxylation and subsequent removal of Cbz group (Li, G.; Angert, H. H.; Sharpless, K. B. *Angew. Chem. Int. Ed. Engl.* **1996**, 35, 2813). Coupling of **39** and **43** with acid **20** provides **40** and **44**, respectively. Esters **40** and **44** are

15 converted to hydroxamic acids following sequence outlined in Scheme 1.


Scheme 6



- 5 A series of compounds of formula (I) wherein A is N-formylhydroxylamino group are prepared following the sequence outlined in Scheme 7. Starting from *trans*-hydroxy ester 45, Wenreib or Roskamp amide formation with *O*-*t*-butylhydroxylamine gives 46 (Levin, J. I.; Turos, E.; Weinreb, S. M. *Syn. Commun.* **1982**, 12, 989 and Wang, W.-B.;
- 10


Roskamp, E. J. *J. Org. Chem.* **1992**, *57*, 6101). β -Lactam is formed under Mitsunobu conditions (Mitsunobu, O. *Synthesis*, **1981**, 1). Opening of lactam **47** with methylamine followed by N-formylation provide **49**. The N-methyl amide moiety of **49** is converted to carboxylic acid by nitrosation with N₂O₄ or NaNO₂, and hydrolysis with LiOOH (Evans, D. A.; Carter, P. H.; Dinsmore, C. J.; Barrow, J. C.; Katz, J. L.; Kung, D. W. *Tetrahedron Lett.* **1997**, *38*, 4535). Acid **50** is converted to **53** as described previously. Acid hydrolysis of t-Butyl group in **53** completes the synthesis.

Scheme 7



A series of compounds of formula (I) wherein A is mercaptomethyl group are prepared following the sequence outlined in Scheme 8. Saponification and hydroboration of **55** give alcohol **57**. Mitsunobu reaction with thioacetic acid followed by lithium hydroxide hydrolysis provides the desired thiol **59**.

Scheme 8




10

A variety of compounds of formula (I) wherein Z-U^a-X^a-Y^a-Z^a is a functionalized phenyl group can be prepared by methods described in Scheme 9. Intermediate **60**, available from schemes described previously, is converted to phenol **61** by hydrogenolysis. Phenol **61** is used as common intermediates for structure diversification. Reaction of **61** with R¹⁰-X provides **62**, an alternative is the reaction of **61** with R¹⁰-OH under Mitsunobu conditions to produce **62**. R¹⁰ can be appended directly to the aromatic ring by converting **61** to an aryl triflate then reaction with an organometallic in the presence of a palladium (0) catalyst to give **63**. **61** can also be reacted with acyl halides or isocyanates to afford **66**. Biaryl ethers **65** can be produced by treatment of **61** with aryl boronic acids in the presence of a copper catalyst.

Esters **62-63** and **65-66** are converted to the hydroxamic acids following the sequences outlined in Scheme 1.

Scheme 9

5




Compounds of formula **76** can be prepared starting from the commercially available 3-hydroxy-2-nitrobenzoic acid **67** (Scheme 10). Conversion of the carboxylic acid to an ester such as an ethyl ester **68** can be accomplished by refluxing in EtOH /benzene in the presence of sulfuric acid. Ester **68** can be reduced to a saturated cyclohexyl ring **69** by

hydrogenation in acidic aqueous solution using a catalyst such as PtO_2 . Coupling of **69** with a benzoic acid derivative **70** using a coupling agent such as BOP produces the amide derivative **71** as the major diastereomer with a *cis, cis*-stereochemistry. The hydroxyl group of **71** can be oxidized using an oxidizing agent such as the Dess-Martin periodinane to give a ketone derivative **72**. Reductive amination of **72** with ammonium acetate or a primary amine using a reducing agent such as $\text{Na(OAc)}_3\text{BH}$ affords the amino derivative **73**.

10 After Boc protection at the amino using di-tert-butyl-dicarbonate, saponification of the ethyl ester **74** at an elevated temperature using a base such as KOH in MeOH/ H_2O followed by coupling of the resulting carboxylic acid with hydroxylamine hydrochloride using a coupling agent such as


15 BOP produces the hydroxamic acid **75**. Removal of the Boc group using an acid such TFA/ CH_2Cl_2 or 4 N HCl in dioxane affords the final compounds of formula **76**.

Scheme 10



Compounds of formula 78 can be obtained by reductive amination of the intermediate 73 with an aldehyde using a reducing agent such as $\text{Na(OAc)}_3\text{BH}$ followed by conversion of the ethyl ester to a hydroxamate as shown in Scheme 11.


Scheme 11



Compounds of formula 80 can be obtained by reductive
 5 amination of the intermediate 72 with a cycloamine such as
 azetidine, pyrrolidine, piperidine or morpholine using a
 reducing agent such as $\text{Na}(\text{OAc})_3\text{BH}$ followed by conversion of
 the ethyl ester to a hydroxamate as shown in Scheme 12.

10


Scheme 12



Compound of formula 89 can be synthesized starting from
 the intermediate 69 which is coupled with 4-benzyloxybenzoic
 15 acid 81 using a coupling agent such as BOP, producing 82 as
 the major diastereomer with a *cis, cis*-stereochemistry


(Scheme 13). The hydroxyl group can be converted to a sulfonate such as a mesylate **83**. Displacement of **83** with sodium azide produces the azido derivative **84** which is subjected to a hydrogenolysis using a catalyst such as Pd-C
5 to give the primary amine **85**. Mono Boc protection at the amino group is accomplished by reaction of **85** with di-tert-butyl-dicarbonate in THF/H₂O using a mixed base such as NaOH/NaHCO₃. Alkylation of **86** with 4-chloromethyl-2-methylquinoline using a base such as potassium carbonate in
10 acetone at reflux affords the intermediate **87**. Following saponification using a base such as KOH in MeOH/H₂O at an elevated temperature, the resulting carboxylic acid **88** is coupled with hydroxylamine hydrochloride using a coupling agent such as BOP. Removal of the Boc group using an acid
15 such as TFA/CH₂Cl₂ produces the final compound **89**.

Scheme 13



Compounds of formula 92 can be prepared starting from the intermediate 87 (Scheme 14). Saponification using a base such as KOH in MeOH at an elevated temperature followed by deprotection of the Boc group using an acid such as TFA in CH₂Cl₂ produces the amino-carboxylic acid intermediate 90. Reductive amination of 90 with a ketone using a reducing agent such as Na(OAc)₃BH produces the secondary amine 91. The hydroxamic acids of formula 92 can be obtained by coupling the carboxylic acid with hydroxylamine hydrochloride using a coupling agent such as BOP.


Scheme 14



Compounds of formula 95 can be obtained by reductive amination of the intermediate 90 with an aldehyde using a reducing agent such as $\text{Na(OAc)}_3\text{BH}$ followed by conversion of the carboxylic acid to a hydroxamic acid as shown in Scheme 15.

10

Scheme 15




Compounds of formula 103 can be prepared starting from the intermediate 85 (Scheme 16). The mono-benzylated amino derivative 97 can be obtained by reductive amination of the

intermediate **85** with excess benzaldehyde using a reducing agent such as $\text{Na}(\text{OAc})_3\text{BH}$ followed by hydrogenation under atmospheric pressure using a catalyst such as Pd-C. Further alkylation at the benzylamino group by reductive amination
5 with an aldehyde using a reducing agent such as $\text{Na}(\text{OAc})_3\text{BH}$ produces the tertiary amino derivative **98**. After removal of the benzyl group by hydrogenation, the secondary amine is protected by reaction with di-tert-butyl-dicarbonate. Alkylation of the phenol derivative **100** with 4-chloromethyl-
10 2-methylquinoline is followed by saponification of the ethyl ester using a base such as KOH in MeOH at reflux. Conversion of the carboxylic acid to a hydroxamic acid followed by acid deprotection of the Boc group affords compounds of formula
103.


15

Scheme 16




Compounds of formula 108 can be prepared starting from
 5 the intermediate 83 (Scheme 17). Displacement of 83 with
 ArOH produces the aryl ether 104. After removal of the
 benzyl group by hydrogenation using a catalyst such as Pd-C,
 the phenol moiety is alkylated with 4-chloromethyl-2-
 methylquinoline. Saponification of the ethyl ester using a
 10 base such as KOH in MeOH at reflux followed by coupling of
 the resulting carboxylic acid with hydroxylamine
 hydrochloride using a coupling agent such as BOP affords
 compounds of formula 108.

Scheme 17




5 The 3-hydroxyl analog of formula 110 can be prepared
 starting from the intermediate 71. Saponification using a
 base such as LiOH followed by coupling the resulting
 carboxylic acid with hydroxylamine hydrochloride using a
 coupling agent such as BOP provides the the final product
 10 with a *cis, cis*-stereochemistry.

Scheme 18



5 The *cis-trans*-diastereomeric analog of **110** can be prepared starting from the same intermediate **71**. Inversion of the chirality at the 3-hydroxyl position can be accomplished by a Mitsunobu reaction with 4-nitrobenzoic acid. Hydrolysis using a base such as KOH removes the 4-nitrobenzoyl moiety and saponifies the ethyl ester. Coupling of the resulting carboxylic acid with hydroxylamine
10 hydrochloride using a coupling agent such as BOP provides compound of formula **112**.


Scheme 19



5 A series of compound of formula (I) where ring B is
 tetrahydropyran are prepared following the sequence outlined
 in Scheme 20. Treatment of the enolate of
 tetrahydropyranone **113** with Mander's reagent provides β -keto
 ester **114**. Condensation of **114** with amine **115** gives enamine
 10 **116**. Reduction of **116** with sodium (triacetoxy)borohydride
 proceeds stereoselectively to give desired amine **117**.
 Hydrogenolysis and coupling with acid **20** provides ester **119**.
 Ester **119** is converted to hydroxamic acid following sequence
 outline in Scheme 1.


15

Scheme 20




5 Compounds of formula (I) wherein ring B is a
 tetrahydrofuran are prepared as outlined in Schemes 21 and
 22. Michael addition of the sodium salt of methyl glycolate
 120 to methyl acrylate and concomitant Dieckman cyclization
 provides the keto-ester 121. Enamine formation with (R)- α -
 10 methylbenzyl amine 115 and diastereoselective reduction
 gives 123. Hydrogenolysis gives the amino acid ester 124.
 124 is coupled to acid 20 and converted to the hydroxamate
 126.

Scheme 21



- 5 An alternative preparation (Scheme 22) of the amino acid ester **124** begins with the intermediate **121**. Enamine formation with NH₄OAc and acetylation gives **128**. Asymmetric hydrogenation using a chiral rhodium catalyst (*J. Am. Chem. Soc.* **1995**, *117*, 9375) and de-acetylation would yield **124**
- 10 that could be converted similarly to hydroxamate **126**.


Scheme 22



Another procedure for the synthesis of cyclic β -amino acids useful for the preparation of compounds of formula I uses the well documented [2+2] cycloaddition of chlorosulfonylisocyanate with olefins (Scheme 23, Dhar, D.N.; Murthy, K.S.K. *Synthesis* 1986, 437-449). When **130** is reacted with chlorosulfonylisocyanate the resulting β -lactam intermediate **131** can be opened to afford cyclic β -amino acids using a variety of conditions, but most conveniently with chlorotrimethylsilane/methanol. The methyl ester **13** can then be converted to compounds of formula I followed our usual procedure of attaching carboxylic acid **20** to provide **132** then hydroxamic acid **133** is formed by our standard conditions. The *trans* β -amino acids **134** are available by equilibration of *cis* amide ester **132** under basic conditions.

15

Scheme 23




An alternative synthesis of **133** begins with formation of benzyl hydroxamate **136** from *trans* β -hydroxy carboxylate **135** (Scheme 24). Intramolecular cyclization of **136** under Mitsunobu conditions (Belletini, J.R.; Miller, M.J.

5 Tetrahedron Letters **1997**, 38, 167-168) then affords benzyl protected hydroxy β -lactam **137**. Removal of the benzyl group by hydrogenolysis and reduction of the intermediate *N*-hydroxy β -lactam provides **131**, which can be converted to final products as shown in the previous scheme.

10

Scheme 24




15 A synthesis of cyclic lactam β -amino acids begins conveniently with ketone **138** (Scheme 25). Oxime **139** is formed with hydroxylamine hydrochloride, sodium bicarbonate in refluxing methanol and is then treated with *p*-toluenesulfonyl chloride to give Beckmann rearrangement precursor **140**. The rearrangement can be driven by a variety of conditions with silica gel/chloroform providing a straightforward mild procedure to form lactam **141**. Conversion of **141** to hydroxamate **142** uses conditions outline

20 in previous schemes.

25


Scheme 25



5 Compounds of formula **147** can be prepared using the
 protocol described in Scheme 26. Alkylation of methyl 4-
 aminobenzoate or methyl 4-methylaminobenzoate **143** with 4-
 chloromethyl-2-methylquinoline using K_2CO_3 in DMF at 100°C
 produced the secondary or tertiary amine **144**. Following
 10 saponification, the resulting carboxylic acid **145** was
 coupled with a cyclic β -aminoacid derivative using a
 coupling agent such as BOP to give the amide **146**.
 Conversion of the ester in **146** to a hydroxamic acid using
 hydroxylamine afforded the final product **147**.


15

Scheme 26



- 5 Compounds of formula **154** can be prepared according to Scheme 27. An aldehyde **148** was treated with hydroxylamine to provide an oxime **149**. Cycloaddition of **149** with an olefin **150** using bleach produced the isoxazoline derivative **151**. Hydrolysis of the ester followed by coupling with a
- 10 cyclic β -aminoacid derivative afforded the amide **153**. Treatment of **153** with a hydroxylamine solution produced the hydroxamic acid **154**.

Scheme 27




5

Compounds of formula **161** can be prepared using the sequence as illustrated in Scheme 28. An aldehyde **155** was treated with hydroxylamine to give an oxime **156**.


Cycloaddition of **146** with an olefin **157** using bleach produced the isoxazoline derivative **158**. Following saponification, the resulting carboxylic acid **159** was condensed with a cyclic β -amino acid to give the amide **160**. Treatment of **160** with a hydroxylamine solution afforded the hydroxamic acid **161**.

15

Scheme 28



- 5 One diastereomer of a compound of Formula I may display superior activity compared with the others. Thus, the following stereochemistries are considered to be a part of the present invention.



- 10 When required, separation of the racemic material can be achieved by HPLC using a chiral column or by a resolution using a resolving agent such as camphonic chloride as in Steven D. Young, et al, *Antimicrobial Agents and Chemotherapy*, 1995, 2602-2605. A chiral compound of

Formula I may also be directly synthesized using a chiral catalyst or a chiral ligand, e.g., Andrew S. Thompson, et al, *Tetr. Lett.* **1995**, 36, 8937-8940.

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments that are given for illustration of the invention and are not intended to be limiting thereof.

EXAMPLES

Abbreviations used in the Examples are defined as follows: "1 x" for once, "2 x" for twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "mL" for milliliter or milliliters, "¹H" for proton, "h" for hour or hours, "M" for molar, "min" for minute or minutes, "MHz" for megahertz, "MS" for mass spectroscopy, "NMR" for nuclear magnetic resonance spectroscopy, "rt" for room temperature, "tlc" for thin layer chromatography, "v/v" for volume to volume ratio. "α", "β", "R" and "S" are stereochemical designations familiar to those skilled in the art.

Example 1

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-(trifluoromethyl)[1,1'-biphenyl]-4-carboxamide

(1a) Tetrakis(triphenylphosphine)palladium(0) (168 g, 0.1 eq) was added to a mixture of methyl-4-iodobenzoate (0.384 g, 1.44 mmol), 2-trifluoromethylphenylboronic acid (0.3 g, 1.1 eq), sodium carbonate (2 M, 2 eq), ethanol (1.5 mL) and benzene (1.5 mL) at rt. The mixture was heated to 70 °C for 24 h and cooled to rt. The mixture was diluted with ether (20 mL) and washed with water and brine (10 mL each), dried (MgSO₄) and concentrated. Silica gel column chromatography

(ethyl acetate-hexane, 5:95) yielded the desired product (364 mg, 90%). MS found: $(M-H)^- = 279$.

(1b) The ester (364 mg, 1.3 mmol) from reaction (1a),
5 lithium hydroxide (1 M, 10 eq) and methanol (13 mL) were stirred at 40 °C for 4.5 h. The pH of the mixture was adjusted to pH=3 with 1 N HCl and then extracted with ethyl acetate (2 x 30 mL), washed with brine (25 mL) dried ($MgSO_4$) and concentrated. Silica gel column chromatography (ethyl
10 acetate-hexane, 1:1) yielded the desired product (247 mg, 71%). MS found: $(M-H)^- = 265$.

(1c) BOP reagent (239 mg, 1.2 eq) was added to a mixture of
(1S,2R)-2-carbomethoxycyclopentyl amine hydrochloride (81
15 mg, 0.45 mmol), the carboxylic acid (120 mg, 1 eq) from reaction (1b), N,N-diisopropylethylamine (0.12 mL, 2.5 eq) and N,N-dimethylformamide (2.5 mL) at rt. After 2.5 h at rt saturated aqueous ammonium chloride (25 mL) was added and the mixture extracted with ethyl acetate (2 x 20 mL). The
20 mixture was washed with water (10 mL), brine (10 mL), dried ($MgSO_4$) and concentrated. Silica gel column chromatography (ethyl acetate-hexane, 1:3) yielded the desired product (147 mg, 83%). MS found: $(M+H)^+ = 392$.

25 (1d) Preparation of hydroxylamine/potassium hydroxide solution: A solution of potassium hydroxide (2.81 g, 1.5 eq) in methanol (7 mL) was added to a hot solution of hydroxylamine hydrochloride (2.34 g, 33.7 mmol) in methanol (12 mL). After the mixture was cooled to room temperature,
30 the precipitate was removed by filtration. The filtrate was used fresh and assumed hydroxylamine concentration of 1.76 M.

The above freshly prepared 1.76 M hydroxylamine solution (0.5 mL, 4 eq) was added to the methyl ester (80
35 mg, 0.20 mmol) from reaction (1c) in methanol (1 mL) and

stirred at room temperature for 5 h. The mixture was adjusted to pH 7 with 1 N hydrochloric and diluted with ethyl acetate (10 mL). The organic layer was washed with brine (5 mL), dried (MgSO_4) and concentrated. Reverse phase
5 HPLC purification (gradient elution, water/acetonitrile 85-15 to 10-90) provided the hydroxamic acid (50 mg, 63%). MS found: $(\text{M}+\text{H})^+=393$.

Example 2

10 N -{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[2-(trifluoromethyl)phenoxy]benzamide

(2a) 4-hydroxybenzoic acid (240 mg, 1.6 mmol), 2-trifluoromethylphenylboronic acid (300 mg, 1 eq), pyridine
15 (0.68 mL, 5 eq), 4A molecular sieves (100 mg), copper (II) acetate (0.32 g, 1 eq) and dichloromethane (15 mL) were stirred under air atmosphere for 4 days. The mixture was filtered through Celite and the bed washed with ethyl acetate-hexane (1:9, 50 mL) and concentrated. Silica gel
20 column chromatography (ethyl acetate-hexane, 1:10) yielded the desired product (49 mg, 10%). MS found: $(\text{M}+\text{H})^+=296$.

(2b) Using procedures analogous to those described for reactions (1b)-(1d), the methyl ester (49 mg, 0.162 mmol)
25 from reaction (2a) was converted to the desired hydroxamic acid (2.6 mg, 4% for 3 steps). MS found: $(\text{M}+\text{H})^+=409$.

Example 3

30 N -{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(3-methyl-2-pyridinyl)benzamide

(3a) Using procedures analogous to those described for reactions (1a)-(1d), 4-carbomethoxyphenylboronic acid (0.72 g, 2 eq) and 2-bromo-3-methylpyridine (0.34 g, 2.0 mmol)

were converted to the desired hydroxamic acid (40 mg, 10% for 4 steps). MS found: $(M+H)^+=340$.

Example 4

5 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}[1,1'-biphenyl]-4-carboxamide

(4a) Using procedures analogous to those described for reactions (1c)-(1d), the amine hydrochloride (106 mg, 0.59 mmol) and 4-biphenylcarboxylic acid (117 mg, 1 eq) were converted to the desired hydroxamic acid (46.6 mg, 36% for 2 steps). MS found: $(M+H)^+=325$.

Example 5

15 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-phenoxybenzamide

(5a) Using procedures analogous to those described for reactions (1c)-(1d), the amine hydrochloride (111 mg) and 4-phenoxybenzoic acid (132 mg, 1 eq) were converted to the desired hydroxamic acid (24.2 mg, 36% for 2 steps). MS found: $(M+H)^+=341$.

Example 6

25 4-(benzyloxy)-*N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide

(6a) Using procedures analogous to those described for reactions (1c)-(1d), the amine hydrochloride (101 mg, 0.56 mmol), 4-benzyloxybenzoic acid (129 mg, 1 eq) were converted to the desired hydroxamic acid (19.1 mg, 26% for 2 steps). MS found: $(M+H)^+=355$.

Example 7

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-methoxy[1,1'-biphenyl]-4-carboxamide

- 5 (7a) Using procedures analogous to those described for reactions (1a)-(1d), 2-methoxyphenylboronic acid (0.163 g, 1.1 eq), methyl 4-iodobenzoate (265 mg, 1.0 mmol) were converted to the desired hydroxamic acid (30 mg, 9% for 4 steps). MS found: (M+H)⁺=355.

10

Example 8

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-methyl[1,1'-biphenyl]-4-carboxamide

- 15 (8a) Using procedures analogous to those described for reactions (1a)-(1d), methyl 4-iodobenzoate (0.100 g, 0.4 mmol) and 2-methylphenylboronic acid (0.066 g, 1.2 eq) were reacted to give the desired hydroxamic acid (9.5 mg, 7% for 4 steps). MS found: (M+H)⁺=339.

20

Example 9

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(2-methoxyphenoxy)benzamide

- 25 (9a) Using procedures analogous to those described for reactions (2a), (1b)-(1d), 4-hydroxybenzoic acid (152 mg, 1.0 mmol) and 2-methoxyphenylboronic acid (304 mg, 2 eq), were reacted to give the desired hydroxamic acid (5.1 mg, 14% for 4 steps). MS found: (M+H)⁺=371.

30

Example 10

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(2-methylphenoxy)benzamide

(10a) Using procedures analogous to those described for reactions (2a), (1b)-(1d), 4-hydroxybenzoic acid (152 mg, 1.0 mmol) and 2-methylphenylboronic acid (272 mg, 2 eq) were reacted to give the desired hydroxamic acid (23 mg, 7% for 4 steps). MS found: (M+H)⁺=355.

Example 11

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(3-methylphenoxy)benzamide

10

(11a) Using procedures analogous to those described for reactions (1a)-(1d), methyl 4-iodobenzoate (0.663 g, 0.25 mmol) and 3-methylphenylboronic acid (0.408 g, 1.2 eq) were reacted to give the desired hydroxamic acid (91.9 mg, 46% for 4 steps). MS found: (M+H)⁺=339.

15

Example 12

4-(5,8-dihydro-4-quinolinyl)-*N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide

20

(12a) Using procedures analogous to those described for reactions (1a)-(1d), 4-carbomethoxyphenylboronic acid (298 mg, 2 eq) and 4-bromoquinoline were reacted to give the desired hydroxamic acid (25 mg, 9% for 4 steps). MS found: (M+H)⁺=376.

25

Example 13

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-3',5'-dimethyl[1,1'-biphenyl]-4-carboxamide

30

(13a) Using procedures analogous to those described for reactions (1a)-(1d), 4-carbomethoxyphenylboronic acid (0.72 g, 2 eq) and 4-bromo-*meta*-xylene (0.37 g, 2.0 mmol) were reacted to give the desired hydroxamic acid (22 mg, 14% for 4 steps). MS found: (M+H)⁺=353.

35

Example 14

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-6-(2-methylphenyl)nicotinamide

5

(14a) Using procedures analogous to those described for reactions (1a)-(1d), methyl 6-(3-methylphenyl)nicotinate (0.3 g, 1.4 mmol) and 2-methylphenylboronic acid (0.21 g, 1.1 eq) were reacted to give the desired product (18 mg, 17%
10 for 4 steps). MS found: (M+H)⁺=340.

Example 15

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-6-(2-methoxyphenyl)nicotinamide

15

(15a) Using procedures analogous to those described for reactions (1a)-(1d), methyl 6-(3-methylphenyl)nicotinate (378 mg, 1.75 mmol) and 2-methoxyphenylboronic acid (292 mg, 1.1 eq) were reacted to give the desired product (10 mg, 6%
20 for 4 steps). MS found: (M+H)⁺=356.

Example 16

(3*S*,4*S*)-*N*-hydroxy-1-isopropyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

25

(16a) A solution of benzyl methyl maleate (15.0 g, 68.2 mmol) in benzene (1 L) at reflux was treated with a mixture of glycine (8.3 g, 2 eq) and para-formaldehyde (8.3 g, 4 eq) portionwise over 1 h. The mixture was heated at reflux for
30 2 h further. The mixture was filtered through a plug of silica and concentrated providing the desired amine (19.3 g, 100%). MS found: (M+H)⁺=264.

(16b) The amine from reaction (16a) (7.3 g, 27.5 mmol) in
35 *N,N*-dimethylformamide was treated with di-*t*-butyl

dicarbonate (9.0 g, 1.5 eq), triethylamine (5.8 mL, 1.5 eq), and hydroxylamine hydrochloride (0.2 g, 0.1 eq) and stirred for 17 h. The mixture was partitioned between water and ether (100 mL each) and the aqueous layer further extracted with ether (100 mL). The combined ether layers were washed with water and brine (100 mL each) dried (MgSO_4) and concentrated. Silica gel column chromatography (ethyl acetate-hexane, 3:2) yielded the desired ester (6.39 g, 64%). MS found: (M-Bu)=308.

(16c) The ester from reaction (16b) (8.3 g, 22.9 mmol) in methanol (100 mL) was treated with 10% palladium hydroxide on carbon (2.28 g, 0.1 eq) and stirred under a balloon of hydrogen for 3.5 h. The mixture was purged with nitrogen, filtered through a plug of Celite®, washed with excess methanol, and the filtrate concentrated providing the desired acid (6.0 g, 96%). MS found: (M+Na)⁺=296.

(16d) The acid from reaction (16c) (2.73 g, 0.01 mmol) in benzene (100 mL) was treated with triethylamine (2.1 mL, 1.5 eq) and diphenylphosphoryl azide (2.58 mL, 1.2 eq) and stirred at room temperature for 1 h. Benzyl alcohol (1.03 mL, 1.0 eq) was added and the mixture heated to reflux for 1.5 h. The mixture was cooled and partitioned between ethyl acetate and saturated aqueous NaHCO_3 (100 mL each). The organic layer was washed further with NaHCO_3 and brine (100 mL each), dried (MgSO_4), and concentrated. Silica gel column chromatography (ethyl acetate-hexane, 3:2) yielded the desired carbamate (2.86 g, 76%). MS found: (M+H)⁺=379.

(16e) The carbamate from reaction (16d) (2.86 g, 7.6 mmol) in methanol (38 mL) was treated with 10% palladium hydroxide on carbon (0.53 g, 0.1 eq) and stirred under a balloon of hydrogen for 1.5 h. The mixture was purged with nitrogen, filtered through a plug of Celite®, washing with excess

methanol, and the filtrate concentrated providing the desired amine (1.85 g, 100%). MS found: (M-Bu)=189.

(16f) The amine from reaction (16e) (11 g, 45 mmol) in DMF
5 (225 mL) was treated with 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid (19.8 g, 1.5 eq), BOP reagent (32.1 g, 1.6 eq) and N,N-diisopropylethylamine (20 mL, 2.5 eq) and stirred for 5 h. The mixture was partitioned between saturated aqueous NH₄Cl and ethyl acetate
10 (500 mL each). The aqueous layer was further extracted with ethyl acetate (3 X 500 mL). The combined layers were dried (MgSO₄) and concentrated. Silica gel column chromatography (ethyl acetate) yielded the desired racemic amide (13 g). Chiral HPLC separation provided the (3*S*,4*S*)-enantiomer (5.5
15 g, 23%, >98%ee), MS found: (M+H)⁺=520, and the (3*R*,4*R*)-enantiomer (4.5 g, 19%). MS found: (M+H)⁺=520.

(16g) The (3*S*,4*S*)-enantiomer from reaction (16f) (2.11 g, 4.06 mmol) in dichloromethane/trifluoroacetic acid (1:1, 16
20 mL) was stirred for 1 h and concentrated. The residue was dissolved in water and lyophilized to provide the desired amine as the bis(trifluoroacetate) salt (2.6 g, 100%). MS found: (M+H)⁺=420.

(16h) The amine from reaction (16g) (699 mg, 1.08 mmol) in
25 dichloromethane (10 mL) was treated with N,N-diisopropylethylamine (0.77 mL, 4 eq), acetone (0.16 mL, 2 eq) and stirred at rt for 10 min. Na(OAc)₃BH (0.46 g, 2 eq) was then added and the mixture stirred for 1 h. The mixture
30 was partitioned between ethyl acetate and saturated aqueous NaHCO₃ and then further extracted with ethyl acetate (4x). The organic layers were dried (MgSO₄) and concentrated. Silica gel column chromatography (methanol/dichloromethane, 1:4) yielded the desired amine (0.411 g, 89%). MS Found:
35 (M+H)⁺=462.

(16i) Preparation of hydroxylamine/potassium hydroxide solution: A solution of potassium hydroxide (2.81 g, 1.5 eq) in methanol (7 mL) was added to a hot solution of hydroxylamine hydrochloride (2.34 g, 33.7 mmol) in methanol (12 mL). After the mixture was cooled to room temperature, the precipitate was removed by filtration. The filtrate was used fresh and assumed hydroxylamine concentration of 1.76 M.

10

The above freshly prepared 1.76 M hydroxylamine solution (7.6 mL, 15 eq) was added to the methyl ester (400 mg, 0.88 mmol) from reaction (16h) in methanol (9 mL) and stirred at room temperature for 0.5 h. The mixture was adjusted to pH 7 with 1 N hydrochloric acid and diluted with brine (50 mL) and extracted with dichloromethane (5 X 60 mL). The organic layers were dried (MgSO₄) and concentrated. Reverse phase HPLC purification (gradient elution, water/acetonitrile 85-15 to 60-40, 0.1% TFA) provided the hydroxamic acid (207 mg, 34%). MS found: (M+H)⁺=463.

20

Example 17

(3S,4S)-1-(2,2-dimethylpropanoyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

25

(17a) The amine from reaction (16g) (270 mg, 0.42 mmol) in dichloromethane (4 mL) was treated with triethylamine (0.57 mL, 10 eq), trimethylacetyl chloride (0.1 mL, 2 eq) and stirred at rt for 1 h. The mixture was partitioned between ethyl acetate and saturated aqueous NaHCO₃ and then further extracted with ethyl acetate (4x). The organic layers were dried (MgSO₄) and concentrated. Silica gel column chromatography (methanol/dichloromethane, 1:4) yielded the desired amide (189 mg, 90%). MS Found: (M+H)⁺=504.

35

(17b) Using procedures analogous to reaction (16i) the methyl ester from reaction (17a) (0.3 g, 6.0 mmol) was converted to the desired hydroxamic acid (107 mg, 30%). MS Found: (M+H)⁺=505.

Example 18

(3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(methylsulfonyl)-3-pyrrolidinecarboxamide

(18a) The amine from reaction (16g) (206 mg, 0.33 mmol) in dichloromethane (3.3 mL) was treated with triethylamine (0.5 mL, 10 eq), methanesulfonyl chloride (0.05 mL, 2 eq) and stirred at rt for 1 h. The mixture was partitioned between ethyl acetate and saturated aqueous NaHCO₃ and then further extracted with ethyl acetate (4x). The organic layers were dried (MgSO₄) and concentrated. Silica gel column chromatography (methanol/dichloromethane, 1:4) yielded the desired amide (128 mg, 57%). MS Found: (M)⁺=498.

(18b) Using procedures analogous to reaction (16i), the methyl ester from reaction (18a) (224 mg, 4.5 mmol) was converted to the desired hydroxamic acid (104 mg, 37%). MS Found: (M+H)⁺=499

Example 19

(3*S*,4*S*)-*N*-hydroxy-1-methyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

(19a) Using procedures analogous to those described for example (16h-i), the amine from reaction (16g) (0.324 g, 0.5 mmol) and formaldehyde (37%, 0.06 mL, 1.5 eq) were converted to the desired hydroxamic acid (155 mg, 25% 2 steps). MS Found: (M+H)⁺=435.

Example 20

tert-butyl (3*S*,4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate

(20a) 1,3-Pyrrolidinedicarboxylic acid, 4-oxo-1-(1,1-dimethylethyl) 3-methyl ester (2.45 g, 10.1 mmol) in benzene (50 mL) was treated with (R)- α -methylbenzyl amine (1.7 mL, 1.3 eq) and Ytterbium triflate (0.12 g, 0.02 eq) and heated to reflux for 3 h. Concentration, followed by silica gel column chromatography (ethyl acetate/hexane, 1:4) yielded the desired amine (2.49 g, 67%). MS Found: (M+H)⁺=347.

(20b) The product from reaction (20a) (1.0 g, 2.9 mmol) in acetonitrile/acetic acid (1:1, 5.8 mL) was treated with NaBH₃CN and stirred for 0.5 h. The mixture was quenched with NaHCO₃ (aq) until pH 7 and extracted with ethyl acetate (3 X 100 mL). The combined layers were dried (MgSO₄) and concentrated. Silica gel column chromatography (ethyl acetate/hexane, 3:1) yielded the (3*S*,4*S*) amine (59.4 mg, 6%), MS Found: (M)⁺=349, the (3*S*,4*R*) amine (415 mg, 41% mmol) MS Found: (M)⁺=349 and the (3*R*,4*S*) amine (246 mg, 24%) MS Found: (M)⁺=349.

(20c) The (3*S*,4*S*) amine from reaction (20b) (59.4 mg, 0.17 mmol) in methanol/water/acetic acid (10:1:0.25, 1 mL) was treated with 10% palladium hydroxide on carbon (12 mg, 0.1 eq) and stirred under a balloon of hydrogen for 1.5 h. The mixture was purged with nitrogen, filtered through a plug of Celite®, washing with excess methanol and the filtrate concentrated providing the crude amine (37.9 mg) that was used without purification. In an analogous reaction to (1f)

the crude amine was converted to the desired amide (64.5 mg, 72% two steps). MS Found: $(M+H)^+=520$.

(20d) Using procedures analogous to reaction (16i), the methyl ester from reaction (20c) (60 mg, 0.12 mmol) was converted to the desired hydroxamic acid (42.4 mg, 58%). MS Found: $(M+H)^+=521$.

Example 21

(3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

(21a) In an analogous procedure to (16g) the product from reaction (20d) (12 mg, 0.02 mmol) was converted to the desired amine (8.7 mg, 72%). MS Found: $(M+H)^+=421$.

Example 22

tert-butyl 4-[cis-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)pyrrolidinyl]-1-piperidinecarboxylate

(22a) In an analogous procedure to (16g) the racemic product from reaction (16h-16i) (0.25 g, 0.4 mmol) and Boc-4-piperidone (115 mg, 1.5 eq) was converted to the desired hydroxamic acid (49.4 mg, 18% 2 steps). MS Found: $(M+H)^+=604$.

Example 23

cis-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(4-piperidinyl)-3-pyrrolidinecarboxamide

(23a) In an analogous procedure to (16g) the product from reaction (22a) (25.2 mg, 0.03 mmol) was converted to the desired amine (21.4 mg, 82%). MS Found: $(M+H)^+=504$.

Example 24

cis-1-[3-[(1,1-dimethylethoxy)carbonyl]pyrrolidinyl]-*N*-
hydroxy-3-[[[4-[(2-methyl-4-
5 quinolinyl)methoxy]phenyl]carbonyl]amino]-4-
pyrrolidinecarboxamide bis(trifluoroacetate)

(24a) In an analogous procedure to (1g) the racemic product
from reaction (16h-16i) (.25 g, 0.4 mmol) and Boc-3-
10 pyrrolidinone (107 mg, 1.5 eq) was converted to the desired
hydroxamic acid (73.1 mg, 26% 2 steps). MS Found:
(M+H)⁺=590.

Example 25

15 *cis-N*-hydroxy-1-[3-pyrrolidinyl]-3-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-4-
pyrrolidinecarboxamide tris(trifluoroacetate)

(25a) In an analogous procedure to (16g), the product from
20 reaction (24a) (31 mg, 0.04 mmol) was converted to the title
compound (27.0 mg, 86%). MS Found: (M+H)⁺=490.

Example 26

tert-butyl (3*R*,4*R*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-
25 methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-
pyrrolidinecarboxylate

(26a) In an analogous procedure to (16h), the (3*R*,4*R*)-
enantiomer from reaction (16f) (0.2 g, 0.4 mmol) was
30 converted to the desired hydroxamic acid (18.3 mg, 7%). MS
Found: (M+H)⁺=521.

Example 27

tert-butyl (3*S*,4*R*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate

5

(27a) In an analogous procedure to (20c-d), the (3*S*,4*R*)-amine from reaction (20b) (0.4 g, 1.2 mmol) was converted to the hydroxamic acid (53.6 mg, 20%, 2 steps). MS Found: (M+H)⁺=521.

10

Example 28

(3*S*,4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

(28a) In an analogous procedure to (16g), the product from reaction (27a) (11 mg, 0.02 mmol) was converted to the desired amine (5 mg, 45%). MS Found: (M+H)⁺=421.

15

Example 29

tert-butyl (3*R*,4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate

20

(29a) In an analogous procedure to (20c-d), the (3*R*,4*S*)-amine from reaction (20b) (0.2 g, 0.6 mmol) was converted to the hydroxamic acid (132 mg, 59%, 2 steps). MS Found: (M+H)⁺=521.

25

Example 30

(3*R*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

30

(30a) In an analogous procedure to (16g), the product from reaction (29a) (10 mg, 0.02 mmol) was converted to the desired amine (9.8 mg, 98%). MS Found: (M+H)⁺=421.

Example 31

N-{(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(4-pyridinyl)benzamide trifluoroacetate

5 (31a) Tetrakis(triphenylphosphine)palladium(0) (0.64 g, 0.1 eq) was added to a mixture of 4-methoxycarbonylphenylboronic acid (2.0 g, 11.1 mmol), 4-bromopyridine hydrochloride (1.03 g, 1 eq), sodium carbonate (2 M, 2 eq), methanol (10 mL) and benzene (10 mL) at rt. The mixture was
10 heated to 70 °C for 2 h and cooled to rt. The mixture was diluted with ethyl acetate and saturated aqueous sodium bicarbonate (100 mL ea). The organic layers were washed with water and brine (100 mL each), dried (MgSO₄), and concentrated. Silica gel column chromatography (ethyl
15 acetate-hexane, 1:1) yielded the desired product (1.0 g, 85%). MS found: (M+H)⁺=214.

(31b) The ester (1.0 mg, 4.7 mmol) from reaction (31a), lithium hydroxide (1 M, 10 eq) and methanol (50 mL) were
20 stirred at 40 °C for 2 h. The pH of the mixture was adjusted to pH=7 with 1 N HCl and then extracted with ethyl acetate (2 x 100 mL), dried (MgSO₄), and concentrated, yielding the desired acid (400 mg, 43%). MS found:
(M+H)⁺=200.

25

(31c) BOP reagent (266 mg, 1.2 eq) was added to a mixture of (1R,2S)-2-carbomethoxycyclopentyl amine hydrochloride (90 mg, 0.50 mmol), the carboxylic acid (100 mg, 1 eq) from
reaction (31b), N,N-diisopropylethylamine (0.22 mL, 2.5 eq)
30 and N,N-dimethylformamide (1 mL) at rt. After 2.5 h at rt, saturated aqueous ammonium chloride (25 mL) was added and the mixture extracted with ethyl acetate (2 x 20 mL). The mixture was washed with water (10 mL), brine (10 mL), dried (MgSO₄), and concentrated. Silica gel column chromatography

(ethyl acetate) yielded the desired product (113 mg, 69%).
MS found: (M+H)⁺=325.

(31d) Freshly prepared 1.76 M hydroxylamine solution (8 mL,
5 20 eq) was added to the methyl ester (233 mg, 0.7 mmol) from
reaction (31c) in methanol (1 mL) and stirred at room
temperature for 0.5 h. The mixture was adjusted to pH 7
with 1 N hydrochloric acid and diluted with ethyl acetate
(10 mL). The organic layer was washed with brine (5 mL),
10 dried (MgSO₄), and concentrated. Reverse phase HPLC
purification (gradient elution, water/acetonitrile 85-15 to
10-90) provided the desired hydroxamic acid (83 mg, 35%).
MS found: (M+H)⁺=326.

15

Example 32

(3*S*,4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-4-({4-[(2-
methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-
pyrrolidinecarboxamide bis(trifluoroacetate)

20 (32a) The amine from reaction (16g) (224 mg, 0.34 mmol) in
dichloromethane (3 mL) was treated with triethylamine (0.24
mL, 5 eq), 3,3-dimethylpropargyl chloride (0.05 mL, 1.2 eq),
water (1.5 mL), catalytic copper(I) chloride and catalytic
copper turnings and stirred at rt for 1 h. The mixture was
25 diluted with dichloromethane and washed with water (50 mL
each), dried (MgSO₄) and concentrated. Silica gel column
chromatography (methanol/dichloromethane, 1:4) yielded the
desired amine (150 mg, 89%). MS Found: (M+H)⁺=486.

30 (32b) In an analogous procedure to (16i) the ester from
reaction (32a) (150 mg, 0.3 mmol) was converted to the
desired hydroxamic acid (8.4 mg, 6%). MS Found: (M+H)⁺=487.

Example 33

(3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-3-pyrrolidinecarboxamide bis(trifluoroacetate).

5

(33a) The amine from reaction (16g) (204 mg, 0.32 mmol) in dichloromethane (3 mL) was treated with triethylamine (0.18 mL, 4 eq), propargyl bromide (80% wt. in toluene, 0.04 mL, 1.1 eq) and stirred for 4 h. The mixture was partitioned
10 between ethyl acetate and water (25 mL, ea) and the organic layer dried (MgSO₄), filtered and concentrated. Silica gel column chromatography (methanol/dichloromethane, 1:4) yielded the desired amine (38 mg, 26%). MS Found: (M+H)⁺=458.

15

(33b) In an analogous procedure to (16i), the ester from reaction (33a) (38 mg, 0.08 mmol) was converted to the desired hydroxamic acid (5 mg, 13%). MS Found: (M+H)⁺=459.

20

Example 34

(3*S*,4*S*)-1-allyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide bis(trifluoroacetate)

25

(34a) Using analogous procedures to (33a-b), the amine from reaction (16g) (250 mg, 0.39 mmol) and allyl bromide (2 eq) was converted to the desired amine and then to the desired hydroxamate (92 mg, 47% 2 steps). MS Found: (M+H)⁺=461.

30

Example 35

(3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propyl-3-pyrrolidinecarboxamide bis(trifluoroacetate)

(35a) Using analogous procedures to (16h-i), the amine from reaction (16g) (250 mg, 0.39 mmol) and propanal (2 eq) was converted to the desired amine and then to the desired hydroxamic acid (38mg, 22% 2 steps). MS Found: $(M+H)^+=463$.

5

Example 36

(3*S*,4*S*)-*N*-hydroxy-1-(2-methyl-2-propenyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide bis(trifluoroacetate)

10

(36a) Using analogous procedures to (33a), the amine from reaction (16g) (224 mg, 0.35 mmol) and 1-bromo-2-methyl propene (1.1 eq) was converted to the desired ester (110 mg, 67%). MS Found: $(M+H)^+=474$.

15

(36b) Preparation of hydroxylamine/sodium methoxide solution: hydroxylamine hydrochloride (2.4 g, 34.5 mmol) and MeOH (9 mL) were heated to 55 °C. Sodium methoxide (25% wt in MeOH, 11.85 mL, 1.5 eq) was added, the mixture stirred at 20 55 °C for 5 minutes and cooled to room temperature then 0 °C. Filtration afforded a clear solution assumed to be ca. 1.64 M. The solution is prepared and used fresh.

A solution of 1.64 M hydroxylamine solution (3 mL, 20 eq) 25 was added to the amine from reaction (36a) (110 mg, 0.45 mmol) in MeOH (3 mL) then stirred for 1h. The mixture was adjusted to pH 7 with 1 N hydrochloric acid (3 mL). Reverse phase HPLC purification (gradient elution, water/acetonitrile 85-15 to 60-40, 0.1% TFA) provided the 30 hydroxamic acid (67 mg, 25%, 2 steps). MS Found: $(M+H)^+=475$.

Example 37

(3*S*, 4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide bis(trifluoroacetate)

5

(37a) The amine from reaction (32a) (268 mg, 0.55 mmol) was treated with 5% Pd/BaSO₄ (0.1 eq) in methanol (5.5 mL) and stirred under a balloon of hydrogen. The catalyst was removed by filtration and the mixture concentrated.

10 Silica gel column chromatography (methanol/dichloromethane, 1:4) yielded the desired olefin (150 mg, 56%) MS Found: (M+H)⁺=488.

(37b) In an analogous procedure to (16i) the ester from
15 reaction (37a) (106 mg, 0.2 mmol) was converted to the desired hydroxamic acid (50 mg, 32%). MS Found: (M+H)⁺=489.

Example 38

(3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-3-pyrrolidinecarboxamide bis(trifluoroacetate)

20

(38a) The amine from reaction (37a) (61 mg, 0.13 mmol) was treated with 5% Rh/C (0.1 eq) in methanol (1.3 mL) and
25 stirred under a balloon of hydrogen. The catalyst was removed by filtration and the mixture concentrated. Silica gel column chromatography (methanol/dichloromethane, 1:4) yielded the desired amine (37 mg, 60%) MS Found: (M+H)⁺=490.

30

(38b) In an analogous procedure to (16i), the ester from reaction (38a) (37 mg, 0.08 mmol) was converted to the desired hydroxamic acid (14 mg, 25%). MS Found: (M+H)⁺=491.

Example 39

(3*S*,4*S*)-*N*-hydroxy-1-isopentyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
bis(trifluoroacetate)

5

(39a) Using analogous procedures to (16h and 36b), the amine from reaction (16g) (102 mg, 0.16 mmol) and isovaleraldehyde (3 eq) were converted to the desired amine and then to the desired hydroxamic acid (65 mg, 58% 2 steps). MS Found:

10 (M+H)⁺=491.**Example 40**

(3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-neopentyl-3-pyrrolidinecarboxamide bis(trifluoroacetate)

15

(40a) Using analogous procedures to (16h and 36b), the amine from reaction (16g) (60 mg, 0.1 mmol) and pivaldehyde (3 eq) was converted to the desired amine and then to the desired

20 hydroxamic acid (44 mg, 64% 2 steps). MS Found: (M+H)⁺=491.**Example 41**

(3*S*,4*S*)-1-butyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
bis(trifluoroacetate)

25

(41a) Using analogous procedures to (16h and 36b), the amine from reaction (16g) (120mg, 0.19 mmol) and butyraldehyde (2 eq) were converted to the desired amine and then to the

30 desired hydroxamic acid (20 mg, 15% 2 steps). MS Found:

(M+H)⁺=477.

Example 42

(3*S*,4*S*)-1-(3-butenyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
bis(trifluoroacetate)

5

(42a) Using analogous procedures to (33a and 36b), the amine from reaction (16g) (216 mg, 0.33 mmol) and 4-bromo-1-butene (2 eq) were converted to the desired amine and then to the desired hydroxamic acid (68 mg, 30% 2 steps). MS Found:
10 (M+H)⁺=475.

Example 43

(3*S*,4*S*)-1-(2-butyryl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
15 bis(trifluoroacetate)

(43a) Using analogous procedures to (33a and 36b), the amine from reaction (16g) (140 mg, 0.22 mmol) and 1-bromo-2-butyne (1.2 eq) were converted to the desired amine and then to the
20 desired hydroxamic acid (50 mg, 32% 2 steps). MS Found:
(M+H)⁺=473.

Example 44

(3*S*,4*S*)-1-(2-furylmethyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
25 bis(trifluoroacetate)

(44a) Using analogous procedures to (16h and 36b), the amine from reaction (16g) (202 mg, 0.48 mmol) and furfural (1.5
30 eq) were converted to the desired amine and then to the desired hydroxamic acid (110 mg, 32% 2 steps). MS Found:
(M+H)⁺=501.

Example 45

(3*S*,4*S*)-*N*-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide bis(trifluoroacetate)

5

(45a) Using analogous procedures to (16h and 36b), the amine from reaction (16 g) (223 mg, 0.53 mmol) and 5-methyl-furfural (1.5 eq) were converted to the desired amine and then to the desired hydroxamic acid (131 mg, 34% 2 steps).

10 MS Found: (M+H)⁺=515.

Example 46

(3*R*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-furancarboxamide trifluoroacetate

15

(46a) Sodium hydride (60% dispersion in mineral oil) (5.28 g, 1.1 eq) in ether (120 mL) was treated with methyl glycolate (10.8 g, 120 mmol) dropwise, slowly. The mixture was stirred for 30 min and cooled to 0°C. Methyl acrylate (12.39 g, 1.2 eq) was added dropwise to the 0°C solution. The mixture was stirred for 15 min, warmed to room temperature and stirred for 1 h. The reaction was cooled to 0°C and quenched by addition of 5% aqueous H₂SO₄ (200 mL).

20
25 The layers were separated and the aqueous layer extracted with ether (2 X 250 mL). The combined ether layers were washed with brine (150 mL), dried with MgSO₄, filtered and concentrated. Flash chromatography (ethyl acetate/hexanes, 75:25) provided the desired keto-ester (9.9 g, 57%).

30

(46b) The keto-ester (3.3 g, 23.0 mmol) from reaction (46a) in benzene (100 mL) was treated with (*R*)-α-methylbenzyl amine (3.0 mL, 1.02 eq) and yttrium(III)triflate (0.29 g, 0.02 eq) and heated to reflux using Dean-Stark conditions for 3h, then treated with more (*R*)-α-methylbenzyl amine

35

(0.5 mL) and heated 1 h further. The solution was cooled to room temperature and washed with water (50 mL), dried with MgSO_4 , filtered and concentrated. Flash chromatography (ethyl acetate/hexanes, 40:60) provided the desired enamine
5 (2.7 g, 48%). MS found: $(\text{M}+\text{H})^+=248$.

(46c) The enamine (3.43 g, 13.9 mmol) from reaction (46b) in acetic acid/dichloromethane/acetonitrile (1:1:1, 42 mL) was treated with $\text{NaBH}(\text{OAc})$, and stirred for 5 h. The
10 reaction was cooled to 0°C and neutralized with saturated aqueous NaHCO_3 and extracted with dichloromethane (3 X 100 mL), dried (MgSO_4), filtered and concentrated. Flash chromatography (ethyl acetate/hexanes, 30:70) provided the desired amine (1.01 g, 29%) as a 3:1 mixture of
15 diastereomers. MS found: $(\text{M}+\text{H})^+=250$.

(46d) A mixture of the amine (838 mg, 3.38 mmol) from reaction (46c), 20% palladium hydroxide on carbon (240 mg, 0.1 eq) in methanol was shaken on a Parr apparatus under 50
20 psi of hydrogen for 2 h. The mixture was filtered and concentrated to provide the amine (495 mg, 100%). MS found: $(\text{M}+\text{H})^+=146$.

(46e) A mixture of the amine (274 mg, 1.89 mmol) from
25 reaction (46d) in DMF (10 mL) was treated with 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid (691 mg, 1.25 eq), BOP reagent (1.23 g, 1.5 eq), N,N -diisopropylethylamine (1.0 mL, 3.0 eq) and stirred for 5 h. The mixture was partitioned between saturated aqueous NH_4Cl and ethyl acetate (25 mL
30 each). The aqueous layer was further extracted with ethyl acetate (3 X 50 mL). The combined layers were dried (MgSO_4) and concentrated. Silica gel column chromatography (gradient elution: ethyl acetate to methanol/ethyl acetate 1:10) yielded the desired amide (600 mg, 76%). MS found
35 $(\text{M}+\text{H})^+=421$. Analytical chiral HPLC (Chiracel OD column, 1:1

hexane/ethanol, 0.75 mL/min, 254 nm) revealed a 77:23 mixture of enantiomers, which were separated on preparative scale (Chiracel OD column, 98:2 methanol/water) providing the faster running isomer (3S,4R)-enantiomer (120 mg, 15%,
5 >98%ee) and the slower running (3R,4S)-enantiomer (440 g, 55%, >98%ee).

(46f) Using conditions similar to those described for reaction (36b), the slower running (3R,4S) isomer (130 mg,
10 0.3 mmol) was converted to the desired hydroxamic acid (108 mg, 65%). MS Found: (M+H)⁺=422.

Example 47

(3S,4R)-N-hydroxy-4-({4-[(2-methyl-4-
15 quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-
furancarboxamide trifluoroacetate

(47a) Using conditions similar to those described for reaction (36b), the faster running (3S,4R) isomer (38 mg,
20 0.09 mmol) was converted to the desired hydroxamic acid (45 mg, 92%). MS Found: (M+H)⁺=422.

Example 48

(3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-
25 quinolinyl)methoxy]benzoyl}amino)-1-(1,3-thiazol-2-
ylmethyl)-3-pyrrolidinecarboxamide bis(trifluoroacetate)

(48a) Using analogous procedures to (16h) and (36b), the amine from reaction (16g) (229 mg, 0.55 mmol) and 2-
30 thiazolecarboxaldehyde (1.5 eq) were converted to the desired amine and then to the desired hydroxamic acid (186 mg, 46%, 2 steps). MS Found: (M+H)⁺=518.

Example 49

(3S,4S)-1-acetyl-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide trifluoroacetate

5

(49a) A BIO-RAD Poly-Prep® chromatography column (0.8 X 4 cm) vessel was charged with a solution of the free base of the amine from reaction (16g) (0.1 g, 0.24 mmol) in dichloromethane (4 mL). The mixture was then treated with PS-DIEA resin (Argonaut Technologies) (215 mg, 3 eq) followed by acetyl chloride (0.026 mL, 1.5 eq). The vessel was sealed and rotated on a Labquake® rotisserie (Barnstead/Thermolyne) for 2 h. PS-Trisamine resin (Argonaut Technologies) (300 mg, 3 eq) was then added, the vessel sealed and rotated for 1 h. The reaction mixture was then filtered and the resins rinsed with dichloromethane (4 mL). The filtrate was concentrated in a test tube to give the desired amide as a white solid that was taken on without further purification. MS found: (M+H)⁺=462.

20

(49b) The crude amide from reaction (49a), in a test tube, was treated with a 1.64M solution of NH₂OH/NaOMe/MeOH, as prepared in example (36b) (2.9 mL, 20 eq), at 0°C and warmed to ambient temperature while agitating on a Vortex (1 h). The mixture was quenched with 1N HCl (2.9 ml) and the ensuing precipitate filtered affording a white solid. The product was converted to its TFA salt by dissolution in 0.2 N TFA (5 mL), filtration through a 0.45 µ PTFE membrane, and freeze-drying yielding the desired hydroxamate as a white amorphous solid (90.7 mg, 66% yield, 2 steps). MS Found: (M+H)⁺=463.

30

Example 50

(3S,4S)-N-hydroxy-1-isobutyryl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide trifluoroacetate

35

(50a) Using procedures analogous to (49a)-(49b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and isobutyryl chloride (0.038 mL, 1.5 eq) were converted to the
5 desired amide and then to the desired hydroxamic acid (112 mg, 77% yield, 2 steps). MS Found (M+H)⁺=491.

Example 51

(3S,4S)-N-hydroxy-1-(3-methylbutanoyl)-4-({4-[(2-methyl-4-
10 quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
trifluoroacetate

(51a) Using procedures analogous to (49a)-(49b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and
15 3-methylbutanoyl chloride (0.044 mL, 1.5 eq) were converted to the desired amide and then to the desired hydroxamic acid (116 mg, 78% yield, 2 steps). MS Found (M+H)⁺=505.

Example 52

(3S,4S)-1-(cyclopropylcarbonyl)-N-hydroxy-4-({4-[(2-methyl-
20 4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
trifluoroacetate

(52a) Using procedures analogous to (49a)-(49b), the free
25 base of the amine from reaction (16g) (0.1g, 0.24 mmol) and cyclopropanecarbonyl chloride (0.033 mL, 1.5 eq) were converted to the desired amide and then to the desired hydroxamic acid (40 mg, 28% yield, 2 steps). MS Found (M+H)⁺=489

30

Example 53

(3S,4S)-1-(cyclobutylcarbonyl)-N-hydroxy-4-({4-[(2-methyl-4-
35 quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
trifluoroacetate

(53a) Using procedures analogous to (49a)-(49b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and cyclobutanecarbonyl chloride (0.042 mL, 1.5 eq) were converted to the desired amide and then to the desired hydroxamic acid (83 mg, 56% yield, 2 steps). MS Found (M+H)⁺=503.

Example 54

(3S,4S)-N-hydroxy-1-(methoxyacetyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide trifluoroacetate

(54a) Using procedures analogous to (49a)-(49b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and methoxyacetyl chloride (0.033 mL, 1.5 eq) were converted to the desired amide and then to the desired hydroxamic acid (85 mg, 59% yield, 2 steps). MS Found (M+H)⁺=493.

Example 55

(3S,4S)-1-(2-furoyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide trifluoroacetate

(55a) Using procedures analogous to (49a)-(49b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and 2-furoyl chloride (0.036 mL, 1.5 eq) were converted to the desired amide and then to the desired hydroxamic acid (75 mg, 50% yield, 2 steps). MS Found (M+H)⁺=515.

30

Example 56

(3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-thienylcarbonyl)-3-pyrrolidinecarboxamide trifluoroacetate

(56a) Using procedures analogous to (49a)-(49b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and

2-thienylcarbonyl chloride (0.039 mL, 1.5 eq) were converted to the desired amide and then to the desired hydroxamic acid (70 mg, 46% yield, 2 steps). MS Found (M+H)⁺=531.

5

Example 57

(3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propionyl-3-pyrrolidinecarboxamide trifluoroacetate

10 (57a) Using procedures analogous to (49a)-(49b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and propionyl chloride (0.031, 1.5 eq) were converted to the desired amide and then to the desired hydroxamic acid (71 mg, 51% yield, 2 steps). MS Found (M+H)⁺=477.

15

Example 58

(3R,4S)-4-{[4-(2-butynyloxy)benzoyl]amino}-N-hydroxy-tetrahydro-3-furancarboxamide

20 (58a) Using procedures analogous to (1c) and (16i) the amine from reaction (46d) (31 mg, 0.21 mmol, 52%ee) and (49 mg, 1.2 eq) were converted the amide and then hydroxamic acid (22 mg, 33%). MS Found (M+H)⁺=319.

25

Example 59

N-{(1R,2S)-2-[(hydroxyamino)carbonyl]-4-oxocyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide trifluoroacetate

(59a) 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide
30 hydrochloride (73.0 g, 1.5 eq) was added to a mixture of (1S,2R)-1-methyl cis-1,2,3,6-tetrahydrophthalate (46.8 g, 254.2 mmol), benzyl alcohol (30.2 g, 1.1 eq) and 4-dimethylaminopyridine (3.0 g, 0.1 eq) in dichloromethane (470 mL) at 0°C and let warm to room temperature. After 3
35 h, the solution was cooled to 0°C and 1N HCl (300 mL) was

added. The mixture was extracted with dichloromethene (2 X 300 mL). The organic layer was washed successively with brine (200 mL), dried (MgSO_4) and concentrated. 70 g of crude product was obtained and purified by silica gel column chromatography (ethyl acetate-hexane (1:10)). The desired compound was obtained as colorless oil (68.8 g, 99%). MS found: $(\text{M}+\text{H})^+=275$.

(59b) The olefin from reaction (59a) (68.8 g, 251 mmol) was added dropwise to a solution of potassium permanganate (125 g, 3.2 eq) in water (400 mL) at 0°C . After 20 min stirring at 0°C , TLC showed the presence of starting olefin. Another portion of water (400 mL) and potassium permanganate (125 g) were added. After 20 min the reaction was complete (by TLC). Sulfur dioxide was bubbled through the mixture at 0°C until the color of the solution turned pink from purple (2 h). The mixture was filtered and the filtrate was acidified by adding concentrated HCl to pH=1. The reaction was extracted with ethyl acetate (5 X 500 mL) and the combined organic layers were dried over sodium sulfate. After filtration and concentration, the target diacid was obtained (74 g, 87% yield) and taken on without further purification. MS found: $(\text{M}+\text{H})^+=339$.

(59c) Sodium acetate (11.4 g, 138 mmol) was added to a solution of the dicarboxylic acid from reaction (59b) (57 g, 169 mmol) in acetic anhydride (43 g, 421 mmol) at rt. The reaction was refluxed for 2h, and cooled to rt. Acetic anhydride was removed by rotary evaporation under reduced pressure. Water (600 mL) was added and the residue was extracted with ethyl acetate (1 L X 2). The combined organic layers were dried over MgSO_4 . After filtration and concentration, the crude ketone was obtained. Purification by silica gel column chromatography (Ethyl acetate 33% in hexane) furnished the target ketone (21 g, 45% yield). MS found: $(\text{M})^+=276$.

(59d) The ketone from reaction (59c) (7g, 25.3mmol), ethylene glycol (15.7 g, 253.3 mmol) and p-toluenesulfonic acid monohydrate (481 mg, 2.5 mmol) were refluxed in benzene (507
5 mL) using Dean-Stark conditions for 1h. After cooling, the reaction was quenched with saturated sodium bicarbonate solution (80mL) and extracted with ethyl acetate (2 X 100mL). The combined organic layers were washed with brine (80 mL), dried over magnesium sulfate, filtered and
10 concentrated. The purification by silica gel column chromatography (Ethyl acetate 33% in hexane) furnished the target ketal (7.8 g, 97% yield). MS found: (M+H)⁺=321.

(59e) The ketal from reaction (59d) (7.1 g, 22.3 mmol) and
15 palladium hydroxide on carbon (20 wt%, 780 mg, 0.1 e q) were stirred in ethyl acetate (11 mL) under hydrogen (balloon) at rt for 45 min. After filtration and concentration, the target carboxylic acid (5.1 g, 99% yield) was obtained. MS found: (M+H)⁺=231.

20

(59f) To a solution of the carboxylic acid from reaction (59e) (447 mg, 1.9 mmol) in acetone was added triethylamine (393 mg, 3.9 mmol) and ethyl chloroformate (316 mg, 2.9 mmol) at -25°C under nitrogen. After stirring at rt for 10
25 min, sodium azide (316 mg, 4.9 mmol) dissolved in water (0.5 mL) was added to the mixture at -10°C. The reaction was stirred at rt for 1h, and quenched with water (20 mL). It was extracted with CH₂Cl₂ (2 X 50 mL), washed with brine (30 mL), dried over MgSO₄, filtered, and concentrated. The crude
30 azide was dissolved in benzene (2.6 mL) and refluxed for 1h. Benzyl alcohol (210 mg, 1.9 mmol) and p-toluenesulfonic acid (18 mg, 0.1 mmol) were added and the mixture was refluxed for 1h. After cooling to rt, the reaction was quenched with water and extracted with CH₂Cl₂ (2 X 50 mL). The combined
35 organic layer was washed with brine (50 mL), dried over MgSO₄, filtered, and concentrated. The crude was purified by

silica gel column chromatography (33%EtOAc in hexane). The target amide (393 mg, 60% yield) was obtained. MS found: $(M+H)^+=236$.

- 5 (59g) The Cbz protected amine from reaction (59f) (3.8 g, 11.3 mmol), triethylamine (1.1 g, 11.3 mmol) and palladium hydroxide on carbon (20 wt%, 400 mg, 0.56 mmol) were stirred in EtOAc (57mL) under hydrogen (50psi) at rt for 2h. After filtration and concentration, the target amine was
10 obtained (2.2 g, 96% yield). MS found: $(M+H)^+=202$.

- (59h) To the solution of the amine from reaction (59g) (2.2 g, 11.3 mmol), 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid (3.49 g, 11.9 mmol) and diisopropylethylamine (3.7 g, 28.3 mmol) in DMF (57 mL) was added BOP reagent (6 g, 13.6 mmol) at 0°C. After stirring at rt for 3h, the reaction was quenched with NH_4Cl (100 mL) at 0°C, extracted with EtOAc (300 mL X 2), washed with brine (100 mL), dried over Na_2SO_4 , filtered and concentrated. The crude (14g) was purified by
15 silica gel column chromatography (Gradient elution ethyl acetate/hexane, 1:1 to ethyl acetate) to give the target compound amide (5.4 g, 99% yield). MS found: $(M+H)^+=477$.
20

- (59i) Using conditions analogous to (36b) and the ester from reaction (59h) (300 mg, 0.63 mmol) was converted to the
25 desired hydroxamic acid (220 mg, 73% yield. $(M+H)^+=478$.

- (59j) The compound from reaction (59i) (24 mg, 0.0511 mmol) was dissolved in TFA (5 mL). After 10 min stirring at rt, TFA was evaporated. The crude was dissolved in DMSO and
30 purified by HPLC. The TFA salt of target hydroxyamine compound was obtained (28 mg, 99% yield). MS found: $(M+H)^+=434$.

Example 60

N-((1R,2S,4R)-4-hydroxy-2-
[(hydroxyamino)carbonyl]cyclopentyl)-4-[(2-methyl-4-
quinolinyl)methoxy]benzamide trifluoroacetate

- 5 (60a) The compound from reaction (59h) (47 mg, 0.1 mmol) in THF (0.4 mL) was treated with HCl (3N solution, 0.4 mL) at rt for 3h. The reaction was quenched with saturated NaHCO₃ to basic solution at 0°C. The mixture was extracted with
10 ethyl acetate (20 mL X 2), washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated. Silica gel chromatography (dichloromethane/methanol, 20:1) provided the desired ketone (25 mg, 59 % yield). MS found: (M+H)⁺=231
- 15 (60b) To a solution of the ketone from reaction (60a) (520 mg, 1.2 mmol) in MeOH (120 mL) was added NaBH₄ at 0°C. The reaction was stirred at rt for 20 min. MeOH was evaporated. The reaction was diluted with ethyl acetate and quenched with saturated aqueous NH₄Cl at 0°C. White solid was
20 filtered and the filtrate was extracted with EtOAc (200 mL X 2), dried over Na₂SO₄, filtered and concentrated. The crude alcohol was purified by silica gel column chromatography (5% MeOH in CH₂Cl₂) to give two diastereomers. Major diastereomer (380 mg, 73% yield) and minor one (95 mg, 18%)
25 were obtained. MS found: (M+H)⁺=435.

- (60c) Using conditions analogous to (36b) and the major diastereomer from reaction (60b) (50 mg, 0.12 mmol) was converted to the desired hydroxamic acid (29 mg, 46% yield).
30 (M+H)⁺=436.

Example 61

N-((1R,2S,4S)-4-hydroxy-2-
[(hydroxyamino)carbonyl]cyclopentyl)-4-[(2-methyl-4-
35 quinolinyl)methoxy]benzamide trifluoroacetate

(61a) Using conditions analogous to (36b) the minor diastereomer from reaction (60b) (50 mg, 0.12 mmol) was converted to the desired hydroxamic acid (57 mg, 91% yield. $(M+H)^+=436$.

5

Example 62

(3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-tetrahydro-2H-pyran-4-yl-3-pyrrolidinecarboxamide bis(trifluoroacetate)

10

(62a) Using analogous procedures to (16h and 36b), the amine from reaction (16g) (205 mg, 0.49 mmol) and tetrahydro-4H-pyran-4-one (0.068 mL, 1.5 eq) were converted to the desired amine and then to the desired hydroxamic acid (100 mg, 28%, 2 steps). MS Found: $(M+H)^+=505$.

15

Example 63

methyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

20

(63a) A BIO-RAD Poly-Prep® chromatography column (0.8 X 4 cm) vessel was charged with a solution of the free base of the amine from reaction (16 g) (0.1 g, 0.24 mmol) in dichloromethane (6 mL). The mixture was then treated with PS-DIEA resin (Argonaut Technologies) (215 mg, 3 eq) followed by methylchloroformate (0.028 mL, 1.5 eq). The vessel was sealed and rotated on a Labquake® rotisserie (Barnstead/Thermolyne) for 6h. PS-Trisamine resin (Argonaut Technologies) (300 mg, 3 eq) was then added, the vessel sealed and rotated for 16h. The reaction mixture was then filtered and the resins rinsed with dichloromethane (4 mL). The filtrate was concentrated in a test tube to give the desired carbamate as a white solid that was taken on without further purification. MS found: $(M+H)^+=478$.

25

30

35

(63b) The crude carbamate from reaction (49a), in a test tube, was treated with a 1.64M solution of NH₂OH/NaOMe/MeOH, as prepared in example (36b) (2.9 mL, 20 eq), at 0°C and warmed to ambient temperature while agitating on a Vortex (1 h). The mixture was quenched with 1N HCl (2.9 mL) and the ensuing precipitate filtered affording a white solid. The product was converted to its TFA salt by dissolution in 0.2 N TFA (5 mL), filtration through a 0.45 µ PTFE membrane, and freeze-drying yielding the desired hydroxamate as a white amorphous solid (119 mg, 84% yield, 2 steps). MS Found: (M+H)⁺=479.

Example 64

ethyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

(64a) Using procedures analogous to (63a)-(63b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and ethylchloroformate (0.034 mL, 1.5 eq) were converted to the desired carbamate and then to the desired hydroxamic acid (136 mg, 94% yield, 2 steps). MS Found (M+H)⁺=493.

Example 65

propyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

(65a) Using procedures analogous to (63a)-(63b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and propylchloroformate (0.040 mL, 1.5 eq) were converted to the desired carbamate and then to the desired hydroxamic acid (134 mg, 90% yield, 2 steps). MS Found (M+H)⁺=507.

Example 66

allyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

5

(66a) Using procedures analogous to (63a)-(63b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and allylchloroformate (0.038 mL, 1.5 eq) were converted to the desired carbamate and then to the desired hydroxamic acid (122 mg, 82% yield, 2 steps). MS Found (M+H)⁺=505.

10

Example 67

isopropyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

15

(67a) Using procedures analogous to (63a)-(63b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and isopropylchloroformate (1M in toluene, 0.36 mL, 1.5 eq) were converted to the desired carbamate and then to the desired hydroxamic acid (127 mg, 85% yield, 2 steps). MS Found (M+H)⁺=507.

20

Example 68

2-propynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

25

(68a) Using procedures analogous to (63a)-(63b), the free base of the amine from reaction (16 g) (0.1 g, 0.24 mmol) and 2-propynylchloroformate (0.035 mL, 1.5 eq) were converted to the desired carbamate and then to the desired hydroxamic acid (88 mg, 60% yield, 2 steps). MS Found (M+H)⁺=503.

30

35

Example 69

2-butynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

5

(69a) Using procedures analogous to (63a)-(63b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and 2-butynylchloroformate (0.041 mL, 1.5 eq) were converted to the desired carbamate and then to the desired hydroxamic acid (96 mg, 63% yield, 2 steps). MS Found (M+H)⁺=517.

10

Example 70

3-butenyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

15

(70a) Using procedures analogous to (63a)-(63b), the free base of the amine from reaction (16 g) (0.1 g, 0.24 mmol) and 3-butenylchloroformate (0.045 mL, 1.5 eq) were converted to the desired carbamate and then to the desired hydroxamic acid (109 mg, 72% yield, 2 steps). MS Found (M+H)⁺=519.

20

Example 71

benzyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

25

(71a) Using procedures analogous to (63a)-(63b), the free base of the amine from reaction (16g) (0.1g, 0.24 mmol) and benzylchloroformate (0.051, 1.5 eq) were converted to the desired carbamate and then to the desired hydroxamic acid (98 mg, 61% yield, 2 steps). MS Found (M+H)⁺=554.

30

Example 72

N-{(1R,2S)-4-(dimethylamino)-2-
[(hydroxyamino)carbonyl]cyclopentyl}-4-[(2-methyl-4-
quinolinyl)methoxy]benzamide bis(trifluoroacetate

5

(72a) Using procedures analogous to examples (36a) and (36b) the ketone from example (60a) (50mg, 0.12mmol) and dimethyl amine were converted to the desired amine and then the desired hydroxamic acid (74 mg, 27% yield). MS found:

10 (M+H)⁺=463

Example 73

(3S,4S)-4-[[4-(2-butyryloxy)benzoyl]amino]-N-hydroxy-1-
isopropyl-3-pyrrolidinecarboxamide

15

(73a) The amide from reaction (16g) (510 mg, 1.10 mmol) in AcOH (2 mL) and dichloromethane (4 mL) was treated with zinc dust (217 mg, 3 eq) and stirred for 24 h at ambient temperature. The remaining zinc was filtered off and the filtrate neutralized with saturated aqueous NaHCO₃ (5 mL) and extracted with ethyl acetate (3 X 10 mL). The combined extracts were dried (MgSO₄) and concentrated. Silica gel chromatography (ethyl acetate) provided the desired phenol (259 mg, 77%). MS Found: (M+H)⁺ 307.

25

(73b) 2-Butyn-1-ol (105 mg, 1.5 eq) was treated with triphenylphosphine (393 mg, 1.5 eq) and diethylazodicarboxylate (0.24 mL, 1.5 eq) in benzene (10 mL). The phenol from reaction (73a) (307 mg, 1.0 mmol) in benzene (5 mL) was added via cannula and the mixture stirred for 12 h. The mixture was quenched with water (20 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were dried (MgSO₄), filtered and concentrated. Silica gel chromatography (ethyl acetate) provided the desired ether (200 mg, 45%). MS Found: (M+H)⁺=459.

35

(73c) Using procedures analogous to (36b), the ester from reaction (73b) (200 mg, 0.44 mmol) was converted to the desired hydroxamic acid (57 mg, 28% yield). MS Found (M+H)⁺=360.

5

Example 74

N-{(1R,2S)-4,4-difluoro-2-
[(hydroxyamino)carbonyl]cyclopentyl}-4-[(2-methyl-4-
10 quinoliny)lmethoxy]benzamide trifluoroacetate

(74a) To a heterogeneous solution of the ketone from example (60a) (50 mg, 0.12 mmol) in toluene (0.5 mL) was added diethylaminosulfur trifluoride (47 mg, 0.29 mmol) at 0°C.
15 The reaction was stirred at rt for 3 days. The mixture was poured into ice water, extracted with EtOAc (10 mL X 2), dried over Na₂SO₄, filtered and concentrated. Crude 60mg was purified by silica gel column chromatography (EtOAc 90% in hexane). The target difluoride compound (18 mg, 34% yield)
20 was obtained. MS found: (M+H)⁺=455.

(74b) Using conditions analogous to (36b) and the ester from example (74a) (18 mg, 0.0.04 mmol) was converted to the desired hydroxamic acid (11 mg, 49% yield. (M+H)⁺=456.

25

Example 75

(3S,4S)-N-hydroxy-1-isopropyl-4-[[4-(2-
methylphenoxy)benzoyl]amino]-3-pyrrolidinecarboxamide
trifluoroacetate

30

(75a) Using procedures analogous to (2a) and (36b), The phenol from reaction (73a) (100 mg, 0.33 mmol) and 2-methylphenylboronic acid (135 mg, 0.4 mmol) were converted the desired ester and then hydroxamic acid (23 mg, 41%
35 yield). MS Found: (M+H)⁺=398.

Example 100

cis-*N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide trifluoroacetate

5
(100a) A mixture of methyl (+/-)-*cis*-2-aminocyclopentanecarboxylate hydrochloride (150 mg, 0.83 mmol), 4-(2-methyl-4-quinolinylmethoxy)benzoic acid (250 mg, 1 eq), DIEA (0.43 mL, 3 eq) and BOP (0.31 g, 1.2 eq) in DMF
10 (4 mL) was stirred at rt for 2 h. Following addition of sat NH₄Cl, the mixture was extracted with ethyl acetate. The extracts were washed with sat NaHCO₃, brine, dried (MgSO₄) and concentrated in vacuo. Silica gel chromatography (ethyl acetate-hexane, 60:40 then 80:20) provided the desired amide
15 (330 mg, 95%). MS (M+H)⁺=419.

(100b) The freshly prepared 1.76 M solution of hydroxylamine (3.0 mL, 9 eq) was added to the ester from (100a) (240 mg, 0.57 mmol) at rt. After 30 min at this temperature, the
20 mixture was acidified to pH 5 with 4 N HCl. The desired hydroxamic acid precipitated out and collected by filtration (146 mg, 61%). The free base was then converted to the trifluoroacetate salt in quantitative yield by reaction with TFA. MS found: (M+H)⁺=420.

25

Example 101

trans-*N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide trifluoroacetate

30

(101a) The *cis*-isomer from (100a) (90 mg, 215 mmol) was dissolved in toluene (10 mL) and heated to reflux for 45 h. The mixture was filtered through a pad of silica gel and filter pad washed with EtOAc until free of product. The

filtrate was concentrated to give a 1:1 mixture of trans and cis isomers (77.2 mg, 86%). MS found: $(M+H)^+ = 419$.

(101b) Following a procedure similar to that used for step
5 (100b), the title compound was prepared. The two isomers were separated by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the trans hydroxamic acid product (25%). MS $(M+H)^+ = 420$.

10

Example 102

(1*S*,2*R*)-*N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide trifluoroacetate

15

(102a-b) Following the procedures similar to that used for steps (100a-b), but using methyl (1*S*, 2*R*)-2-aminocyclopentanecarboxylate hydrochloride (Davies, S. G.; Ichihara, O.; Lenoir, I.; Walters, A. S. *J. Chem. Soc. Perkin Trans.* **1994**, 1411), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS $(M+H)^+ = 420$.

25

Example 103

(1*R*,2*S*)-*N*-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide trifluoroacetate

30

(103a-b) Following the procedures similar to that used for steps (100a-b), but using methyl (1*R*, 2*S*)-2-aminocyclopentanecarboxylate hydrochloride (Davies, S. G.; Ichihara, O.; Lenoir, I.; Walters, A. S. *J. Chem. Soc.*

Perkin Trans. 1994, 1411), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS

5 (M+H)⁺=420.

Example 104

cis-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-
10 *cyclohexanecarboxamide trifluoroacetate*

(104a-b) Following the procedures similar to that used for steps (100a-b), but using (+/-)-*cis-2-aminocyclohexanecarboxylate hydrochloride*, the title
15 compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=434.

Example 105

trans-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-
20 *cyclohexanecarboxamide trifluoroacetate*

(105a-b) Following the procedures similar to that used for steps (101a-b), but using the cyclohexane analogue, the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic
25 acid product. MS (M+H)⁺=434.
30

Example 108

trans-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-
[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-
pyrrolidinecarboxamide trifluoroacetate

5

(108a) A solution of benzyl methyl fumarate (26.4 g, 113 mmol) in toluene (200 mL) was heated to reflux. A suspension of glycine (11.0 g, 1.3 eq) and para-formaldehyde (4.40 g, 1.3 eq) in toluene (50 mL) was added over 1 h. The mixture
10 was maintained at reflux for 2 h after completion of addition. Additional amount of para-formaldehyde (1 eq) and glycine (1 eq) were added. After additional 30 min at reflux, the mixture was cooled and filtered. The filtrate was diluted with ethyl acetate (300 mL) and washed with sat
15 Na₂CO₃ (2 x 10 mL), brine (10 mL), dried (MgSO₄) and concentrated. The crude material was used in the next step without purification. MS (M+H)⁺=278.

(108b) DIEA (34.8 mL, 1.8 eq) and (BOC)₂O (36.3 mL, 1.5 eq)
20 were added to a solution of the crude amine from (108a) in CH₂Cl₂ (600 mL) at 0 °C. After 2 days at rt, additional amount of DIEA (1 eq) and (BOC)₂O (1 eq) were added. After a total of 3 days, the mixture was washed with sat NaHCO₃ (2 x 20 mL), brine (20 mL), dried (MgSO₄) and concentrated in
25 vacuo. Silica gel chromatography (ethyl acetate-hexane, 10:90 then 20:80) provided the desired product (7.60 g, 20% over 2 steps). MS (M+H)⁺=378.

(108c) A mixture of the benzyl ester from (108b) (7.40 g, 19.6 mmol) and Pd(OH)₂ on carbon (1.90 g) in methanol (150 mL) was purged with hydrogen and stirred under balloon pressure hydrogen for 3 h. The catalyst was removed by filtration and the filtrate was concentrated to give the
30 desired carboxylic acid (5.64 g, 100%). MS (2M-H)⁻=573.

35

(108d) Et₃N (3.7 mL, 1.5 eq) and DPPA (4.6 mL, 1.2 eq) were added to a solution of the carboxylic acid from (108c) (5.12 g, 17.8 mmol) in benzene (150 mL). After 2 h at rt, benzyl alcohol (2.2 mL, 1.2 eq) was added. The mixture was heated to reflux for 1 h, cooled to rt, washed with sat NaHCO₃ (2 x 10 mL), brine (10 mL), dried (MgSO₄) and concentrated in vacuo. Silica gel chromatography (ethyl acetate-hexane, 20:80 then 30:70) provided the desired product (4.50 g, 64%). MS (M+H)⁺=393.

10

(108e) A mixture of the Cbz-protected intermediate from (108d) (2.30 g, 5.86 mmol) and Pd on carbon (0.60 g) in methanol (100 mL) was purged with hydrogen and stirred under balloon pressure hydrogen for 2 h. The catalyst was removed by filtration and the filtrate was concentrated to give the desired amine (1.52 g, 100%). MS (2M+H)⁺=517.

(108f) Following the procedures similar to that used for step (100a), but using the amine from (108e) (1.35 g, 523 mmol), the amide was prepared. Silica gel chromatography (ethyl acetate-hexane, 50:50 then 60:40) provided the desired product (2.70 g, 85%). MS (M+H)⁺=534.

(108g) Following the procedures similar to that used for step (100b), the ester from (108f) (165 mg, 260 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product (85 mg, 52%). MS (M+H)⁺=521.

30

Example 109

trans-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide bis(trifluoroacetate)

35

(109a) The product from example 108 (50 mg, 0.079 mmol) was mixed with TFA (1 mL) and CH₂Cl₂ (2 mL) and stirred for 1 h. Concentration in vacuo provided the title compound (52 mg, 100%). MS (M+H)⁺=421.

5

Example 110

cis-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide trifluoroacetate

10

(110a-b) Following the procedures similar to that used for steps (101a-b), the intermediate from (108f) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=521.

15

Example 111

cis-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide bis(trifluoroacetate)

20

(111a) Following the procedure similar to that used for step (109a), the product from (110a) was converted to the title compound. MS (M+H)⁺=421.

25

Example 112

(3*S*,4*R*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide trifluoroacetate

30

(112a) DIEA (82 mL, 2.5 eq) and (BOC)₂O (36.0 g, 1.3 eq) were added to a solution of methyl 4-oxo-3-piperidinecarboxylate (24.6 g, 137 mmol) in CH₂Cl₂ (600 mL) at 0°C. After at rt

overnight, sat NaHCO_3 (50 mL) was added. The mixture was washed with water (2x30 mL), brine (30 mL), dried (MgSO_4) and concentrated in vacuo. Silica gel chromatography (ethyl acetate-hexane, 50:50) provided the desired product (29.8 g, 93%).

(112b) $\text{Yb}(\text{OTf})_3$ (1.41 g, 0.02 eq) was added to a mixture of the intermediate from (112a) (29.2 g, 113 mmol) and (R)- α -methylbenzylamine (16.1 mL, 1.1 eq) in benzene. The mixture was heated to reflux for 3 h with azotropic removal of water using a Dean-Stark trap. The mixture was concentrated in vacuo. The residue was filtered through a silica gel pad and the filter cake washed with ethyl acetate-hexane (10:90) until free of product. The filtrate was concentrated to give the desired enamine product (40.8 g, 100%). MS $(\text{M}+\text{H})^+=361$.

(112c) $\text{NaHB}(\text{OAc})_3$ (58.8 g, 2.5 eq) was added to a solution of the enamine from (112b) (40.0 g, 111 mmol) in acetic acid (180 mL) and acetonitrile (180 mL) at 0°C . After 2 h at 0°C , the mixture was concentrated in vacuo. The residue was diluted with CH_2Cl_2 (1 L), washed with Na_2CO_3 (3x50 mL), brine (50 mL), dried (MgSO_4) and concentrated in vacuo. Silica gel chromatography (ethyl acetate-hexane, 10:90 then 20:80) provided the desired amine product as a 5:1 mixture of two diastereomers as judged by ^1H NMR (37.0 g, 92%). MS $(\text{M}+\text{H})^+=363$.

(112d) $\text{Pd}(\text{OH})_2$ on C (6.0 g) was added to the amine from (112c) (36.8 g, 101 mmol) in methanol (600 mL), water (60 mL) and acetic acid (15 mL). The mixture was purged with hydrogen and stirred under balloon pressure hydrogen overnight. Following removal of catalyst by filtration, the

filtrate was concentrated to give the desired amine (22.8 g, 87%). MS (M+H)⁺=259.

(112e) Following the procedure similar to that used for steps (100a), the amine from (112d) (10.0 g, 38.7 mmol) was coupled with 4-(2-methyl-4-quinolinylmethoxy)benzoic acid. Silica gel chromatography (ethyl acetate-hexane, 50:50 then 70:30) gave the desired amide (10.4 g, 50%). The enantiomeric purity of the amide was improved to >99% ee by crystallization with CHCl₃ (80 mL), ethyl acetate (10 mL) and hexane (10 mL). The material recovery from the crystalization was 63%. MS (M+H)⁺=534.

(112f) Following the procedure similar to that used for steps (100b), the intermediate from (112e) (80 mg, 0.150 mmol) was converted to the hydroxamic acid. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid product (43 mg, 44%). MS (M+H)⁺=535.

Example 113

(3*S*,4*S*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide trifluoroacetate

(113a-d) Following the procedures similar to that used for steps (112b-e), but using (*S*)- α -methylbenzylamine in step (112b), the (3*R*,4*S*) amide enantiomer was prepared. MS (M+H)⁺=534.

(113e-f) Following the procedures similar to that used for steps (101a-b), the amide from (113d) was converted to the title compound. The product was purified by reverse phase

HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid product. MS (M+H)⁺=535.

5

Example 114

(3*S*,4*S*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

10 (114a) Following the procedure similar to that used for step (109a), the product from (113f) was converted to the title compound. MS (M+H)⁺=435.

Example 115

15 (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

(115a) Following the procedure similar to that used for step
20 (109a), the product from (112f) was converted to the title compound. MS (M+H)⁺=435.

Example 116

(3*S*,4*R*)-1-[(butoxy)carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-
25 piperidinecarboxamide trifluoroacetate

(116a) Following the procedure similar to that used for step
(109a), the intermediate from (112e) (2.24 g, 4.20 mmol) was
30 converted to the desired amine bis-TFA salt (3.16 g, 100%).
MS (M+H)⁺=434.

(116b) DIEA (0.17 mL, 5 eq) and *n*-butyl chloroformate (30 mg, 1.1 eq) were added to the amine from (116a) (150 mg,

0.199 mmol) in CH_2Cl_2 . After 30 min at rt, ethyl acetate (100 mL) and sat NaHCO_3 (3 mL) were added. The mixture was washed with water (2x3 mL) and brine (3 mL), dried (MgSO_4) and concentrated in vacuo. The crude material was taken to the next step without further purification. $\text{MS}^-(\text{M}+\text{H})^+=534$.

(116c) Following the procedures similar to that used for step (100b), the crude material from (116b) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid product (38 mg, 29% for two steps). $\text{MS}^-(\text{M}+\text{H})^+=535$.

15

Example 117

(3*S*,4*R*)-*N*-hydroxy-1-[[[(1-methylethyl)oxy]carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide trifluoroacetate

(117a-b) Following the procedures similar to that used for steps 116b and 100b, but with isopropyl chloroformate in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. $\text{MS}^-(\text{M}+\text{H})^+=521$.

Example 118

(3*S*,4*R*)-*N*-hydroxy-1-(methylsulfonyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide trifluoroacetate

30

(118a-b) Following the procedures similar to that used for steps 116b and 100b, but with MsCl in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an

35

acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=513.

Example 119

5 (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-3-piperidinecarboxamide trifluoroacetate

(119a-b) Following the procedures similar to that used for steps 116b and 100b, but with benzenesulfonyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=575.

15

Example 120

(3*S*,4*R*)-1-acetyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide trifluoroacetate

20

(120a-b) Following the procedures similar to that used for steps 116b and 100b, but with acetic anhydride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=477.

25

Example 121

(3*S*,4*R*)-1-benzoyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide trifluoroacetate

30

(121a-b) Following the procedures similar to that used for steps 116b and 100b, but with benzoyl chloride in step (116b), the title compound was prepared. The product was

35

purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=539.

5

Example 122

(3*S*,4*R*)-1-(2,2-dimethylpripionyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide trifluoroacetate

10 (122a-b) Following the procedures similar to that used for steps 116b and 100b, but with trimethylacetyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give
15 the hydroxamic acid product. MS (M+H)⁺=519.

Example 123

(3*S*,4*R*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-
20 piperidinecarboxamide trifluoroacetate

(123a-b) Following the procedures similar to that used for steps 116b and 100b, but with 3,3-dimethylbutyryl chloride in step (116b); the title compound was prepared. The
25 product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=533.

Example 124

30 (3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-3-piperidinecarboxamide trifluoroacetate

(124a-b) Following the procedures similar to that used for
35 steps 116b and 100b, but with 4-morpholinecarbonyl chloride

in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=548.

5

Example 125

(3*S*,4*R*)-1-(dimethylcarbamyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide trifluoroacetate

10

(125a-b) Following the procedures similar to that used for steps 116b and 100b, but with dimethylcarbamyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=506.

15

Example 126

(3*S*,4*R*)-*N*-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

20

(126a) DIEA (0.23 mL, 5 eq) and 37% aqueous formaldehyde (24 mg, 1.1 eq) were added to the amine intermediate from (116a) (200 mg, 0.258 mmol) in 1,2-dichloroethane (6 mL). After 30 min at rt, NaHB(OAc)₃ (82 mg, 1.5 eq) was added. After additional 1 h at rt, sat NaHCO₃ (3 mL) and ethyl acetate (100 mL) were added. The mixture was washed with water (2x5 mL) and brine (5 mL), dried (MgSO₄) and concentrated in vacuo. The crude material was used in the next step without further purification. MS (M+H)⁺=448.

25

30

(126b) Following the procedures similar to that used for step (100b), the crude intermediate from (126a) was converted to the title compound. The product was purified by

35

reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (50 mg, 32% for two steps). MS (M+H)⁺=449.

5

Example 127

(3*S*,4*R*)-1-ethyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

10 (127a-b) Following the procedures similar to that used for steps 126a and 100b, but with acetaldehyde in step (126b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic
15 acid product. MS (M+H)⁺=463.

Example 128

(3*S*,4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-3-
20 piperidinecarboxamide bis(trifluoroacetate)

(128a-b) Following the procedures similar to that used for steps 126a and 100b, but with propionaldehyde in step (126b), the title compound was prepared. The product was
25 purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=477.

Example 129

30 (3*S*,4*R*)-*N*-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

(129a-b) Following the procedures similar to that used for
35 steps 126a and 100b, but with acetone in step (126b), the

title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=477.

5

Example 130

(3*S*,4*R*)-1-(cyclopropylmethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

10

(130a-b) Following the procedures similar to that used for steps 126a and 100b, but with cyclopropanecarboxaldehyde in step (126b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=489.

15

Example 131

(3*S*,4*R*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

20

(131a-b) Following the procedures similar to that used for steps 126a and 100b, but with trimethylacetaldehyde in step (126b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=505.

25

30

Example 132

(3*S*,4*R*)-1-benzyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

(132a-b) Following the procedures similar to that used for steps 126a and 100b, but with benzaldehyde in step (126b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=525.

Example 133

(3S,4R)-1-(2-thiazolylmethyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

(133a-b) Following the procedures similar to that used for steps 126a and 100b, but with 2-thiazolecarboxaldehyde in step (126b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=532.

Example 134

(3S,4S)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

(134a). A mixture of ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate hydrochloride (50 g, 168 mmol), (BOC)₂O (50 g, 1.36 eq), Et₃N (35.2 mL, 1.5 eq), Pd(OH)₂ on C (10 g) and ethanol (400 mL) was hydrogenated at 50 psi overnight. Following removal of catalyst by filtration, the filtrate was concentrated, diluted with ethyl acetate (1 L), washed with 0.5 N HCl (300 mL), sat NaHCO₃ (150 mL), brine (100 mL), dried (MgSO₄) and concentrated in vacuo. Silica gel chromatography (ethyl acetate-hexane, 5:95 then 10:90) provided the desired product (39.0 g, 86%). MS (M+H)⁺=272.

(134b-e) Following the procedures similar to that used for steps (112b-e), the intermediate from (134a) was converted to the desired amide. The material obtained through this route was 40% ee as determined by analytical chiral HPLC.

- 5 The enantiomeric purity of the major enantiomer was improved to >99% ee using preparative chiral HPLC. The minor enantiomer was also collected. MS (M+H)⁺=548.

- (134f) Following the procedures similar to that used for step (100b), the major enantiomer from (134e) (100 mg, 0.180 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid product (83.5 mg, 72%). MS
15 (M+H)⁺=535.

Example 135

- (3*R*,4*S*)-1-[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-
[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-
20 4-piperidinecarboxamide trifluoroacetate

- (135a-b) Following the procedures similar to that used for steps (101a-b), the minor enantiomer from (134e) was converted to the title compound. The product was purified by
25 reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=535.

Example 136

- 30 (3*R*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

(136a) Following the procedure similar to that used for step (109a), the product from (135b) was converted to the title compound. MS (M+H)⁺=435.

5

Example 137

(3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

10 (137a) Following the procedure similar to that used for step (109a), the product from (134f) was converted to the title compound. MS (M+H)⁺=435.

Example 138

15 (3*S*, 4*S*)-*N*-hydroxy-1-[[[(2-methylpropyl)oxy]carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

(138a) Following the procedure similar to that used for step
20 (109a), the major enantiomer from (134e) (500 mg, 0.913 mmol) was converted to the desired amine bis-TFA salt (616 mg, 100%). MS (M+H)⁺=448.

(138b-c) Following the procedures similar to that used for
25 steps 116b and 100b, but with the amine from (138a) and isobutyl chloroformate in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid
30 product. MS (M+H)⁺=535.

Example 139

(3*S*, 4*S*)-*N*-hydroxy-1-(methoxycarbonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

5

(139a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and methyl chloroformate in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=493.

10

Example 140

(3*S*, 4*S*)-*N*-hydroxy-1-[(1-methylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

15

(140a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and isopropyl chloroformate in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=521.

20

25

Example 141

(3*S*, 4*S*)-*N*-hydroxy-1-(methylsulfonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

30

(141a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and methanesulfonyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC

35

on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=513.

5

Example 142

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-4-piperidinecarboxamide trifluoroacetate

10 (142a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and benzenesulfonyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an
15 acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=575.

Example 147

(3*S*,4*S*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

20

(147a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and *t*-butylacetyl chloride in step (116b), the title compound was
25 prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=533.

30

Example 148

(3*S*,4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

35

(148a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and trimethylacetyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=519.

Example 149

(3S,4S)-1-benzoyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

(149a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and benzoyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=539.

Example 150

(3S,4S)-1-[(pyridin-3-yl)carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

(150a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and nicotinoyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=540.

Example 151

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiophenecarbonyl)-4-piperidinecarboxamide trifluoroacetate

5

(151a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and 2-thiophenecarbonyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=545.

10

Example 152

(3*S*,4*S*)-1-(dimethylcarbonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

15

(152a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and dimethylcarbonyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=506.

20

25

Example 153

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-4-piperidinecarboxamide trifluoroacetate

30

(153a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and 4-morpholinecarbonyl chloride in step (116b), the title compound was prepared. The product was purified by reverse

35

phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=548.

5

Example 154

(3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[2-(2-thienyl)ethyl]carbonyl]-4-piperidinecarboxamide trifluoroacetate

10

(154a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and 2-(thien-2-yl)ethyl isocyanate in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=588.

15

Example 155

(3*S*, 4*S*)-1-[(1,1-dimethylethyl)carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

20

(155a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (138a) and *t*-butyl isocyanate in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=534.

25

30

Example 156

(3*S*, 4*S*)-*N*-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

35

(156a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and para-formaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=449.

10

Example 157

(3*S*,4*S*)-1-ethyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

15 (157a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and acetaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=463.

20

Example 158

25 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-4-piperidinecarboxamide bis(trifluoroacetate)

(158a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and propionaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=477.

35

Example 159

(3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

5

(159a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and acetone in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=477.

10

Example 160

(3*S*,4*S*)-1-cyclobutyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

15

(160a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and cyclobutanone in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=489.

20

25

Example 161

(3*S*,4*S*)-1-butyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

30

(161a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and butyraldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an

35

acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=491.

Example 162

5 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-methylpropyl)-4-piperidinecarboxamide bis(trifluoroacetate)

(162a-b) Following the procedures similar to that used for
10 steps 126a and 100b, but with the amine from (138a) and isobutyraldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid
15 product. MS (M+H)⁺=491.

Example 163

(3*S*,4*S*)-1-(cyclopropylmethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-
20 piperidinecarboxamide bis(trifluoroacetate)

(163a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and cyclopropanecarboxaldehyde in step (126a), the title
25 compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=489.

30

Example 164

(3*S*,4*S*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-
piperidinecarboxamide bis(trifluoroacetate)

(164a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and trimethylacetaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=505.

Example 165

(3*S*,4*S*)-1-cyclopentyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

(165a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and cyclopentanone in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=503.

Example 166

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropyranyl)-4-piperidinecarboxamide bis(trifluoroacetate)

(166a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and tetrahydro-4*H*-pyran-4-one in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=519.

Example 167

(3*S*,4*S*)-1-benzyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

5

(167a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and benzaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=525.

10

Example 168

15

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiazolylmethyl)-4-piperidinecarboxamide bis(trifluoroacetate)

20

(168a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and 2-thiazolecarboxaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=532.

25

Example 169

30

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-pyridinylmethyl)-4-piperidinecarboxamide bis(trifluoroacetate)

(169a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and 4-

35

pyridinecarboxaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=526.

Example 170

(3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-pyridinylmethyl)-4-piperidinecarboxamide bis(trifluoroacetate)

(170a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and 2-pyridinecarboxaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=526.

Example 171

(3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-pyridinylmethyl)-4-piperidinecarboxamide bis(trifluoroacetate)

(171a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and 3-pyridinecarboxaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=526.

Example 172

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*trans*-3-phenyl-2-propenyl)-4-piperidinecarboxamide bis(trifluoroacetate)

5

(172a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (138a) and *trans*-cinnamaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=551.

10

Example 173

15

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-phenyl-4-piperidinecarboxamide bis(trifluoroacetate)

(173a) A mixture of the amine from (138a) (100 mg, 0.223 mmol, free base), benzenboronic acid (54.5 mg, 2 eq), copper (II) acetate monohydrate (133.8 mg, 3 eq), pyridine (0.054 mL, 3 eq), 4 Å molecular sieve (165 mg) and CH₂Cl₂ (2 mL) were stirred overnight with the flask open to the atmosphere. The mixture was filtered and the filtrate concentrated in vacuo. Silica gel chromatography (ethyl acetate-hexane, 60:40 then 70:30) provided the desired product (94 mg, 80%). MS (M+H)⁺=524.

20

25

(173b) Following the procedures similar to that used for step (100b), the intermediate from (173a) (94 mg, 0.180 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (74 mg, 56%). MS (M+H)⁺=511.

35

Example 174.

(3R,4S)-1-(2,2-dimethylpropionyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

5

(174a-b) Following the procedures similar to that used for steps 101a and 109a, the minor enantiomer from (134e) was epimerized with DBU and deprotected. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the trans isomer. MS (M+H)⁺=448.

(174c-d) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (174b) and trimethylacetyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid. MS (M+H)⁺=519.

20

Example 175

(3R,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-methyl-4-piperidinecarboxamide bis(trifluoroacetate)

25

(175a-b) Following the procedures similar to that used for steps 126a and 100b, but with the amine from (174b) and para-formaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=449.

30

Example 176

(3*R*,4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

5

(176a-b) Following the procedures similar to that used for steps 116b and 100b, but with the amine from (174b) and dimethylcarbamyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=506.

10

Example 177

15

(3*S*,4*S*)-1-hexyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

(177a-b) Following the procedures similar to that used for steps 126a and 100b, but using the amine from (138a) and hexanal in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS

20

25 (M+H)⁺=519.

Example 178

(3*S*,4*S*)-1-(2-fluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

30

(178a) A mixture of the amine from (138a) (800 mg, 1.20 mmol), 1-bromo-2-fluoroethane (0.27 mL), 3 eq), K₂CO₃ (1.20 g, 10 eq) and NaI (580 mg, 3 eq) in acetone (20 mL) was

heated to reflux for 6 h, cooled to rt and filtered. The filtrate was concentrated and purified by silica gel chromatography (methanol-dichloromethane, 5:95) to give the desired product (450 mg, 76%). MS (M+H)⁺=538.

5

(178b) Following the procedures similar to that used for step (100b), the intermediate from (178a) (350 mg, 0.710 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (170 mg, 34%). MS (M+H)⁺=481.

10

Example 179

(3*S*,4*S*)-1-(2,2-difluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

15

(179a-b) Following the procedures similar to that used for steps (178a and 100b), but the amine from (138a) and 2-bromo-1,1-difluoroethane in step (178a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=499.

20

25

Example 180

(3*S*,4*S*)-*N*-hydroxy-1-(1-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

30

(180a-b) Following the procedures similar to that used for steps (126a and 100b), but using the amine from (138a) and 2-butanone in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-

18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS
(M+H)⁺=491.

5

Example 181

(3*S*,4*S*)-1-(1-ethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

10 (181a-b) Following the procedures similar to that used for steps (126a and 100b), but using the amine from (138a) and 3-pentanone in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA
15 gradient, to give the hydroxamic acid product. MS
(M+H)⁺=505.

Example 182

(3*S*,4*S*)-1-[1-[[[(1,1-dimethylethyl)oxy]carbonyl]-4-tetrahydropiperidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

20

(182a-b) Following the procedures similar to that used for steps (126a and 100b), but using the amine from (138a) and Boc-4-piperidone in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid
25 product. MS (M+H)⁺=618.

30

Example 183

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-

tetrahydropiperidinyl)-4-piperidinecarboxamide
tris(trifluoroacetate)

(183a) Following the procedure similar to that used for step
5 (109a), the product from (182b) was converted to the title
compound. MS (M+H)⁺=518.

Example 184

(3*S*,4*S*)-1-[1-[[{(1,1-dimethylethyl)oxy}carbonyl]-3-
10 tetrahydropyrrolidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-4-
piperidinecarboxamide bis(trifluoroacetate)

(184a-b) Following the procedures similar to that used for
15 steps (126a and 100b), but using the amine from (138a) and
N-Boc-3-pyrrolidinone in step (126a), the title compound was
prepared. The product was purified by reverse phase HPLC on
a Vydac C-18 semiprep column eluting an
acetonitrile:water:TFA gradient, to give the hydroxamic acid
20 product. MS (M+H)⁺=604.

Example 185

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-
25 tetrahydropyrrolidinyl)-4-piperidinecarboxamide
tris(trifluoroacetate)

(185a) Following the procedure similar to that used for step
(109a), the product from (184b) was converted to the title
30 compound. MS (M+H)⁺=505.

Example 186

(3*S*,4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

5

(186a) A solution of 3-chloro-3-methyl-1-butyne (0.51 ml, 1 eq) in dichloromethane (2 mL) was added dropwise to a mixture of the amine from (138a) (2.00 g, 4.47 mmol), CuCl (1 mg), Cu (1 mg), Et₃N (1.30 mL, 2 eq), water (15 mL) and
10 dichloromethane (30 mL). After stirring under N₂ for 4 days, the mixture was diluted with dichloromethane and water. The organic phase was separated and purified by silica gel chromatography (methanol-dichloromethane, 5:95) to give the desired product (1.76 g, 76%). MS (M+H)⁺=514.

15

(186b) Following the procedures similar to that used for step (100b), the intermediate from (186a) (200 mg, 0.389 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep
20 column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (95 mg, 33%). MS (M+H)⁺=501.

Example 187

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-thiophenylmethyl)-4-piperidinecarboxamide
25 bis(trifluoroacetate)

(187a-b) Following the procedures similar to that used for steps (126a and 100b), but using the amine from (138a) and 3-thiophenecarboxaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an
30

acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=531.

Example 188

5 (3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide trifluoroacetate

(188a) Following the procedures similar to that used for
10 steps (126a), but using the amine from (138a) (4.00 g, 5.92 mmol) and acetone, the title compound was prepared. Silica gel chromatography (methanol-dichloromethane, 5:95 then 7:93) gave the desired product (2.36 g, 81%). MS (M+H)⁺=490.

15

(188b) *m*-CPBA (102 mg, 1 eq, 55% pure) was added to a solution of the tert-amine from (188a) (160 mg, 0.327 mmol) in dichloromethane (4 mL). After 30 min at rt, the mixture was treated with saturated NaHSO₃ (1.5 mL) and saturated
20 NaHCO₃ (1.5 mL), and immediately extracted with ethyl acetate. The extracts were washed with brine, dried and concentrated (MgSO₄). Silica gel chromatography (methanol-dichloromethane, 5:95 then 10:90) gave the tertiary amine *N*-oxide (140 mg, 85%). MS (M+H)⁺=506.

25

(188c) Following the procedures similar to that used for step (100b), the intermediate from (188b) (30 mg, 0.059 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep
30 column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (25 mg, 69%). MS (M+H)⁺=493.

Example 189

(3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

5

(189a) The momo-*N*-oxide from (188b) (110 mg, 0.218 mmol) was dissolved in dichloromethane (2 mL) and treated with *m*-CPBA (68.3 mg, 1 eq, 55% pure) for 30 min. TLC showed clean conversion to the bis-*N*-oxide product. The mixture was
10 treated with saturated NaHSO₃ (1.5 mL) and saturated NaHCO₃ (1.5 mL), and extracted with ethyl acetate. The NaHSO₃ treatment resulted in partial reduction of the tertiary amine *N*-oxide and therefore gave a mixture of bis-*N*-oxide and quinoline mono-*N*-oxide. The extracts were washed with
15 brine, dried and concentrated (MgSO₄). Silica gel chromatography (methanol-dichloromethane, 5:95 then 8:92 then 10:90 then 15:85) gave the mono-*N*-oxide at the quinoline nitrogen (50 mg, 44%) and bis-*N*-oxide (40 mg, 35%). MS for mono-*N*-oxide (M+H)⁺=506, for bis-*N*-oxide
20 (M+H)⁺=522.

(189b) Following the procedures similar to that used for step (100b), the mono-*N*-oxide from (189a) (48 mg, 0.095 mmol) was converted to the title compound. The product was
25 purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (30 mg, 52%). MS (M+H)⁺=493.

Example 190

30 (3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide

(190a) Following the procedures similar to that used for step (100b), the bis-N-oxide from (189a) (38 mg, 0.073 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (23 mg, 62%). MS (M+H)⁺=509.

Example 191

(3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide bis(trifluoroacetate)

(191a) A mixture of the amine from (138a) (2.00 g, 2.96 mmol), *t*-butyl bromoacetate (1.15 g, 2 eq), Cs₂CO₃ (4.82 g, 5 eq) and DMSO (25 mL) was stirred at rt for 1 h. Following addition of sat NH₄Cl (15 mL) and ethyl acetate (200 mL), the mixture was washed with water (2x10 mL), brine (10 mL), dried (MgSO₄) and concentrated. Silica gel chromatography (ethyl acetate) provided the desired product (1.40 g, 80%). MS (M+H)⁺=562.

(191b) The *t*-butyl ester from (191a) (1.20 g, 2.14 mmol) was treated with TFA (5 mL) in dichloromethane (5 mL) for 3 h and concentrated to give the desired carboxylic acid (1.70 g, 100%). MS (M+H)⁺=506.

(191c) Following the procedure similar to that used for steps (100a), The acid from (191b) (300 mg, 0.378 mmol) was coupled with morpholine. Silica gel chromatography (methanol-dichloromethane, 5:95) gave the desired amide (130 mg, 59%). MS (M+H)⁺=575.

(191d) Following the procedures similar to that used for step (100b), the product from (191c) (130 mg, 0.223 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (70 mg, 53%). MS (M+H)⁺=562.

Example 192

(3*S*,4*S*)-1-[2-(*N,N*-dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-
[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-
4-piperidinecarboxamide bis(trifluoroacetate)

(192a-b) Following the procedures similar to that used for steps (100a-b), but using the acid from (191b) and dimethylamine in step (100a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=520.

Example 193

(3*S*,4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

(193a) A precooled solution (0 °C) of *t*-Butylsulfinyl chloride (210 mg, 2 eq) in dichloromethane (10 mL) was added dropwise to a solution of triethylamine (1.03 mL, 10 eq) and the amine from (138a) (500 mg, 0.74 mmol) in dichloromethane (10 mL) at 0 °C. After 1 h at 0 °C, the mixture was quenched with sat NaHCO₃ and extracted with dichloromethane. The extracts were dried (MgSO₄) and concentrated. Silica gel chromatography (methanol-dichloromethane, 5:95) gave the

desired sulfinamide (400 mg, 98%) as a 1:1 mixture epimeric at sulfur center. MS (M+H)⁺=552.

(193b) Ruthenium(III) chloride monohydrate (0.4 mg) and NaIO₄ (46 mg, 1.2 eq) were added to a mixture of the sulfinamide from (193a) (100 mg, 0.180 mmol), dichloromethane (2 mL), acetonitrile (2 mL) and water (3 mL) at 0 °C. After 1 h at 0 °C, the mixture was extracted with dichloromethane. The combined extracts were dried (MgSO₄) and concentrated to give the desired sulfonamide as a crude material. MS (M+H)⁺=568.

(193c) Following the procedures similar to that used for step (100b), the crude product from (193b) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acid (47 mg, 39% for two steps). MS (M+H)⁺=555.

Example 194

(3*S*,4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

(194a) Following a procedure similar to that used for step (189a), the sulfinamide from (193a) (220 mg, 0.400 mmol) was oxidized to the sulfonamide quinoline *N*-oxide (250 mg crude weight). MS (M+H)⁺=584.

(194b) Following the procedures similar to that used for step (100b), the crude product from (194a) (100 mg) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the

desired hydroxamic acid (64 mg, 65% for two steps). MS
(M+H)⁺=571.

Example 195

5 (3*S*,4*S*)-1-(benzenesulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide trifluoroacetate

(195a-b) Following the procedures similar to that used for
10 steps (116b and 100b), but using the amine from (138a) and benzenesulfonyl chloride in step (116b), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid
15 product. MS (M+H)⁺=575.

Example 196

(3*S*,4*S*)-1-(*t*-butylsulfinyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-
20 piperidinecarboxamide trifluoroacetate

(196a) Following the procedures similar to that used for step (100b), the 1:1 mixture of sulfinamide from (193a) was converted to the title compound. The two isomers were
25 separated by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the desired hydroxamic acids. MS (M+H)⁺=539.

Example 197

30 (3*S*,4*S*)-*N*-hydroxy-1-(2-hydroxyethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

(197a) Following the procedure similar to that used for step (126a), the amine from (138a) (225 mg, 0.333 mmol) was reacted with (t-butyldimethylsilyloxy)acetaldehyde via reductive amination. Silica gel chromatography (ethyl acetate-hexane, 30:70, then methanol-dichloromethane, 5:95) gave the desired product (150 mg, 74%) MS (M+H)⁺=606.

(197b) A 1 M THF solution of TBAF (0.50 mL, 2 eq) was added to the product from (197a) (150 mg, 0.248 mmol) in THF (6 mL). The mixture was stirred for 30 min, diluted with sat NH₄Cl (5 mL) and ethyl acetate (100 mL), washed with water (5 mL), brine (5 mL), dried (MgSO₄) and concentrated. Silica gel chromatography (methanol-dichloromethane, 5:95) gave the desired alcohol (100 mg, 82%). MS (M+H)⁺=492.

15

(197c) Following the procedures similar to that used for step (100b), the product from (197b) (100 mg, 0.203 mmol) was converted to the title compound. Purification by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, gave the desired hydroxamic acid (35 mg, 24%). MS (M+H)⁺=479.

20

Example 198

(3S,4S)-1-[2-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]ethyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide bis(trifluoroacetate)

25

(198a) Following the procedure similar to that used for step (126a), the amine from (138a) (200 mg, 0.296 mmol) was reacted with t-butyl N-(2-oxoethyl)carbamate via reductive amination. Silica gel chromatography (methanol-dichloromethane, 5:95) gave the desired product (150 mg, 86%). MS (M+H)⁺=591.

30

(198b) Following the procedures similar to that used for step (100b), the product from (198a) (120 mg, 0.203 mmol) was converted to the title compound. The product was
5 purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product (80 mg, 49%). MS (M+H)⁺=578.

Example 199

10 (3*S*,4*S*)-1-(2-aminoethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide tris(trifluoroacetate)

(199a) Following the procedure similar to that used for step
15 (109a), the product from (198b) was converted to the title compound. MS (M+H)⁺=478.

Example 200

(3*S*,4*S*)-1-[2-(*N,N*-dimethylamino)ethyl]-*N*-hydroxy-3-[[[4-[(2-
20 methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide tris(trifluoroacetate)

(200a) Following the procedure similar to that used for step (109a), the product from (198a) (380 mg, 0.643 mmol) was
25 deprotected to give the desired product (550 mg, 100%). MS (M+H)⁺=491.

(200b) Following the procedure similar to that used for step (126a), the amine from (200a) (300 mg, 0.351 mmol) was
30 reacted with formaldehyde via reductive amination. Silica gel chromatography (methanol-dichloromethane-ammonium hydroxide, 10:90:0 then 10:88:2) gave the dimethylamino product (160 mg, 88%). MS (M+H)⁺=519.

(200c) Following the procedure similar to that used for step (100b), the product from (200b) (150 mg, 0.289 mmol) was converted to the title compound. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product (140 mg, 57%). MS (M+H)⁺=506.

Example 201

(3*S*,4*S*)-1-[(2*S*)-2-aminopropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide tris(trifluoroacetate)

(201a-c) Following the procedures similar to that used for steps (126a, 100b and 109a), but using the amine from (138a) and *N*-t-Boc-L-alaninal in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=492.

Example 202

(3*S*,4*S*)-1-[(2*R*)-2-amino-3-hydroxypropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide tris(trifluoroacetate)

(202a-c) Following the procedures similar to that used for steps (126a, 100b and 109a), but using the amine from (138a) and *S*-(-)-3-tert-butoxycarbonyl-4-formyl-2,2-dimethyl-1,3-oxazolidine in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=508.

Example 203 -

(3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[[(2*R*)-2-pyrrolidinyl]methyl]-4-piperidinecarboxamide
5 tris(trifluoroacetate)

(203a-c) Following the procedures similar to that used for steps (126a, 100b and 109a), but using the amine from (138a) and *N*-(tert-butoxycarbonyl)-D-prolinal in step (126a), the
10 title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=518.

15

Example 204

(3*S*,4*R*)-*N*-hydroxy-1-(2-hydroxyethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

20 (204a-c) Following the procedures similar to that used for steps (126a, 197b and 100b), but using the amine from (116a) and (t-butyldimethylsilyloxy)acetaldehyde in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column
25 eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=479.

Example 205

30 (3*S*,4*R*)-1-(2-aminoethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide tris(trifluoroacetate)

(205a-c) Following the procedures similar to that used for steps (126a, 100b and 109a), but using the amine from (116a)

and t-butyl N-(2-oxoethyl)carbamate in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=478.

Example 206

(3*S*,4*R*)-1-cyclobutyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide bis(trifluoroacetate)

(206a-b) Following the procedures similar to that used for steps (126a and 100b), but using the amine from (116a) and cyclobutanone in step (126a), the title compound was prepared. The product was purified by reverse phase HPLC on a Vydac C-18 semiprep column eluting an acetonitrile:water:TFA gradient, to give the hydroxamic acid product. MS (M+H)⁺=489.

Example 207

(3*R*,4*R*)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-2*H*-pyran-3-carboxamide

(207a) LiHMDS (1.0 M in THF, 52.5 mL, 1.05 eq) was added dropwise to a -78°C solution of tetrahydro-4*H*-pyran-4-one (5.0 g, 50 mmol) in THF (200 mL). The resulting solution was stirred at -20°C for 1 h, then cooled back to -78°C. To this mixture was added methyl cyanoformate (4.75 mL, 1.2 eq) dropwise. Ten min after completion of the addition, the reaction was quenched with aqueous NH₄Cl and extracted with ether (200 mL). The organic layer was washed with brine (100 mL), dried (MgSO₄), and concentrated. Silica gel column chromatography (ether-hexane, 1:4, 2:3, then 3:2) yielded an

oil containing both ketone and enol forms of the product (5.4 g, ca. 30 % purity). MS found: $(M+H)^+ = 159.1$.

(207b) The ester from (207a) was dissolved in benzene (200 mL) and treated with (R)- α -methylbenzylamine (3 mL) and ytterbium(III) trifluoromethanesulfonate (200 mg). The mixture was heated to reflux under Dean-Stark conditions for 2 h, concentrated, and purified by silica gel column chromatography (ethyl acetate-hexane, 1:4) to yield the
10 desired enamine as a white solid (3.6 g, 27.5% for 2 steps).

(207c) The enamine from (207b) (3.5 g, 13.4 mmol) in acetonitrile-acetic acid (1:1, 80 mL) was treated with $\text{NaBH}(\text{OAc})_3$ and stirred for 2 h at 0 °C. Following
15 concentration in vacuo, the residue was dissolved in ether (200 mL), washed with saturated NaHCO_3 until the aqueous phase was basic, dried (MgSO_4), and concentrated to yield an oil (3.39 g, 96%). MS Found: $(M+H)^+ = 264.3$.

(207d) The intermediate from (207c) (1.86 g, 7.06 mmol) in methanol (100 mL) was treated with 10% palladium hydroxide on carbon (0.6 g, 3.5 % mol) and aqueous 1N hydrochloric acid (10 mL, 1.4 eq) and stirred under a H_2 -balloon for 72 h. The catalyst was removed by filtration. Removal of solvent
25 provided the desired amine as hydrochloric acid salt (1.42 g, 100%). MS Found: $(M+H)^+ = 160.3$.

(207e) To a mixture of the amine from (207d) (1.0 g, 5.11 mmol) and 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid
30 (1.50 g, 1.0 eq) in N,N-dimethylformamide (20 mL) was added BOP reagent (2.30 g, 1.02 eq) and N,N-diisopropylethylamine (2.2 mL, 2.5 eq) at room temperature. After 2 h at room temperature, saturated aqueous NaHCO_3 (50 mL) was added and the mixture extracted with ethyl acetate (2 x 50 mL), washed
35 with brine (20 mL), dried (MgSO_4) and concentrated. Silica

gel column chromatography (ethyl acetate-hexane, 3:2 then 4:1) yielded the desired amide (1.6 g, 72%). The above amide was submitted for a chiral HPLC separation (OJ, hexane-isopropanol-methanol, 60:20:20, 1.2 mL/min @ 240 nm and ambient temperature) to provide the (3R,4R) isomer in enantiomerically pure form (980 mg, 58% recovery, >99% ee). MS Found: (M+H)⁺ = 435.1.

(207f) Freshly prepared 1.76 M hydroxylamine solution (example 1d) (20 mL, 20 eq.) was added to the methyl ester (0.78 g, 1.80 mmol) from reaction (207e) and stirred at room temperature for 10 min. The mixture was adjusted to pH 7 with 1 N hydrochloric acid. The resulting precipitate was collected by filtration and recrystallized from hot methanol (80 mL) to yield the free base form of the hydroxamic acid. The free base was treated with dichloromethane (30 mL) and trifluoroacetic acid (0.1 mL, 1.5 eq) and stirred until homogeneous. The mixture was concentrated and lyophilized to afford the TFA salt of the desired hydroxamic acid (0.50 g, 50%). MS Found: (M+H)⁺ = 436.1.

Example 208

(3S,4S)-1-tert-butyl-N-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide bis(trifluoroacetate)

(208a) To a solution of the alcohol (0.95 g, 3.09 mmol) from reaction (222a) in dichloromethane (30 mL) was added, at 0°C, triethylamine (0.65 mL, 1.5 eq), and methanesulfonyl chloride (0.29 mL, 1.2 eq). After 15 min at 0°C, the reaction was quenched with saturated NaHCO₃ (10 mL), extracted with dichloromethane, washed with brine, dried (MgSO₄), concentrated and purified by silica gel chromatography (40% then 50% ethyl acetate/hexane) to yield the mesylate (0.99 g, 83%). MS found: (M+Na)⁺=408.

(208b) To a -78°C solution of the mesylate (0.90 g, 2.33 mmol) from reaction (208a) in dichloromethane (100 mL) was bubbled ozone until the reaction solution turned blue. The reaction was purged with nitrogen until colorless. Triphenylphosphine (0.73 g, 1.2 eq) was added, and the mixture was stirred at ambient temperature for 2 h, concentrated and purified by silica gel chromatography (60% ethyl acetate/hexane) to yield the desired aldehyde (0.81 g, 90%). MS found: $(\text{M}+\text{Na})^{+}=410$.

(208c) A mixture of the aldehyde (0.81 mg, 2.09 mmol) from the reaction (208b), *tert*-butylamine (1.14 mL, 5.2 eq) and sodium triacetoxyborohydride (1.33 g, 3.0 eq) in dichloroethane (40 mL) was stirred in a sealed flask at room temperature for 4 h, then 80°C overnight. The reaction was quenched with saturated NaHCO_3 , extracted with dichloromethane (2x50 mL), washed with brine (50 mL), dried (MgSO_4), concentrated and purified twice by silica gel chromatography (60% ethyl acetate/hexane) to yield the desired cyclized tertiary amine (0.37 g, 40%). MS found: $(\text{M}+\text{H})^{+}=349$.

(208d) A mixture of the amine (0.32 g, 0.92 mmol) from reaction (208c), Pd/C (64 mg, 20% wt) and 1 N hydrogen chloride in ethyl ether (1.0 mL) in methanol (20 mL) was stirred under a hydrogen-balloon for 1 h. After removal of catalyst by filtration, the filtrate was concentrated to afford the deprotected amine hydrochloride (0.23 g, 100%). MS found: $(\text{M}+\text{H})^{+}=215$.

(208e) Following a procedure analogous to that used in reaction (16f), the amine hydrochloride (0.23g, 0.92 mmol) from reaction (208d) was coupled with 4-(2-methyl-4-quinolinylmethoxy)benzoic acid. Silica gel chromatography

(3% methanol/dichloromethane) provided the desired amide (0.37 g, 82%). MS found: $(M+H)^+=490$.

(208f) Following a procedure analogous to that used in reaction (1d), the methyl ester (0.25 g, 0.51 mmol) from reaction (208e) was treated with hydroxylamine solution. Purification by reverse phase HPLC (15-40% acetonitrile/water) yielded the desired hydroxamic acid (0.26 g, 71%). MS found: $(M+H)^+=491$.

10

Example 209

tert-butyl 2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate bis(trifluoroacetate)

15

(209a) The amine from reaction (138a) (250 mg, 0.370 mmol), *tert*-butyl 2-bromoisobutyrate (0.69 mL, 10 eq) and potassium carbonate (760 mg, 15 eq) were added to acetone (20 mL) and heated to reflux for 24 h. The mixture was cooled to rt and concentrated in vacuo. Purification of the residue by silica gel column chromatography (5:95, methanol:methylene chloride) gave the desired tertiary amine (50 mg, 23%). MS found: $(M+H)^+=590$.

20

(209b) Following a procedure similar to that used for reaction (100b), the tertiary amine from reaction (209a) (50 mg, 0.0848 mmol) was treated with hydroxylamine. Purification by reverse phase HPLC, using acetonitrile:water:TFA as eluant, provided the title hydroxamic acid (22 mg, 32%) as bis-TFA salt. MS found: $(M+H)^+=577$.

30

Example 210

2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoic acid bis(trifluoroacetate)

5

(210a) Following a procedure similar to that used for reaction (109a), the hydroxamic acid from reaction (209b) was treated with TFA. Purification by reverse phase HPLC, using acetonitrile:water:TFA as eluant, provided the title
10 hydroxamic acid (8 mg, 58%) as bis-TFA salt. MS found: (M+H)⁺=521.

Example 211

methyl 2-[(3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate bis(trifluoroacetate)

15

(211a) Following a procedure similar to that used for reaction (209a), The amine from reaction (138a) (200 mg,
20 0.296 mmol) was treated with methyl 2-bromoisobutyrate (0.55 mL, 10 eq). Purification of the residue by silica gel column chromatography (5:95, methanol:methylene chloride) gave the desired tertiary amine (150 mg, 93%). MS found: (M+H)⁺=548.

25

(211b) Following a procedure similar to that used for reaction (100b), the tertiary amine from reaction (211a) (150 mg, 0.274 mmol) was treated with hydroxylamine. Purification by reverse phase HPLC, using
30 acetonitrile:water:TFA as eluant, provided the title hydroxamic acid (40 mg, 20%) as bis-TFA salt. MS found: (M+H)⁺=535.

Example 212

(3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide bis(trifluoroacetate)

5

(212a) Following a procedure similar to that used for reaction (209a), The amine from reaction (138a) (2.00 g, 2.96 mmol) was treated with tert-butyl bromoacetate (1.15 g, 2 eq). Purification of the residue by silica gel column chromatography (ethyl acetate) gave the desired tertiary amine (1.40 g, 80%). MS found: (M+H)⁺=562.

(212b) Following a procedure similar to that used for reaction (109a), the tertiary amine from reaction (212a) (1.20 g, 2.14 mmol) was treated with TFA. The mixture was concentrated in vacuo to provide the desired carboxylic acid (1.70 g, 100%) as bis-TFA salt. MS found: (M+H)⁺=506.

(212c) Following a procedure similar to that used for reaction (16f), the carboxylic acid from reaction (212b) (300 mg, 0.378 mmol) was treated with morpholine. Purification of the residue by silica gel column chromatography (5:95, methanol:methylene chloride) gave the desired amide (130 mg, 60%). MS found: (M+H)⁺=575.

25

(212d) Following a procedure similar to that used for reaction (100b), the amide from reaction (212c) (130 mg, 0.226 mmol) was treated with hydroxylamine. Purification by reverse phase HPLC, using acetonitrile:water:TFA as eluant, provided the title hydroxamic acid (70 mg, 40%) as bis-TFA salt. MS found: (M+H)⁺=562.

30

Example 213

(3*S*,4*S*)-1-[2-(dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide bis(trifluoroacetate)

5

(213a) Following a procedure similar to that used for reaction (16f), the carboxylic acid from reaction (212b) (300 mg, 0.378 mmol) was treated with dimethylamine hydrogen chloride. The crude amide (200 mg) was used for the next
10 step without further purification. MS found: (M+H)⁺=533.

(213b) Following a procedure similar to that used for reaction (100b), the amide from reaction (213a) (200 mg, 0.378 mmol) was treated with hydroxylamine. Purification by
15 reverse phase HPLC, using acetonitrile:water:TFA as eluant, provided the title hydroxamic acid (90 mg, 32% for two steps) as bis-TFA salt. MS found: (M+H)⁺=520.

Example 214

20 (3*S*,4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide bis(trifluoroacetate)

(214a) A mixture of the intermediate from (186a) (1.0 g, 1.95 mmol) and Pd/BaSO₄ (0.10g, 5% wt.) in ethanol (50 mL)
25 was stirred under a hydrogen balloon for 40 min. After removal of catalyst by filtration, the filtrate was concentrated and purified by silica gel chromatography (5% methanol/dichloromethane) to yield the alkene (0.87 g, 87%).
30 MS found: (M+H)⁺=516.

(214b) Following a procedure analogous to that used in reaction (1d), the ethyl ester (0.15 g, 0.29 mmol) from reaction (214a) was treated with hydroxylamine solution.

Purification by reverse phase HPLC (15-40% acetonitrile/water) yielded the desired hydroxamic acid (0.09 g, 43%). MS found: $(M+H)^+=503$.

5

Example 215

(3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-4-piperidinecarboxamide bis(trifluoroacetate)

- 10 (215a) A mixture of the intermediate from (214a) (0.20 g, 0.388 mmol) and Rh/C (20 mg, 5% wt.) in ethanol (20 mL) was stirred under a hydrogen balloon for 4 h. After removal of catalyst by filtration, the filtrate was purified by silica gel chromatography (5% methanol/dichloromethane) to yield
15 the alkane (0.176 g, 88%). MS found: $(M+H)^+=518$.

(215b) Following a procedure analogous to that used in reaction (1d), the ethyl ester (0.12 g, 0.23 mmol) from reaction (215a) was treated with hydroxylamine solution.

- 20 Purification by reverse phase HPLC (15-40% acetonitrile/water) yielded the desired hydroxamic acid (82 mg, 48%). MS found: $(M+H)^+=505$.

Example 216

25

(3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-4-piperidinecarboxamide bis(trifluoroacetate)

- (216a) A mixture of the free base of the intermediate from
30 (138a) (0.30 g, 0.67 mmol), propargyl bromide (80% wt. in toluene, 0.1 mL, 0.90 mmol), potassium carbonate (0.46 g, 5 eq) and sodium iodide (0.135 g, 1.35 eq) in acetone (10 mL) was refluxed for 2 h. The mixture was then cooled to room temperature, quenched with saturated NH_4Cl (20 mL), extracted

with ethyl acetate (2 x 20 mL), washed with brine (10 mL), dried (MgSO₄) and concentrated. Silica gel chromatography (5% methanol/dichloromethane) yielded the desired product (0.27 g, 83%). MS found: (M+H)⁺=486.

5

(216b) Following a procedure analogous to that used in reaction (1d), the ethyl ester (0.25 g, 0.52 mmol) from reaction (216a) was treated with hydroxylamine solution. Purification by reverse phase HPLC (15-40%

10 acetonitrile/water) yielded the desired hydroxamic acid (0.26 g, 72%). MS found: (M+H)⁺=473.

Example 217

(3*S*,4*S*)-1-allyl-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
15 bis(trifluoroacetate)

(217a-b) Following procedures analogous to that used in reaction (186a) and (1d), the intermediate from reaction (138a) (0.20 g, 0.45 mmol) was alkylated with allyl bromide, then treated with hydroxylamine solution. Purification by reverse phase HPLC (15-40% acetonitrile/water) yielded the
20 desired hydroxamic acid (75 mg, 26% for 2 steps). MS found: (M+H)⁺=475.

25

Example 218

(3*S*,4*S*)-*N*-hydroxy-1-(1-methyl-2-propynyl)-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
bis(trifluoroacetate)

30

(218a-b) Following procedures analogous to that used in reaction (186a) and (1d), the intermediate from reaction (138a) (0.20 g, 0.45 mmol) was alkylated with 3-chloro-1-butyne, then treated with hydroxylamine solution.

Purification by reverse phase HPLC (15-40% acetonitrile/water) yielded the desired hydroxamic acid (100.5 mg, 40% for 2 steps). MS found: (M+H)⁺=487.

5

Example 219

(3*S*,4*S*)-*N*-hydroxy-1-(1-methyl-2-propenyl)-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide bis(trifluoroacetate)

10 (219a) A mixture of hydroxamic acid from example 218 (20 mg, 0.028 mmol) and 5% wt. Pd/BaSO₄ (4 mg, 20% wt.) in methanol (2 mL) was stirred under a hydrogen-balloon for 20 min. After removal of catalyst by filtration, the filtrate was concentrated and lyophilized to yield the title product (17
15 mg, 87%). MS found: (M+H)⁺=489.

Example 220

N-{(1*R*,2*S*)-4,5-dihydroxy-2-
20 [(hydroxyamino)carbonyl]cyclohexyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide trifluoroacetate

(220a) To a -20°C solution of 1-methyl-(1*S*, 2*R*)-(+)-cis-1,2,3,6-tetrahydrophthalate (2.21 g, 12.0 mmol) and triethylamine (3.34 mL, 2.0 eq) in tetrahydrofuran (30 mL)
25 was added ethyl chloroformate (1.72 mL, 1.5 eq). After 5 min at -20°C, the CCl₄/dry ice bath was replaced with ice-water bath. A solution of sodium azide (1.95 g, 2.5 mmol) in water (10 mL) was added. The mixture was stirred at ambient temperature for 30 min, diluted with water (50 mL),
30 extracted with ethyl acetate (2X100 mL), washed with brine (50 mL), dried (MgSO₄), and concentrated. The oil residue was treated with benzene (30 mL) and heated to reflux for 1 h. The mixture was finally treated with 1 N hydrochloric acid (24 mL) and stirred at room temperature for 40 h. The

aqueous layer was separated, washed with ethyl ether (2x5 mL), concentrated and pumped in vacuo to yield the desired amine hydrochloride (1.40 g, 61%).

- 5 (220b) Following a procedure analogous to that used in reaction (16f), the amine hydrochloride (1.20 g, 5.72 mmol) from reaction (220a) was coupled with 4-(2-methyl-4-quinolinylmethoxy)benzoic acid. Silica gel chromatography (60% then 70% ethyl acetate/hexane) provided the desired
10 amide (1.40 g, 57%). MS found: (M+H)⁺=431.

- (220c) To a mixture of the amide from reaction (220b) (0.30 g, 0.70 mmol) in water (1 mL) and acetone (8 mL) was added 4-methylmorpholine N-oxide (0.16 g, 2 eq) and OsO₄ (4% in
15 water, 0.2 mL, 0.05 eq). After 4 h at room temperature, the reaction was quenched with 30% NaHSO₃ (3 mL), and stirred for 30 min before extracted with ethyl acetate (2X50 mL). The extracts were combined, washed with water (10 mL), brine (10 mL), dried (MgSO₄), and concentrated. Purification by silica
20 gel chromatography (5% methanol/dichloromethane) and recrystallization from methanol yielded the lower R_f isomer as the desired diol (0.16 g, 50%). MS found: (M+H)⁺=465.

- (220d) Following a procedure analogous to that used in
25 reaction (1d), the diol from reaction (220c) (0.15 g, 0.30 mmol) was treated with hydroxylamine solution. Purification by reverse phase HPLC (15-40% acetonitrile/water) yielded the desired hydroxamic acid (98 mg, 55%). MS found:
(M+H)⁺=466.

30

Example 221

(5S)-N-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-piperidinecarboxamide trifluoroacetate

35

- (221a) A solution of benzyl (S)-(-)-tetrahydro-5-oxo-3-furanyl carbamate (2.00 g, 8.50 mmol) in THF (50 mL) was added dropwise to LDA (17.9 mmol, 2.1 eq) in THF (150 mL) at -78°C over 10 minutes. After additional 10 min at that temperature, tert-butyl bromoacetate (3.77 mL, 3 eq) was added. The mixture was stirred at -78°C for 1 h, quenched with a solution of acetic acid (1 mL) in THF (4 mL) and warmed to rt. Following removal of solvent in vacuo, the residue was diluted with ethyl acetate (300 mL), washed with water (2x10 mL), and brine (10 mL), dried (MgSO₄) and concentrated. ¹H-NMR analysis of the crude material indicated presence of two isomers in 3:2 ratio. Silica gel column chromatography (2:8, ethyl acetate:hexanes) gave the major lactone (950 mg, 32%). MS found: (M+Na)⁺=506.
- (221b) The lactone from reaction (221a) (2.70 g, 7.72 mmol) in THF (40 mL) was treated with 1 N LiOH (10 mL, 1.3 eq) at 0 °C and stirred at that temperature for 1 h. The mixture was adjusted to pH4-5 with 1 N HCl and concentrated. The residue was diluted with ethyl acetate (200 mL), washed with water (10 mL), brine (10 mL), dried (MgSO₄) and concentrate in vacuo. The crude carboxylic acid (3.00 g) was taken to the next step without further purification. MS found: (M+Na)⁺=390.
- (221c) The crude carboxylic acid from reaction (221b) (3.00 g) in methanol (20 mL) and benzene (80 mL) was treated with 2.0 M hexane solution of (trimethylsilyl)diazomethane (5 mL, 1.3 eq) at rt. After 10 min at rt, the mixture was concentrated and purified by silica gel column chromatography (3:7, ethyl acetate:hexanes) to provide the desired methyl ester (1.46 g, 50% for two steps). MS found: (M+Na)⁺=404.

(221d) The ester from reaction (221c) (780 mg, 2.04 mmol) in methylene chloride (20 mL) was treated with triethylamine (0.43 mL, 1.5 eq) and methanesulfonyl chloride (0.19 mL, 1.3 eq) at 0°C and stirred at that temperature for 1 h. The mixture was quenched with saturated NaHCO₃ (10 mL) and diluted with ethyl acetate (200 mL). The mixture was washed with water (10 mL), and brine (10 mL), dried (MgSO₄) and concentrated. The residue was purified by silica gel column chromatography (3:7, ethyl acetate:hexanes) to provide the desired mesylate (870 mg, 93%). MS found: (M+H)⁺=460.

(221e) The mesylate from reaction (221d) (700 mg, 1.52 mmol) and sodium azide (990 mg, 10 eq) were dissolved in DMF (10 mL) and heated to 90°C for 1 h. The mixture was cooled down to rt, treated with saturated NaHCO₃ (5 mL) and ethyl acetate (200 mL), washed with water (10 mL), brine (10 mL), dried (MgSO₄) and concentrate in vacuo. Purification of the residue by silica gel column chromatography (2:8, ethyl acetate:hexanes) gave the desired azide (580 mg, 94%). ¹H NMR showed a 4:1 mixture due to partial epimerization at alpha position of the ester. MS found: (M+H)⁺=407.

(221f) The azide from reaction (221e) (190 mg, 0.467 mmol) in methanol (4 mL) was treated with tin(II) chloride (177 mg, 2 eq) and stirred at rt for 2 h. Additional portion of tin(II) chloride (177 mg, 2 eq) was added and the mixture stirred for 2 h. Following addition of saturated NaHCO₃ (5 mL) and ethyl acetate (100 mL), the mixture was washed with water (2x5 mL), and brine (5 mL), dried (MgSO₄), treated with 1 N HCl in ether (1 mL) and concentrated. The crude amine hydrochloride salt (220 mg) was taken to the next step without further purification. MS found: (M+H)⁺=381.

(221g) Following a procedure similar to that used for reaction (109a), the amine from reaction (221f) (220 mg) was

treated with TFA. The crude carboxylic acid (250 mg) was taken to the next step without further purification. MS found: $(M+H)^+=325$.

- 5 (221h) Following a procedure similar to that used for reaction (16f), the carboxylic acid from reaction (212g) (280 mg) was treated with BOP reagent. Purification of the residue by silica gel column chromatography (7:3 ethyl acetate:hexane, then 5:95 methanol:methylene chloride) gave
10 the desired lactam (29 mg, 20% for 3 steps). MS found: $(M+Na)^+=329$.

- (221i) The lactam from reaction (221h) (29 mg, 0.0948 mmol) in methanol (8 mL) was treated with 20% $Pd(OH)_2$ on carbon (20
15 mg) and stirred under hydrogen balloon for 2 h. The mixture was filtered and the filtrate was concentrated to provide the desired amine (16 mg, 100%). MS found: $(M+CH_3CN)^+=205$.

- (221j) Following a procedure similar to that used for
20 reaction (16f), the amine from reaction (212i) (15 mg, 0.0871 mmol) was coupled with 4-(2-methyl-4-quinolinylmethoxy)benzoic acid. Purification of the residue by silica gel column chromatography (7:3 ethyl acetate:hexanes, then 5:95 methanol:methylene chloride) gave
25 the amide compound (25 mg, 64%). MS found: $(M+H)^+=448$.

- (221k) Following a procedure similar to that used for reaction (100b), the intermediate from reaction (221j) (25 mg, 0.0559 mmol) was treated with hydroxylamine.
30 Purification by reverse phase HPLC, using acetonitrile:water:TFA as eluant, provided the title hydroxamic acid (6.5 mg, 21%) as bis-TFA salt. MS found: $(M+H)^+=449$.

Example 222

(3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-piperidinecarboxamide trifluoroacetate

5

(222a) Isobutylene (100 mL) was condensed into a solution of L-ASP(OMe)-OH hydrogen chloride (10.0 g, 54.4 mmol) in dioxane (100 mL) and sulfuric acid (10 mL) in a 350-mL pressure bottle. The resultant mixture was shaken
10 mechanically at rt for 4 h and poured into a cold mixture of 1 N NaOH (500 mL) and ether (250 mL). The aqueous phase was extracted with ethyl acetate (3x200 mL). The combined organic extracts were washed with brine (30 mL), dried (MgSO₄) and concentrated to provide the desired ester (2.10
15 g, 19%). MS found: (M+H)⁺=204.

(222b) Following a procedure similar to that used for reaction (126a), the ester from reaction (222a) (2.10 g, 10.3 mmol) was treated with benzaldehyde (1.26 mL, 1.2 eq).
20 Purification of the residue by silica gel column chromatography (3:7 ethyl acetate:hexanes) gave the desired amine (2.00 g, 66%). MS found: (M+H)⁺=294.

(222c) A mixture of the amine for reaction (222b) (2.60 g, 8.86 mmol), potassium phosphate (3.76 g, 2 eq), Lead (II) nitrate (2.35 g, 0.8 eq) and 9-phenylfluorenyl-9-bromide (3.13 g, 1.1 eq) in acetonitrile (100 mL) was shaken at rt for 15 h. Following addition of methylene chloride (200 mL and the mixture was filtered through a silica gel pad. The
30 filtrate was concentrated and purified by silica gel column chromatography (1:9 ethyl acetate:hexanes) to provide the desired tertiary amine (4.80 g, 100%). MS found: (M+Na)⁺=556.

(222d) A 0.5 M toluene solution of potassium bis(trimethylsilyl)amide (32.2 mL, 2 eq) and allyl iodide (1.47 mL, 2 eq) were added sequentially to a solution of the amine from reaction (222c) (4.30 g, 8.06 mmol) in THF (100 mL) at -20°C. After 2 h at -20°C, the mixture was quenched with pH7 phosphate buffer (30 mL). The aqueous phase was extracted with ethyl acetate (2x100 mL). The combined organic layers were washed with brine (20 mL), dried (MgSO₄) and concentrated. ¹H NMR analysis of the crude material showed a 5:1 mixture of two isomers. Silica gel column chromatography (5:95 ethyl acetate:hexanes) gave the major isomer (3.00 g, 78%). MS found: (M+Na)⁺=596.

(222e) O₃ was bubbled into a solution of the intermediate from reaction (222d) (500 mg, 0.872 mmol) in methylene chloride (30 mL) at -78°C until the solution turned blue (approximately 2 min). The mixture was bubbled with N₂ until the blue color disappeared, and then treated with triphenylphosphine (458 mg, 2 eq). After 4 h at rt, the mixture was concentrated and purified by silica gel column chromatography (1:9 ethyl acetate:hexanes) to provide the desired aldehyde (380 mg, 76%). MS found: (M+Na)⁺=598.

(222f) Sodium triacetoxyborohydride (423 mg, 6 eq) was added to a solution of the aldehyde from reaction (222e) (190 mg, 0.330 mmol) and ammonium acetate (255 mg, 10 eq) in acetic acid (2 mL) and acetonitrile (2 mL) at 0°C. After 30 minutes at 0°C, another portion of sodium triacetoxyborohydride (282 mg, 4 eq) was added. After an additional 30 minutes at 0 °C, the mixture was diluted with ethyl acetate (100 mL) and washed with saturated ammonium chloride (5 mL), brine (5 mL), dried (MgSO₄) and concentrated. Purification of the residue by silica gel column chromatography (1:1 ethyl acetate:hexanes, then 1:9 methanol:methylene chloride) gave

the desired primary amine (80 mg, 42%). MS found:
(M+H)⁺=577.

(222g) The amine from reaction (222f) (80 mg, 0.139 mmol)
5 was treated with TFA (2 mL) at rt for 3 h and concentrated.
The crude carboxylic acid (70 mg) was taken to the next step
without further purification. MS found: (M+H)⁺=281.

(222h) Following a procedure similar to that used for
10 reaction (16f), the carboxylic acid from reaction (222g) (70
mg) was treated with BOP reagent. Purification of the
residue by silica gel column chromatography (1:1 ethyl
acetate:hexane, then 5:95 methanol:methylene chloride) gave
the desired lactam (25 mg, 69% for 2 steps). MS found:
15 (M+H)⁺=263.

(222i-k) Following the procedure similar to that used for
steps from (221i-k), but using the lactam from reaction
(222h) (25 mg, 0.0953 mmol), the title compound was
20 prepared. The product was purified by reverse phase HPLC,
using acetonitrile:water:TFA as eluant, to provide the
desired hydroxamic acid (6.5 mg, 13% for 3 steps) as bis-TFA
salt. MS found: (M+H)⁺=449.

25

Example 223

(3*S*,4*S*)-3-[[4-(2-butynyloxy)benzoyl]amino]-*N*-hydroxy-1-
isopropyl-4-piperidinecarboxamide trifluoroacetate

(223a) The intermediate from reaction (134e) (1.0 g, 1.83
30 mmol) was treated with Pd(OH)₂/C (0.20 g, 20% wt.) and
ethanol (20 mL). The resulting mixture stirred under
hydrogen balloon overnight. After removal of catalyst by
filtration, the filtrate was concentrated and purified by
silica gel chromatography to yield the phenol (0.60 g, 84%).
35 MS found: (M+H)⁺=393.

(223b) The phenol from reaction (223a) (0.10 g, 0.26 mmol) was alkylated with 1-bromo-2-butyne (0.03 mL, 1.3 eq) and K_2CO_3 (0.18 g, 5 eq) in acetonitrile (5 mL) at reflux for 3 h. The mixture was cooled to room temperature and partitioned between water (10 mL) and ethyl acetate (50 mL). The organic layer was separated, dried ($MgSO_4$), concentrated and purified by silica gel chromatography (40% ethyl acetate/hexane) to yield the desired product (0.11 g, 99%).
10 MS found: $(M+H)^+=445$.

(223c) The intermediate from reaction (223b) (0.10 g, 0.23 mmol) was treated with dichloromethane (2 mL) and trifluoroacetic acid (1 mL) at room temperature for 1 h, then concentrated and pumped in vacuo overnight to give the amine TFA salt (0.1 g, 100%). MS found: $(M+H)^+=345$.
15

(223d-e) Following procedures analogous to that used in reaction (16h) and (1d), the intermediate from reaction (223c) (72 mg, 0.16 mmol) was converted to the title compound (37 mg, 71%). MS found: $(M+H)^+=374$.
20

Example 224

(3*S*,4*S*)-3-{[4-(2-butyntyloxy)benzoyl]amino}-*N*-hydroxy-4-piperidinecarboxamide trifluoroacetate.
25

(224a) Following a procedure analogous to that used in reaction (1d), the intermediate from reaction (223c) (27 mg, 0.08 mmol) was converted to the title compound (10 mg, 28%).
30 MS found: $(M+H)^+=332$.

Example 225

tert-butyl (3*S*,4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-1-piperidinecarboxylate trifluoroacetate
35

(225a) To a 0°C solution of the phenol from reaction (223a) (0.10 g, 0.255 mmol) and 2-methyl-3-hydroxymethyl-pyridine (38 mg, 1.2 eq) in THF (2 mL) was added triphenylphosphine (80 mg, 1.2 eq) and diethyl azodicarboxylate (0.05 mL, 1.2 eq). After stirred at room temperature overnight, the mixture was quenched with saturated NH₄Cl, extracted with ethyl acetate (2x20 mL), dried (MgSO₄), concentrated and purified by silica gel chromatography (80% ethyl acetate/hexane) to yield the desired product (0.12 g, 100%). MS found: (M-H)⁻=496.

(225b) Following a procedure analogous to that used in reaction (1d), the intermediate from reaction (225a) (0.12 g, 0.25 mmol) was treated with hydroxylamine solution. Purification by reverse phase HPLC (25-50% acetonitrile/water) yielded the desired hydroxamic acid (67 mg, 52%). MS found: (M+H)⁺=485.

20

Example 226

(3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide bis(trifluoroacetate)

(226a) The hydroxamic acid from reaction (225b) (20 mg, 0.033 mmol) was treated with dichloromethane (2 mL) and trifluoroacetic acid (0.2 mL) at room temperature for 1 h. After removal of solvent in vacuo, the residue was purified by reverse phase HPLC (5-30% acetonitrile/water) to yield the titled compound (10 mg, 49%). (M+H)⁺=385.

30

Example 227

tert-butyl (3*S*,4*S*)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-4-[(hydroxyamino)carbonyl]-1-piperidinecarboxylate

35

(227a) To a mixture of the phenol from reaction (223a) (0.10 g, 0.255 mmol) and 2,5-dimethylbenzyl chloride (0.05 mL, 1.3 eq) in DMSO (1 mL) was added sodium iodide (51 mg, 1.3 eq) and Cs₂CO₃ (0.25 g, 3.0 eq). After 2 h at room temperature, the reaction mixture was quenched with saturated NH₄Cl, extracted with ethyl acetate (2x20 mL), dried (MgSO₄), concentrated and purified by silica gel chromatography (50% ethyl acetate/hexane) to yield the desired product (0.10 g, 77%). MS found: (M+H)⁺=511.

(227b) Following a procedure analogous to that used in reaction (1d), the intermediate from reaction (227a) (0.10 g, 0.20 mmol) was converted to the desired hydroxamic acid (92 mg, 97%). MS found: (M-H)⁻=496.

Example 228

(3*S*,4*S*)-3-((4-[(2,5-dimethylbenzyl)oxy]benzoyl)amino)-*N*-hydroxy-4-piperidinecarboxamide trifluoroacetate

20

(228a) The hydroxamic acid from reaction (227b) (26 mg, 0.053 mmol) was treated with dichloromethane (2 mL) and trifluoroacetic acid (1 mL) at room temperature for 1 h. After removal of solvent in vacuo, the residue was purified by reverse phase HPLC (30-55% acetonitrile/water) to yield the titled compound (9.5 mg, 35%). (M+H)⁺=398.

Example 301

(*cis*,*cis*)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide bis-trifluoroacetate salt

30

(301a) To a solution of 3-hydroxy-2-nitrobenzoic acid (10 g, 54.6 mmol) in EtOH (150 mL) and benzene (150 mL) was added concentrated sulfuric acid (40 mL). The mixture was heated

35

at reflux for 48 hours with azeotropic removal of water and concentrated on a rotary evaporator. The residue was dissolved in EtOAc (200 mL) and the resulting solution was washed with saturated NaHCO_3 (2x100 mL) and brine (2x100 mL).
5 The organic layer was dried (MgSO_4) and concentrated on a rotary evaporator to give the ethyl ester (11g, 95%) as a solid. MS-ESI $(\text{M}+\text{H})^+=212.1$.

(301b) The above compound (11g, 52.1 mmol) was mixed with
10 0.5% aqueous HCl (200 mL) and PtO_2 (2.2 g) in a Parr bottle. The mixture was hydrogenated on a Parr shaker at 55 psi for 24 hours. The catalyst was filtered off and the filtrate was concentrated on a rotary evaporator. The residue was dried *in vacuo* to give the crude ethyl 2-amino-3-
15 hydroxycyclohexylcarboxylate (12 g, 100%). MS-ESI $(\text{M}+\text{H})^+=188.1$

(301c) To a solution of 301b (1.8 g, 8 mmol) and 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid (1.7 g, 6 mmol) in
20 DMF (10 mL) cooled in an ice bath was added BOP (3.1 g, 7 mmol) followed by N-methylmorpholine (3 g, 30 mmol). The mixture was stirred at room temperature overnight. EtOAc (100 mL) was added and the solution was washed with brine (2x50 mL), NaHCO_3 (2x50 mL) and brine (2x50 mL), dried
25 (MgSO_4) and concentrated on a rotary evaporator. The crude product was chromatographed on a silica gel column (10% $\text{MeOH}/\text{CH}_2\text{Cl}_2$) to provide 301c (0.8 g, 30%) as a solid. MS-ESI $(\text{M}+\text{H})^+=449.2$.

30 (301d) Compound 301c (350 mg, 0.78 mmol) was dissolved in chloroform (10 mL)/TFA (0.5 mL). To it was added Dess-Martin periodinane (365 mg, 0.86 mmol) and the solution was stirred for 2 hours. Insoluble material was filtered off and the filtrate was concentrated on a rotary evaporator to provide
35 the crude ketone product as a solid. MS-ESI $(\text{M}+\text{H})^+=461.2$.

(301e) To a solution of 301d (120 mg, 0.21 mmol) in DMF (2 mL) was added acetic acid (0.2 mL) followed by NH_4OAc (90 mg, 1.2 mmol) and $\text{Na}(\text{OAc})_3\text{BH}$ (120 mg, 0.6 mmol). The mixture was stirred at room temperature for 3 hours and purified using reverse phase HPLC to provide the amino product (55 mg, 40%) as a powder. MS-ESI $(\text{M}+\text{H})^+=462.3$.

(301f) Compound 301e (40 mg, 0.058 mmol) was dissolved in DMF (1 mL) and to it was added N-methylmorpholine (40 mg, 0.4 mmol) followed by di-tert-butyl-dicarbonate (22 mg, 0.1 mmol). The mixture was stirred at room temperature for 5 hours and purified using reverse phase HPLC to provide the Boc-protected product (20 mg, 51%) as a powder. MS-ESI $(\text{M}+\text{H})^+=562.3$.

(301g) A mixture of 301f (20 mg, 0.03 mmol) in MeOH (2 mL) and 1 N KOH (0.5 mL) was heated at 60 °C for 1 hour and the solution was concentrated on a rotary evaporator. The residue was dissolved in DMSO/HOAc and purified using reversed phase HPLC to provide the carboxylic acid (16 mg, 83%) as a powder. MS-ESI $(\text{M}+\text{H})^+=534.2$.

(301h) To a solution of 301g (15 mg, 0.023 mmol) in DMF (1 mL) was added N-methylmorpholine (20 mg, 0.2 mmol) followed by hydroxylamine hydrochloride (10 mg, 0.14 mmol). After all solid was dissolved, the solution was cooled in an ice bath and to it was added BOP (22 mg, 0.05 mmol). The mixture was stirred for 30 min at room temperature. Purification using reversed phase HPLC provided the hydroxamic acid (10 mg, 67%) as a powder. MS-ESI $(\text{M}+\text{H})^+=549.3$.

(301i) Compound 301h (10 mg) was dissolved in a mixed solvent of 40% TFA in CH_2Cl_2 (1 mL) and after 30 min, the solvent was removed by evaporation. The residue was

dissolved in water/acetonitrile. Lyophilization provided the desired product as a powder. MS-ESI (M+H)⁺=449.3.

Example 302

5 (*cis,cis*)-3-Methylamino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide bis-trifluoroacetate salt

(302a) To a solution of 301d (100 mg, 0.17 mmol) in DMF (1
10 mL) was added HOAc (48 mg, 0.8 mmol) followed by methylamine (2 M solution in THF, 0.4 mL, 0.8 mmol) and Na(OAc)₃BH (80 mg, 0.4 mmol). The mixture was stirred for 3 hours at room temperature. Purification using reversed phase HPLC provided the methylamino product (70 mg, 58%) as a powder. MS-ESI
15 (M+H)⁺=476.3.

(302b) Compound 302a (70 mg, 0.1 mmol) was reacted with di-tert-butyl-dicarbonate using the procedure described in (301f) to provide the Boc-protected product (55 mg, 80%) as
20 a powder. MS-ESI (M+H)⁺=576.3.

(302c) The final product was obtained by saponification of the ethyl ester 302b followed by coupling of the carboxylic acid with hydroxylamine hydrochloride and removal of the Boc
25 group using procedures similar to those described in (301g)-(301i). MS-ESI (M+H)⁺=463.3.

Example 303

30 (*cis,cis*)-3-Dimethylmino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(N-hydroxy)cyclohexylcarboxamide bis-trifluoroacetate salt

(303a) To a solution of 302a (100 mg, 0.14 mmol) in DMF (1 mL) was added formaldehyde (37% aqueous solution, 82 mg, 1
35 mmol) followed by N-methylmorpholine (100 mg, 1 mmol) and

Na(OAc)₃BH (84 mg, 0.4 mmol). The mixture was stirred for 2 hours at room temperature. Purification using reversed phase HPLC provided the dimethylamino product (100 mg, 99%) as a powder. MS-ESI (M+H)⁺=490.2.

5

(303b) The final compound was obtained by saponification of the ethyl ester 303a followed by coupling the resulting carboxylic acid with hydroxylamine hydrochloride using procedures similar to those described in (301g) and (301h).

10 . MS-ESI (M+H)⁺=477.3.

Example 304

(*cis,trans*)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(N-
15 hydroxy)cyclohexylcarboxamide bis-trifluoroacetate salt

(304a) To a solution of 301b (3.6 g, 16 mmol) and 4-benzyloxybenzoic acid (3.7 g, 16 mmol) in DMF (10 mL) cooled in an ice bath was added BOP (8 g, 18 mmol) followed by N-methylmorpholine (7.4 mL, 64 mmol). The mixture was stirred at room temperature overnight and diluted with EtOAc (150 mL). The resulting solution was washed with NaHCO₃ (2x70 mL) and brine (2x70 mL), dried (MgSO₄) and concentrated on a rotary evaporator. The residue was chromatographed on a
20 silica gel column (5% MeOH/CH₂Cl₂) to provide the amide product (2.3 g, 36%) as a solid. MS-ESI (M+H)⁺=398.2.

(304b) To a solution of 304a (2.3 g, 5.8 mmol) in CHCl₃ (15 mL) cooled in an ice bath was added N-methylmorpholine (1.1 mL, 10 mmol) followed by methanesulfonyl chloride (0.7 g, 6 mmol). The mixture was stirred in the ice bath for 2 hours and at room temperature overnight. The solvent was removed by concentration and the residue was dissolved in EtOAc. The resulting solution was washed with brine, dried (MgSO₄) and
30 concentrated. Chromatography on a silica gel column (50%

EtOAc/hexane) provided the mesylate (1.6 g, 60%) as a solid.
MS-ESI (M+H)⁺=476.2.

(304c) A mixture of 304b (1.2 g, 2.5 mmol) and sodium azide
5 (0.33 g, 5.1 mmol) in DMF (15 mL) was heated at 100 °C for 5
hours. DMF was removed by evaporation in vacuo. The residue
was dissolved in EtOAc and the resulting solution was washed
with brine, dried (MgSO₄) and concentrated. Chromatography on
a silica gel column (40% EtOAc/hexane) provided the azido
10 product (0.69 g, 65%) as a solid. MS-ESI (M+H)⁺=423.1.

(304d) Compound 304c (0.69 g, 1.6 mmol) was dissolved in
MeOH (20 mL) in a Parr bottle and to it was added 4 N HCl in
dioxane (0.5 mL) followed by 10% Pd-C (0.1 g). The mixture
15 was hydrogenated on a Parr shaker at 50 psi for 4 hours. The
catalyst was filtered off and the filtrate was concentrated
on a rotary evaporator to provide the amino product (0.55 g,
99%) as a solid. MS-ESI (M+H)⁺=307.2.

20 (304e) To a solution of 304d (0.55 g, 1.6 mmol) in THF (15
mL) and water (2 mL) cooled in an ice bath was added 1 N
NaOH (1.6 mL) followed by NaHCO₃ (0.5 g, 6 mmol) and di-tert-
butyl-dicarbonate (0.35 g, 1.6 mmol). The mixture was
stirred 4 hours at room temperature. EtOAc (150 mL) was
25 added and the solution was washed with brine (2x60 mL),
dried (MgSO₄) and concentrated on a rotary evaporator to give
the crude Boc-protected product that was used for the next
reaction without purification. MS-ESI (M+H)⁺=407.2.

30 (304f) A mixture of 304e (0.65 g, 1.6 mmol), 4-chloromethyl-
2-methylquinoline (0.36 g, 1.6 mmol) and K₂CO₃ (1 g, 7.2
mmol) in acetone (15 mL) was heated at reflux for 4 hours.
EtOAc (150 mL) was added and the resulting solution was
washed with brine (2x60 mL), dried (MgSO₄), and concentrated
35 on a rotary evaporator. Purification using reversed phase

HPLC provided 304f (0.68 g, 67%) as a powder. MS-ESI
(M+H)⁺=562.3.

(304g) Compound 304f (0.37 g, 0.65 mmol) was dissolved in
5 MeOH (5 mL) and KOH (0.15 g) in water (1 mL) was added. The
mixture was heated at 50°C for 1 hour and acidified with 0.2
mL HOAc. Purification on reversed phase HPLC provided the
carboxylic acid (0.25 g, 70%) as a powder. MS-ESI
(M+H)⁺=534.2.

10

(304h) To a solution of 304g (58 mg, 0.1 mmol) in DMF (2 mL)
was added hydroxylamine hydrochloride (32 mg, 0.4 mmol)
followed by N-methylmorpholine (0.06 mL, 0.5 mmol). After
all solid was dissolved, the solution was cooled in an ice
15 bath. To it was added BOP (54 mg, 0.12 mmol) and the mixture
was stirred for 1 hour. Purification on reversed phase HPLC
provided the hydroxamic acid as a powder. MS-ESI
(M+H)⁺=549.2.

20 (304i) Compound 304h (30 mg) was treated with TFA (1
mL)/CH₂Cl₂ (3 mL) for 20 min and the solution was
concentrated on a rotary evaporator. The residue was taken
up in water/acetonitrile. Lyophilization provided the final
product as a powder. MS-ESI (M+H)⁺=449.2.

25

Example 305

(*cis,trans*)-3-Dimethylmino-2-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-
hydroxy)cyclohexylcarboxamide bis-trifluoroacetate salt

30

(305a) Compound 304g (160 mg) was treated with TFA (1
mL)/CH₂Cl₂ (3 mL) for 20 min and the solution was
concentrated on a rotary evaporator. MS-ESI (M+H)⁺=434.2.

(305b) To a solution of 305a (50 mg, 0.075 mmol) in THF (2 mL) was added formaldehyde (37% aqueous solution, 0.04 mL, 0.42 mmol) followed by N-methylmorpholine (40 mg, 0.4 mmol) and NaBH₃CN (24 mg, 0.4 mmol). After stirring at room temperature for 1 hour, the mixture was purified on reversed phase HPLC to provide the dimethylamino product (48 mg, 92%) as a powder. MS-ESI (M+H)⁺=462.2.

(305c) Coupling of 305b with hydroxylamine hydrochloride using a procedure similar to that described in (304h) provided the hydroxamic acid as a powder. MS-ESI (M+H)⁺=477.3.

Example 306

(*cis,trans*)-3-(1-Methyl-1-ethylmino)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide bis-trifluoroacetate salt

(306a) To a solution of compound 305a (52 mg, 0.08 mmol) in THF (2 mL) was added acetone (0.1 mL) followed by N-methylmorpholine (40 mg, 0.4 mmol) and Na(OAc)₃BH (25 mg, 0.12 mmol). The mixture was stirred at room temperature overnight. Concentration on a rotary evaporator followed by purification on reversed phase HPLC provided the desired product (45 mg, 80%) as a powder. MS-ESI (M+H)⁺=476.2.

(306b) Coupling of 306a with hydroxylamine hydrochloride using a procedure similar to that described in (304h) provided the hydroxamic acid as a powder. MS-ESI (M+H)⁺=491.3.

Example 307

(*cis,trans*)-3-Methylamino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide bis-trifluoroacetate salt

(307a) To a solution of compound 304d (0.166 g, 0.39 mmol) and benzaldehyde (0.042 g, 0.4 mmol) in THF (5 mL) was added Na(OAc)₃BH (0.1 g, 0.5 mmol). The mixture was stirred for 1
5 hour at room temperature. The product formed was a bis-benzylated product. More benzaldehyde (0.042 g, 0.4 mmol) and Na(OAc)₃BH were added. The mixture was stirred for another hour and purified on reversed phase HPLC to provide the bis-benzylated product (0.15 g, 78%) as a powder. MS-
10 ESI (M+H)⁺=487.3.

(307b) Compound 307a (0.15 g, 0.3 mmol) was dissolved in MeOH (10 mL) and 10% Pd-C (30 mg) was added. The mixture was hydrogenated at atmospheric pressure for 3 hours. The
15 catalyst was filtered off and the filtrate was concentrated on a rotary evaporator. Purification on reversed phase HPLC provided the mono-benzylated product (114 mg, 75%) as a powder. MS-ESI (M+H)⁺=397.2.

(307c) To a solution of 307b (81 mg, 0.16 mmol) and Na(OAc)₃BH (20 g, 0.32 mmol) in THF (2 mL) was added N-methylmorpholine (40 mg, 0.4 mmol) followed by formaldehyde (37% aqueous solution, 25 mg, 0.3 mmol). The mixture was stirred for 1 hour and concentrated on a rotary evaporator.
25 Chromatography on a silica gel column (10% MeOH/CH₂Cl₂) provided the N-benzyl-N-methyl product (60 mg, 94%) as a solid. MS-ESI (M+H)⁺=411.2.

(307d) Compound 307c (60 mg, 0.15 mmol) was dissolved in EtOH (5 mL) in a Parr bottle and to it was added 4 N HCl in dioxane (0.1 mL) followed by 10% Pd-C (10 mg). The mixture was hydrogenated on a Parr shaker at 50 psi for 4 hours. The catalyst was filtered off and the filtrate was concentrated on a rotary evaporator to provide the methylamino product as
35 a solid. MS-ESI (M+H)⁺=321.2.

- (307e) To a solution of 307d (46 mg, 0.13 mmol) in THF (4 mL)/saturated aqueous NaHCO₃ solution (1 mL) cooled in an ice bath was added 1 N NaOH (0.13 mL) followed by di-tert-butyl-
5 dicarbonate (28 mg, 0.13 mmol). The mixture was stirred at room temperature overnight. EtOAc (50 mL) was added and the solution was washed with brine (2x20 mL), dried (MgSO₄) and concentrated on a rotary evaporator. MS-ESI (M+H)⁺=421.1.
- 10 (307f) A mixture of the crude product 307e, 4-chloromethyl-2-methylquinoline (30 mg, 0.13 mmol), K₂CO₃ (138 mg, 1 mmol) and Bu₄NI (20 mg, 0.13 mmol) in DMF (2 mL) was heated at 60 °C for 5 hours. Purification using reversed phase HPLC
15 provided the desired product (68 mg, 90%) as a powder. MS-ESI (M+H)⁺=576.3.

- (307g) The final product was obtained by saponification of the ethyl ester 307f followed by acid deprotection of the Boc group using procedures similar to those described in
20 (304g)-(304i). MS-ESI (M+H)⁺=463.2.

Example 308

- (*cis,cis*)-3-Hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-
25 hydroxy)cyclohexylcarboxamide trifluoroacetate salt

- This compound was obtained by saponification of the ethyl ester intermediate 301c followed by coupling the resulting carboxylic acid with hydroxylamine hydrochloride using
30 procedures similar to those described in (304g) and (304h). MS-ESI (M+H)⁺=450.2.

Example 309

- N-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[[[2-methyl-4-quinolinyl)methyl]amino]benzamide
35

(309a) A mixture of methyl 4-aminobenzoate (1.51 g, 10 mmol), 4-chloromethyl-2-methylquinoline hydrochloride (2.28 g, 10 mmol) and K_2CO_3 (3.2 g, 25 mmol) in DMF (20 mL) was stirred at 100°C overnight. EtOAc (200 mL) was added. The solution was washed with water 2x, brine 2x, dried ($MgSO_4$) and concentrated. Flash chromatography on silica eluting with EtOAc/hexanes (2:1) provided the desired product (600 mg, 20%). MS m/z 307.1 ($M+H$)⁺.

10

(309b) To a solution of 309a (400 mg, 1.3 mmol) in MeOH (5 mL) and THF (5 mL) was added 1 N KOH (5 mL). The solution was stirred at 80°C for 3 h and concentrated. The residue was taken up in 1 N HCl solution (4 mL) and the solvent was removed under reduced pressure. The resulting residue was dissolved in MeOH. Insoluble materials were filtered off and the filtrate was concentrated to give the desired carboxylic acid product that was used for the next reaction without purification. MS m/z 293.2 ($M+H$)⁺.

20

(309c) To a solution of 309b (200 mg, 0.684 mmol), ethyl *cis*-2-aminocyclopentanecarboxylate hydrochloride (108 mg, 0.6 mmol) and triethylamine (303 mg, 3 mmol) in DMF (3 mL) cooled in an ice bath was added BOP (266 mg, 0.6 mmol). The solution was stirred at room temperature for 2 h. Purification by reversed phase HPLC provided the desired product (130 mg, 34%) as a bis-trifluoroacetate. MS m/z 418.2 ($M+H$)⁺.

(309d) Compound 309c (120 mg, 0.186 mmol) was dissolved in a 1.7 M hydroxylamine solution (3 mL). The reaction was stirred at room temperature for 20 min and quenched with a solution of 4 N HCl in dioxane (0.5 mL). The solvents were removed under reduced pressure and the residue was purified

by reversed phase HPLC to give the desired product (90 mg, 75%) as a powder. MS m/z 419.1 (M+H)⁺.

Example 310

5 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-{methyl[(2-methyl-4-quinolinyl)methyl]amino}benzamide

(310a) This compound was prepared using procedures analogous to those described for Example 309. MS m/z 433.2 (M+H)⁺.

10

Example 311

N-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-(3-phenyl-4,5-dihydro-5-isoxazolyl)benzamide

15 (311a) To a stirred solution of benzaldehyde oxime (605 mg, 5 mmol) and methyl 4-vinylbenzoate (810 mg, 5 mmol) in CH₂Cl₂ (20 mL) was added a bleach solution (30 mL). The mixture was stirred at room temperature for 4 h and diluted with CH₂Cl₂. The organic phase was separated, washed with brine
20 2x, dried (MgSO₄) and concentrated. Chromatography on a silica gel column eluting with EtOAc/hexanes (1:2) provided the desired product (500 mg, 36%) as a solid. MS m/z 323.2 (M+H)⁺.

25 (311b) To a solution of 3a (500 mg, 1.78 mmol) in THF (10 mL) was added 1 N KOH (5 mL). The solution was stirred at room temperature overnight and acidified with 1 N HCl to pH=3. The resulting solution was extracted with EtOAc 2x. The combined organic phase was washed with brine 2x, dried
30 (MgSO₄) and concentrated to give the desired acid (400 mg, 84%). MS m/z 268.2 (M+H)⁺.

(311c) To a solution of 3b (133 mg, 0.5 mmol), ethyl *cis*-2-aminocyclopentanecarboxylate hydrochloride (116 mg, 0.6
35 mmol) and triethylamine (303 mg, 3 mmol) in DMF (3 mL)

cooled in an ice bath was added BOP (253 mg, ~0.6 mmol). The solution was stirred at room temperature for 2 h. Purification by reversed phase HPLC provided the desired product (170 mg, 84%) as a powder. MS m/z 407.1 (M+H)⁺.

5

(311d) Compound 3c (170 mg, 0.41 mmol) was dissolved in a 1.7 M hydroxylamine solution (3 mL). After stirring at room temperature for 20 min, a solution of TFA (0.3 mL) in CH₂Cl₂ (2 mL) was added slowly. The solvents were removed under reduced pressure and the residue was purified by reversed phase HPLC to give the desired product (90 mg, 56%) as a powder. MS m/z 394.1 (M+H)⁺.

10

Example 312

15 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

(312a) This compound was prepared using procedures analogous to those described for Example 311. MS m/z 395.1 (M+H)⁺.

20

Example 313

N-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(3-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

25 (313a) This compound was prepared using procedures analogous to those described for Example 311. MS m/z 395.2 (M+H)⁺.

Example 314

30 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(2-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

(314a) This compound was prepared using procedures analogous to those described for Example 311. MS m/z 395.2 (M+H)⁺.

Example 315

N-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-quinolinyl)-4,5-dihydro-5-isoxazolyl]benzamide

5 (315a) This compound was prepared using procedures analogous to those described for Example 311. MS *m/z* 445.1 (*M*+*H*)⁺.

Example 316

4-[3-(2,6-Dimethyl-4-pyridinyl)-4,5-dihydro-5-isoxazolyl]-*N*-
10 {*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide

(316a) This compound was prepared using procedures analogous to those described for Example 311. MS *m/z* 423.1 (*M*+*H*)⁺.

15 **Example 317**

N-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-3-methoxy-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide

(317a) This compound was prepared using procedures analogous
20 to those described for Example 311. MS *m/z* 425.1 (*M*+*H*)⁺.

Example 318

3-Hydroxy-*N*-{*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
25

(318a) This compound was prepared using procedures analogous to those described for Example 311. MS *m/z* 411.1 (*M*+*H*)⁺.

Example 319

30 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(2-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide

(319a) To a solution of methyl 4-formylbenzoate (10 g, 61 mmol) in MeOH (100 mL) was added hydroxylamine hydrochloride
35 (7 g, 100 mmol) followed by triethylamine (13.9 mL, 100

mmol). The mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and the residue was taken up in EtOAc (300 mL). The solution was washed with brine 3x, dried (MgSO_4), and concentrated. Flash chromatography on silica eluting with EtOAc/hexanes (2:1) provided the desired oxime product (2.5 g, 23%) as a solid. MS m/z 180.1 ($\text{M}+\text{H}$)⁺.

(319b) To a solution of 11a (716 mg, 4 mmol) and 2-vinylpyridine (525 mg, 5 mmol) in CH_2Cl_2 (20 mL) was added a solution of bleach (30 mL). The solution was stirred at room temperature overnight and diluted with CH_2Cl_2 . The organic phase was separated, washed with brine 2x, dried (MgSO_4) and concentrated. Chromatography on a silica gel column eluting with EtOAc/hexanes (2:1) provided the desired product (800 mg, 73%) as a solid. MS m/z 283.2 ($\text{M}+\text{H}$)⁺.

(319c) To a solution of 11b (800 mg, 2.83 mmol) in THF (5 mL) and MeOH (3 mL) was added a solution of 1 N KOH (5 mL). The solution was stirred at room temperature for 4 h and acidified with a solution of 1 N HCl (6 mL). The solvents were removed under reduced pressure. The residue was dissolved in MeOH, the insoluble materials were filtered off and the filtrate was concentrated to give the desired carboxylic acid that was used for the next reaction without purification. MS m/z 269.2 ($\text{M}+\text{H}$)⁺.

(319d) To a solution of 11c (152 mg, 0.5 mmol), ethyl *cis*-2-aminocyclopentanecarboxylic acid hydrochloride (116 mg, 0.6 mmol) and triethylamine (303 mg, 3 mmol) in DMF (3 mL) cooled in an ice bath was added BOP (253 mg, 0.6 mmol). The solution was stirred at room temperature for 4 h. Purification by reversed phase HPLC provided the desired product (190 mg, 73%) as a TFA salt. MS m/z 408.1 ($\text{M}+\text{H}$)⁺.

35

(319e) Treatment of 11d with a solution of hydroxylamine following the procedure described in (311d) provided the desired hydroxamic acid. MS m/z 395.1 (M+H)⁺.

5

Example 320

N-(*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl)-4-[5-(4-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide

(320a) This compound was prepared using procedures analogous to those described for Example 319. MS m/z 395.1 (M+H)⁺.

10

Example 501

N-(4-[(hydroxyamino)carbonyl]-3-pyrrolidinyl)-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide
bis(trifluoroacetate)

15

(501a) Indole 5-carboxylic acid (0.5 g, 3.1 mmol) was added to a suspension of sodium hydride (0.27 g, 6.8 mmol, 60% oil dispersion) (washed with hexanes) in DMF (20 mL) cooled to 0°C. The reaction was allowed to stir for 1 h and the 4-chloromethyl-2-methyl-quinoline (0.72 g, 3.8 mmol) was added. The reaction was allowed to warm to room temperature and stirred overnight. The reaction was neutralized with 1 N HCl and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate and concentrated to give the 1-[(2-methyl-5,8-dihydro-4-quinolinyl)methyl]-1*H*-indole-5-carboxylic acid (0.68 g, 69%) as a brown residue, MS (M+H)⁺ = 317.

20

25

(501b) Thionyl chloride (5 mL) was added to a suspension of the 1-[(2-methyl-5,8-dihydro-4-quinolinyl)methyl]-1*H*-indole-5-carboxylic acid from step (501a) (0.67 g, 2.1 mmol) in methylene chloride (15 mL) and was heated to reflux for 2 h. The reaction was cooled to room temperature, concentrated in vacuo to give the 1-[(2-methyl-5,8-dihydro-4-

30

35

quinolinyl)methyl]-1H-indole-5-carbonyl chloride (0.68 g, 80%) as a yellow solid.

(501c) The 1-tert-butyl 3-methyl 4-amino-1,3-pyrrolidinedicarboxylate (0.10 g, 0.41 mmol) was combined with the acid chloride from step (501b) (0.10 g, 0.32 mmol) in methylene chloride (15 mL) and water saturated sodium bicarbonate (15 mL). The reaction was stirred for 3.5 h, partitioned between methylene chloride and water. The organic layer was washed with brine, dried over magnesium sulfate and concentrated to give a solid. This was purified by flash chromatography on silica gel eluting hexane: ethyl acetate (30:60, v:v) to give the 1-tert-butyl 3-methyl 4-[(1-[(2-methyl-4-quinolinyl)methyl]-1H-indol-5-yl)carbonyl]amino]-1,3-pyrrolidinedicarboxylate (0.120 g, 70%) as a solid, MS (M+H)⁺ = 543.

(501d) TFA (2mL) was added to a solution of the coupled product (0.11 g, 0.2 mmol) from step (501c) in methylene chloride (3 mL) at room temperature. The reaction was complete after stirring for 2 h and was concentrated to give methyl 4-[(1-[(2-methyl-4-quinolinyl)methyl]-1H-indol-5-yl)carbonyl]amino]-3-pyrrolidinecarboxylate (0.165 g, 100%) as an oil, MS (M+2H)⁺⁺ = 222.

(501e) Following a procedure analogous to that used in example (1d) for the conversion to the hydroxamic acid, but using the methyl ester step (501d) the title compound (0.065 g, 23%) was prepared as a white amorphous solid, MS (M+H)⁺ = 444.

Example 502

N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1H-indole-5-carboxamide trifluoroacetate

(502a) Following a procedure analogous to that used in example (501) but using the methyl 2-aminocyclopentanecarboxylate, the title compound (0.038 g. 32%) was prepared as a solid, MS (M+H)⁺ = 443.

5

Example 503

N-hydroxy-3-({6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthoyl}amino)-4-piperidinecarboxamide
bis(trifluoroacetate)

10

(503a) Following a procedure analogous to that used in example (501) but using the methyl 3-amino-4-piperidinecarboxylate and 6-hydroxy-1-naphthoic acid, the title compound (0.015 g. 39%) was prepared as a white
15 amorphous solid, MS (M+H)⁺ = 485.

Example 504

N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthamide trifluoroacetate

20

(504a) Following a procedure analogous to that used in example (501) but using the methyl 2-aminocyclopentanecarboxylate and 6-hydroxy-1-naphthoic acid, the title compound (0.11 g. 57%) was prepared as a white
25 amorphous solid, MS (M+H)⁺ = 470.

Example 505

N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-2-naphthamide trifluoroacetate

30

(505a) Following a procedure analogous to that used in example (501) but using the methyl 2-aminocyclopentanecarboxylate and 6-hydroxy-2-naphthoic acid, the title compound (0.06 g. 23%) was prepared as a white
35 amorphous solid, MS (M+H)⁺ = 470.

Example 506

N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-1,2,3,4-tetrahydro-1-isoquinolinecarboxamide bis(trifluoroacetate)

(506a) Following a procedure analogous to that used in example (501) but using the methyl 2-aminocyclopentanecarboxylate and 2-(tert-butoxycarbonyl)-6-hydroxy-1,2,3,4-tetrahydro-1-isoquinolinecarboxylic acid the title compound (0.050 g. 29%) was prepared as a white amorphous solid, MS (M+H)⁺= 475.

Example 507

N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-benzimidazole-5-carboxamide trifluoroacetate

(507a) Following a procedure analogous to that used in example (501) but using the methyl 2-aminocyclopentanecarboxylate and 1*H*-benzimidazole-5-carboxylic acid the title compound (0.020 g. 5%) was prepared as a white amorphous solid, MS (M+H)⁺= 444.

Example 508

N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-4-carboxamide trifluoroacetate

(508a) Following a procedure analogous to that used in example (501) but using the methyl 2-aminocyclopentanecarboxylate and 1*H*-indole-4-carboxylic acid, the title compound (0.085 g. 56%) was prepared as a white amorphous solid, MS (M+H)⁺= 443.

Example 700

(±)-cis-N-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide, trifluoroacetate

5

(700a) Chlorosulfonylisocyanate (4.80 g, 33.9 mmol) in methylene chloride (2 mL) was added dropwise to cycloheptene in methylene chloride (25 mL) then heated to reflux under nitrogen for 10 h. The reaction was quenched by dropwise addition of water then extracted with methylene chloride (2X). The combined organic layers were washed with water (1X) and brine (1X) then dried over magnesium sulfate. The solvent was evaporated *in vacuo* and the residue diluted with ether (15 mL). The ether solution was added dropwise to a solution of 10% sodium sulfite/ether (2:1, 75 mL) maintaining the pH between 7 and 8 with 10% sodium hydroxide. After the addition was complete stirring was continued for 0.5 h then the reaction was extracted with ether (3X). The combined organic layers were washed with water (1X) and brine (1X) then dried over magnesium sulfate. The solvent was evaporated *in vacuo* to provide 700a (3.76 g, 87%) as a waxy yellow solid. MS: APc $[M+(CH_3CN+H)]^+=181$.

(700b) Chlorotrimethylsilane (5.87 g, 54 mmol) was added dropwise to 700a (3.76 g, 27.0 mmol) in methanol (75 mL) at room temperature under nitrogen. After stirring for 2 h the solvent was evaporated *in vacuo* and the residue titrated with ether. The white solid was filtered then dried under vacuum for 24 h to provide 700b (4.52 g, 81%). MS: ESI $[M+H]^+=172$.

(700c) N-Methyl morpholine (0.73 g, 7.22 mmol) was added dropwise to 700b (0.5 g, 2.41 mmol), BOP reagent (1.17 g, 2.65 mmol), and 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid (0.71 g, 2.41 mmol) in dimethylformamide (10 mL) at 0°C

under nitrogen. The reaction was allowed to warm to room temperature then stirred overnight. The solvent was removed in vacuo and the residue taken up in ethyl acetate (100 mL). The solution was washed with water (2X), saturated sodium bicarbonate (2X), and brine (1X) then dried over magnesium sulfate. The solvent was removed in vacuo and the residue purified by flash chromatography (SiO₂, 75%-100% ethyl acetate/hexanes) to provide 700c (0.963 g, 89%) as a viscous light yellow oil. MS: ESI [M+H]⁺=447.

10

(700d) A solution of basic hydroxylamine was prepared by adding potassium hydroxide (2.81g, 50.2 mmol) in methanol (7 mL) to hydroxylamine hydrochloride (2.34g, 33.7 mmol) in hot methanol (12 mL). The solution was allowed to cool to ambient temperature and the solid potassium chloride was filtered. The hydroxylamine solution (15 mL) was added in one portion to 700c (0.25g, 0.56 mmol) and stirred for 6 h. The reaction was quenched with 1N hydrogen chloride (~15 mL) until the pH was approximately 6. The solvent was removed in vacuo and the residue taken up in 1N hydrogen chloride/methanol (1:1) then purified by C₁₈ HPLC to provide example 700 (88 mg, 32%). MS: ESI [M+H]⁺=448.

20

Example 701

(±)-trans-N-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide, trifluoroacetate

25

(701a) Diazabicyclo[5.4.0]undec-5-ene (0.39 g, 2.58 mmol) was added to 700c (0.23 g, 0.52 mmol) in xylenes (10 mL) then heated at 100°C for 8 h and 110°C for 14 h. The solvent was evaporated in vacuo and the residue purified by flash chromatography (SiO₂, 65% ethyl acetate/hexanes) to provide 701a (103 mg, 45%) with >90% isomeric purity. MS: ESI [M+H]⁺=447.

35

(701b) Example 701 was prepared in a procedure analogous to 700d. MS: ESI $[M+H]^+=448$.

5

Example 702

(4*S*,5*R*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxohexahydro-1*H*-azepine-4-carboxamide trifluoroacetate

- 10 (702a) Diphenylphosphoryl azide (4.72 g, 17.1 mmol) was added dropwise to 1-methyl (1*S*,2*R*)-(+)-cis-1,2,3,6-tetrahydrophthalate (2.63 g, 14.3 mol) and triethylamine (2.17 g, 41.2 mmol) in benzene (20 mL) at room temperature. After stirring for 2 h benzyl alcohol (1.85 g, 17.1 mmol)
- 15 was added and the reaction was heated to reflux for 3 h. The mixture was cooled to room temperature and diluted with ethyl acetate (150 mL). The solution was washed with water (1X), 10% citric acid (1X), saturated sodium bicarbonate (1X), and brine (1X) then dried over magnesium sulfate. The
- 20 solvent was evaporated in vacuo and the residue purified by flash chromatography (SiO₂, 20-30% ethyl acetate/hexanes as solvent). The product 702a (2.69, 65%) was isolated as a brittle foam. MS: ESI $[M+H]^+=290$.
- 25 (702b) Borane:tetrahydrofuran (1M, 9.66 mL, 9.66 mmol) was added dropwise to 702a (2.15 g, 7.43 mmol) in anhydrous tetrahydrofuran (20 mL) at 0°C under nitrogen. The reaction was allowed to warm to room temperature over 1.5 h then cooled again to 0°C and quenched by the dropwise addition of
- 30 a with of 30% hydrogen peroxide (4.5 mL) and 1N sodium hydroxide (10 mL). After the addition was completed the mixture was stirred 15 m then quenched with 10% sodium sulfite. The solution was extracted with ethyl acetate (3X) and the combined organic extracts were washed with 10%
- 35 sodium sulfite (2X) and brine (1X). After drying over

magnesium sulfate the solvent was removed in vacuo and the product 702b (2.35 g, 100%) was carried forward without further purification. MS: APc $[M+H]^+=308$.

- 5 (702c) Pyridinium dichromate (4.19 g, 11.1 mmol) was added in one portion to 702b (7.43 mmol) and powdered 3 Å molecular sieves (5 g) in methylene chloride (30 mL) then stirred for 3 h at ambient temperature. The reaction was filtered through celite under vacuum washing with methylene chloride.
- 10 The solvent was evaporated in vacuo and the residue purified by flash chromatography (SiO_2 , 50% ethyl acetate/hexanes) to provide 702c (1.68 g, 74%) as a viscous light yellow oil. MS: APc $[M+H]^+=306$.
- 15 (702d) Hydroxylamine hydrochloride (1.53 g, 22.0 mmol) was added in one portion to 702c (1.68 g, 5.50 mmol) and sodium bicarbonate (1.53 g, 18.2 mmol) in methanol (25 mL) then heated to reflux for 3 h. The mixture was cooled to ambient temperature then diluted with water (50 mL) and extracted
- 20 with chloroform (4X). The combined organic extracts were washed with brine (1X) then dried over magnesium sulfate. The solvent was evaporated in vacuo and the residue purified by flash chromatography (SiO_2 , 50% ethyl acetate/hexanes) to provide 702d (1.46 g, 83%) as a viscous light yellow oil.
- 25 MS: ESI $[M+H]^+=321$.

- (702e) 702d (1.46 g, 4.56 mmol) in methylene chloride (10 mL) was added dropwise to p-toluenesulfonyl chloride (1.04 g, 5.47 mmol) and pyridine (0.54 g, 6.84 mmol) in methylene
- 30 chloride (20 mL) at room temperature. The reaction was stirred for 14 h then diluted with methylene chloride (80 mL). The solution was washed with 1N hydrochloric acid (2X), saturated sodium bicarbonate (2X), and brine (1X) then dried over magnesium sulfate. The solvent was evaporated in
- 35 vacuo and the tosylate ($[M+H]^+=475$) was taken up in ethanol

- free chloroform (40 mL) and added to dry silica gel (20 g). The reaction was stirred for 4 h then poured onto the top of a flash column (SiO₂, 80 g, 50% ethyl acetate hexanes to 50% methanol/ethyl acetate) and eluted. The mixture of four regioisomeric lactams were purified by C₁₈ HPLC (CH₃CN/water, 0.1% trifluoroacetic acid) to provide 702e-a, 702e-b, 702e-c, and 702e-d (410 mg, 267 mg, 364 mg, 195 mg, respectively, 85%). MS: APc [M+H]⁺=321 for all samples.
- 10 (702f) Methanol (10 mL) was carefully added to 10% Pd on C (0.17 g) and 702e-c (264 mg, 1.14 mmol) under a bed of nitrogen. A hydrogen balloon was attached via a three-way stopcock and the atmosphere was removed and replaced with hydrogen three times. After 0.5 h the hydrogen was removed and replaced with nitrogen then the catalyst removed by vacuum filtration through celite. The solvent was removed in vacuo to provide 702f (239 mg, 100%) as a viscous oil. MS: ESI [M+H]⁺=187.
- 20 (702g) In a procedure analogous to 700c, 702f was coupled to 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid to provide 702g (0.28 g, 53%) as a viscous clear oil. MS: ESI [M+H]⁺=462.
- 25 (702h) In a procedure analogous to 700d, 702g was converted to the hydroxamic acid example 702 were the regiochemistry was proven by 2D ¹HNMR. MS: ESI [M+H]⁺=463.

Example 703 and Example 704

- 30 (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-4-carboxamide trifluoroacetate and (3*S*,4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-3-carboxamide trifluoroacetate and
- 35 (4*S*,5*R*)-*N*-hydroxy-5-({4-[(2-methyl-4-

quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1H-azepine-
4-carboxamide trifluoroacetate

(703a) In a series of procedures analogous to steps 702f
5 through 702h, 702e-a was converted to example 703.

(704) In a series of procedures analogous to steps 702f
through 702h 702e-b was converted example 704.

10 **Example 705 and Example 706**

(2*S*,3*R*)-*N*-hydroxy-3-({4-[(2-methyl-4-
quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide
ditrifluoroacetate and (2*R*,3*R*)-*N*-hydroxy-3-({4-[(2-methyl-4-
quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide
15 ditrifluoroacetate

(705a,706a) Di-*t*-butyl dicarbonate (8.60 g, 39.4 mmol) in
tetrahydrofuran (20 mL) was added dropwise to trans-3-
hydroxy-*L*-proline (5.16 g, 39.4 mmol) in mixture of 1*N*
20 sodium hydroxide (43.3 mL) and tetrahydrofuran (20 mL) at
ambient temperature. The solution was stirred overnight
then extracted with pet ether (2X). The pet ether extracts
were washed with saturated sodium bicarbonate (3X) then the
combined aqueous layers were carefully acidified with sodium
25 hydrogensulfate monohydrate. The aqueous solution was
extracted with ethyl acetate (3X) and the combined organic
layers were dried over magnesium sulfate. The solvent was
removed *in vacuo* to give 706a/707a (8.29 g, 91%). MS: ESI⁻
[M-H]⁻=230.

30
(705b,706b) *N*-Methyl morpholine (7.25 g, 71.7 mmol) was
added in a slow stream to 705a,706a (8.29 g, 35.8 mmol), BOP
reagent (17.4 g, 39.4 mmol), and *N*-benzylhydroxylamine
hydrochloride (7.44 g, 46.6 mmol) in dimethylformamide (75
35 mL) under nitrogen. The reaction was stirred overnight and

the solvent was evaporated *in vacuo*. The residue was taken up in ethyl acetate (300 mL) and washed with water (2X), 10% citric acid (2X), saturated sodium bicarbonate (2X), and brine (1X) then dried over magnesium sulfate. The solvent
5 was removed *in vacuo* and the residue purified by flash chromatography (SiO₂, 50%-80% ethyl acetate/hexanes) to provide 706b,707b (6.11 g, 51%) as a viscous oil. MS: ESI [M+H]⁺=337.

10 (705c,706c) Diazoethyldicarboxylate (3.16 g, 18.2 mmol) was added dropwise to 705b,706b (6.11 g, 18.2 mmol) and triphenylphosphine (5.24 g, 20.0 mmol) in anhydrous tetrahydrofuran (50 mL) at room temperature under nitrogen. After stirring overnight the solvent was evaporated *in vacuo*
15 and the residue purified by flash chromatography (SiO₂, 20%-30% ethyl acetate/hexanes) to provide 706c,707c (4.61 g, 80%). MS: APc [M+H]⁺=319.

(705d,706d) Methanol (75 mL) was carefully added to
20 705c,706c (4.61 g, 14.5 mmol) and Pd on C (10%, 1.3 g) under a bed of nitrogen. A hydrogen balloon was attached via a 3-way stopcock and the atmosphere was removed and replace with hydrogen three times. After 1.5 h the hydrogen was removed and the reaction was vented with nitrogen. The catalyst was
25 removed by vacuum filtration through celite and the solvent was removed *in vacuo* to provide 706d,707d (3.09 g, 93%). MS: APc [M+H]⁺=229.

(705e,706e) Sodium acetate (23.8 g, 290 mmol) was added to
30 705d,706d (3.09 g, 13.5 mmol) in water/tetrahydrofuran (200 mL, 1/1) at room temperature. Titanium trichloride (36.7 g, 12 wt% in 21% HCl_(aq), 29.0 mmol) was added dropwise and stirring was continued for 3 h at room temperature. The reaction mixture was extracted with ethyl acetate (1X) then
35 titanium dioxide was removed from the aqueous layer by

vacuum filtration through celite. The aqueous layer was extracted again with ethyl acetate (2X) and the combined ethyl acetate layers were washed with brine (1X). The solvent was removed in vacuo and the resulting solid was
5 recrystallized from ethyl acetate/hexanes to provide 706e,707e (1.64 g, 57%). MS: CI [(M-C₄H₈)+H]⁺=157.

(705f,706f) Chlorotrimethylsilane (256 mg, 2.36 mmol) was added dropwise to 705e,706e (250 mg, 1.18 mmol) in methanol
10 (2 mL) at room temperature under nitrogen. After stirring for 2 h the solvent was evaporated in vacuo and the residue titrated with ether. The white solid was filtered then dried under vacuum for 24 h to provide an inseparable mixture of Boc protected β-amino acid and Boc deprotected β-
15 amino acid 706f,707f (235 mg) that was taken forward without further purification. MS: CI [(M-NH₃)+H]⁺=128.

(705g,706g) In a procedure analogous to 700c, 705f,706f (281 mg) was coupled to 4-[(2-methyl-4-quinolinyl)methoxy]benzoic
20 acid to provide 706g,707g-a (Boc deprotected, 78 mg, MS ESI: [M+H]⁺=420) and 706g,707g-b (Boc protected, 29 mg, [M+H]⁺=520).

(705h,706h) Examples 706 and 707 were prepared from
25 705g,706g-a using a procedure analogous to 700d. Example 707 was the first off the C₁₈ HPLC column (MS: ESI [M+H]⁺=421) and example 706 was the first (MS: ESI [M+H]⁺=421).


30


Example 707

tert-butyl (2S,3R)-2-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate trifluoroacetate

(707a) Example 707 was prepared from 705g, 705g-b using a procedure analogous to 700d. Example 708 was isolated as a single diastereomer. MS: ESI $[M+H]^+=521$.

Table 1





Ex	R	R ²	MS [M+H]
1	4-(2-trifluoromethylphenyl) benzoyl	---	393
2	4-(2-trifluoromethoxyphenyl) benzoyl	---	409
3	4-(3-methyl-2-pyridinyl)benzoyl	---	340
4	4-phenylbenzoyl	---	325
5	4-phenoxybenzoyl	---	341
6	4-benzyloxybenzoyl	---	355
7	4-(2-methoxyphenyl)benzoyl	---	355
8	4-(2-methylphenyl)benzoyl	---	339
9	4-(2-methoxyphenoxy)benzoyl	---	371
10	4-(2-methylphenoxy)benzoyl	---	355
11	4-(3-methylphenyl)benzoyl	---	339
12	4-(4-quinolinyl)benzoyl	---	376
13	4-(3,5-dimethylphenyl)benzoyl	---	353
14	5-[2-(2-methylphenyl)] pyridinylcarbonyl	---	340
15	5-[2-(2-methoxyphenyl)] pyridinylcarbonyl	---	356
16	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Isopropyl	463
17	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2,2-dimethylpropionyl	505
18	4-(2-methyl-4-	methanesulfonyl	499

	quinolinylmethoxy) benzoyl		
19	4-(2-methyl-4-quinolinylmethoxy) benzoyl	Methyl	435
20	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1,1-dimethyl-ethoxy) carbonyl	521
21	4-(2-methyl-4-quinolinylmethoxy) benzoyl	H	421
22	4-(2-methyl-4-quinolinylmethoxy) benzoyl	4-[N-(1,1-dimethyl-ethoxy) carbonyl] piperidinyl	604
23	4-(2-methyl-4-quinolinylmethoxy) benzoyl	4-piperidinyl	504
24	4-(2-methyl-4-quinolinylmethoxy) benzoyl	3-[N-(1,1-dimethyl-ethoxy) carbonyl] pyrrolidinyl	590
25	4-(2-methyl-4-quinolinylmethoxy) benzoyl	pyrrolidinyl	490
26	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1,1-dimethyl-ethoxy) carbonyl	521
27	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1,1-dimethyl-ethoxy) carbonyl	521
28	4-(2-methyl-4-quinolinylmethoxy) benzoyl	H	421
29	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1,1-dimethyl-ethoxy) carbonyl	521
30	4-(2-methyl-4-quinolinylmethoxy) benzoyl	H	421
31	4-(4-pyridinyl) benzoyl	---	326
32	4-(2-methyl-4-quinolinylmethoxy) benzoyl	1,1-dimethyl-2-propynyl	487
33	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-propynyl	459

34	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-propenyl	461
35	4-(2-methyl-4-quinolinylmethoxy)benzoyl	propyl	463
36	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-methyl-2-propenyl	475
37	4-(2-methyl-4-quinolinylmethoxy)benzoyl	1,1-dimethyl-2-propenyl	489
38	4-(2-methyl-4-quinolinylmethoxy)benzoyl	1,1-dimethylpropyl	491
39	4-(2-methyl-4-quinolinylmethoxy)benzoyl	3-methylbutyl	491
40	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2,2-dimethylpropyl	491
41	4-(2-methyl-4-quinolinylmethoxy)benzoyl	butyl	477
42	4-(2-methyl-4-quinolinylmethoxy)benzoyl	3-butenyl	475
43	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-butyryl	473
44	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-furylmethyl	501
45	4-(2-methyl-4-quinolinylmethoxy)benzoyl	(5-methyl-2-furyl)methyl	515
46	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	422
47	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	422
48	4-(2-methyl-4-quinolinylmethoxy)benzoyl	1,3-thiazol-2-ylmethyl	518
49	4-(2-methyl-4-quinolinylmethoxy)benzoyl	acetyl	463
50	4-(2-methyl-4-quinolinylmethoxy)benzoyl	isobutyryl	491

51	4-(2-methyl-4-quinolinylmethoxy)benzoyl	3-methylbutanoyl	505
52	4-(2-methyl-4-quinolinylmethoxy)benzoyl	cyclopropylcarbonyl 1	489
53	4-(2-methyl-4-quinolinylmethoxy)benzoyl	cyclobutylcarbonyl	503
54	4-(2-methyl-4-quinolinylmethoxy)benzoyl	methoxyacetyl	493
55	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-furoyl	515
56	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-thienylcarbonyl	531
57	4-(2-methyl-4-quinolinylmethoxy)benzoyl	propionyl	477
58	4-(2-butynyloxy)benzoyl	---	319
59	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	434
60	4-(2-methyl-4-quinolinylmethoxy)benzoyl	OH	436
61	4-(2-methyl-4-quinolinylmethoxy)benzoyl	OH	436
62	4-(2-methyl-4-quinolinylmethoxy)benzoyl	tetrahydro-2H-pyran-4-yl	505
63	4-(2-methyl-4-quinolinylmethoxy)benzoyl	methoxycarbonyl	479
64	4-(2-methyl-4-quinolinylmethoxy)benzoyl	ethoxycarbonyl	493
65	4-(2-methyl-4-quinolinylmethoxy)benzoyl	propyloxycarbonyl	507
66	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-propenyloxycarbonyl 1	505
67	4-(2-methyl-4-quinolinylmethoxy)benzoyl	isopropyloxycarbonyl yl	507

68	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-propynyloxycarbonyl	503
69	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-butyloxycarbonyl	517
70	4-(2-methyl-4-quinolinylmethoxy)benzoyl	3-butenyloxycarbonyl	519
71	4-(2-methyl-4-quinolinylmethoxy)benzoyl	benzyloxycarbonyl	554
72	4-(2-methyl-4-quinolinylmethoxy)benzoyl	dimethylamino	463
73	4-(2-butyloxy)benzoyl	isopropyl	360
74	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	456
75	4-(2-methylphenoxy)benzoyl	isopropyl	398
100	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	420
101	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	420
102	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	420
103	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	420
104	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	434
105	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	434
108	4-(2-methyl-4-quinolinylmethoxy)benzoyl	(1,1-dimethylethoxy) carbonyl	521
109	4-(2-methyl-4-quinolinylmethoxy)benzoyl	H	421
110	4-(2-methyl-4-quinolinylmethoxy)benzoyl	(1,1-dimethylethoxy) carbonyl	521
111	4-(2-methyl-4-	H	421

	quinolinylmethoxy)benzoyl		
112	4-(2-methyl-4-quinolinylmethoxy)benzoyl	(1,1-dimethyl-ethoxy) carbonyl	535
113	4-(2-methyl-4-quinolinylmethoxy)benzoyl	(1,1-dimethyl-ethoxy) carbonyl	535
114	4-(2-methyl-4-quinolinylmethoxy)benzoyl	H	435
115	4-(2-methyl-4-quinolinylmethoxy)benzoyl	H	435
116	4-(2-methyl-4-quinolinylmethoxy)benzoyl	butoxycarbonyl	535
117	4-(2-methyl-4-quinolinylmethoxy)benzoyl	(1-methyl-ethoxy) carbonyl	521
118	4-(2-methyl-4-quinolinylmethoxy)benzoyl	methanesulfonyl	513
119	4-(2-methyl-4-quinolinylmethoxy)benzoyl	benzenesulfonyl	575
120	4-(2-methyl-4-quinolinylmethoxy)benzoyl	acetyl	477
121	4-(2-methyl-4-quinolinylmethoxy)benzoyl	benzoyl	539
122	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2,2-dimethylpropionyl	519
123	4-(2-methyl-4-quinolinylmethoxy)benzoyl	3,3-dimethylbutanoyl	533
124	4-(2-methyl-4-quinolinylmethoxy)benzoyl	4-morpholinecarbonyl	548
125	4-(2-methyl-4-quinolinylmethoxy)benzoyl	dimethylcarbamyl	506
126	4-(2-methyl-4-quinolinylmethoxy)benzoyl	methyl	449
127	4-(2-methyl-4-quinolinylmethoxy)benzoyl	ethyl	463
128	4-(2-methyl-4-	n-propyl	477

	quinolinylmethoxy) benzoyl		
129	4-(2-methyl-4-quinolinylmethoxy) benzoyl	isopropyl	477
130	4-(2-methyl-4-quinolinylmethoxy) benzoyl	cyclopropylmethyl	489
131	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2,2-dimethylpropyl	505
132	4-(2-methyl-4-quinolinylmethoxy) benzoyl	-benzyl	525
133	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-thiazolylmethyl	532
134	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1,1-dimethyl-ethoxy) carbonyl	535
135	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1,1-dimethyl-ethoxy) carbonyl	535
136	4-(2-methyl-4-quinolinylmethoxy) benzoyl	H	435
137	4-(2-methyl-4-quinolinylmethoxy) benzoyl	H	435
138	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(2-ethyl-propyloxy) carbonyl	535
139	4-(2-methyl-4-quinolinylmethoxy) benzoyl	methoxycarbonyl	493
140	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1-methyl-ethoxy) carbonyl	521
141	4-(2-methyl-4-quinolinylmethoxy) benzoyl	methanesulfonyl	513
142	4-(2-methyl-4-quinolinylmethoxy) benzoyl	benzenesulfonyl	575
147	4-(2-methyl-4-quinolinylmethoxy) benzoyl	3,3-dimethylbutanoyl	533
148	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2,2-dimethylpropionyl	519
149	4-(2-methyl-4-	benzoyl	539

	quinolinylmethoxy) benzoyl		
150	4-(2-methyl-4-quinolinylmethoxy) benzoyl	nicotinoyl	540
151	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-thiophenecarbonyl	545
152	4-(2-methyl-4-quinolinylmethoxy) benzoyl	dimethylcarbamyl	506
153	4-(2-methyl-4-quinolinylmethoxy) benzoyl	4-morpholinecarbonyl	548
154	4-(2-methyl-4-quinolinylmethoxy) benzoyl	[2-(2-thienyl) ethyl] carbamyl	588
155	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1,1-dimethyl-ethyl) carbamyl	534
156	4-(2-methyl-4-quinolinylmethoxy) benzoyl	Methyl	449
157	4-(2-methyl-4-quinolinylmethoxy) benzoyl	Ethyl	463
158	4-(2-methyl-4-quinolinylmethoxy) benzoyl	n-propyl	477
159	4-(2-methyl-4-quinolinylmethoxy) benzoyl	isopropyl	477
160	4-(2-methyl-4-quinolinylmethoxy) benzoyl	cyclobutyl	489
161	4-(2-methyl-4-quinolinylmethoxy) benzoyl	n-butyl	491
162	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-methylpropyl	491
163	4-(2-methyl-4-quinolinylmethoxy) benzoyl	cyclopropylmethyl	489
164	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2,2-dimethylpropyl	505
165	4-(2-methyl-4-quinolinylmethoxy) benzoyl	cyclopentyl	503
166	4-(2-methyl-4-	4-	519

	quinolinylmethoxy)benzoyl	tetrahydropyranyl	
167	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Benzyl	525
168	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-thiazolylmethyl	532
169	4-(2-methyl-4-quinolinylmethoxy)benzoyl	4-picolyl	526
170	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-picolyl	526
171	4-(2-methyl-4-quinolinylmethoxy)benzoyl	3-picolyl	526
172	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Trans-cinnamyl	551
173	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Phenyl	511
174	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Pivoly	519
175	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Methyl	449
176	4-(2-methyl-4-quinolinylmethoxy)benzoyl	dimethylcarbamy	506
177	4-(2-methyl-4-quinolinylmethoxy)benzoyl	n-hexyl	519
178	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-fluoroethyl	481
179	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2,2-difluoroethyl	499
180	4-(2-methyl-4-quinolinylmethoxy)benzoyl	1-methylpropyl	491
181	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-ethylpropyl	505
182	4-(2-methyl-4-quinolinylmethoxy)benzoyl	4-[N-(1,1-dimethyl-ethoxy)carbonyl]	618

		piperidinyl	
183	4-(2-methyl-4-quinolinylmethoxy)benzoyl	4-piperidinyl	518
184	4-(2-methyl-4-quinolinylmethoxy)benzoyl	3-[N-(1,1-dimethyl-ethoxy)carbonyl]pyrrolidinyl	604
185	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Pyrrolidinyl	505
186	4-(2-methyl-4-quinolinylmethoxy)benzoyl	1,1-dimethyl-2-propynyl	501
187	4-(2-methyl-4-quinolinylmethoxy)benzoyl	(3-thiophenyl)methyl	531
188	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Isopropyl	493
189	4-(2-methyl-1-oxo-4-quinolinylmethoxy)benzoyl	Isopropyl	493
190	4-(2-methyl-1-oxo-4-quinolinylmethoxy)benzoyl	Isopropyl	509
191	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-oxo-2-(4-morpholinyl)ethyl	562
192	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-dimethylamino-2-oxoethyl	520
193	4-(2-methyl-4-quinolinylmethoxy)benzoyl	t-butylsulfonyl	555
194	4-(2-methyl-1-oxo-4-quinolinylmethoxy)benzoyl	t-butylsulfonyl	571
195	4-(2-methyl-4-quinolinylmethoxy)benzoyl	Benzenesulfonyl	575
196	4-(2-methyl-4-quinolinylmethoxy)benzoyl	t-butylsulfinyl	539
197	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-hydroxyethyl	479
198	4-(2-methyl-4-	2-[(1,1-dimethyl-	578

	quinolinylmethoxy) benzoyl	ethoxy) carbonyl] aminoethyl	
199	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-aminoethyl	478
200	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-(N,N-dimethylamino) ethyl	506
201	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-aminopropyl	492
202	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-amino-3-hydroxypropyl	508
203	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(2-pyrrolidinyl)methyl	518
204	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-hydroxyethyl	479
205	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-aminoethyl	478
206	4-(2-methyl-4-quinolinylmethoxy) benzoyl	Cyclobutyl	489
207	4-(2-methyl-4-quinolinylmethoxy) benzoyl	---	436
208	4-(2-methyl-4-quinolinylmethoxy) benzoyl	tert-butyl	491
209	4-(2-methyl-4-quinolinylmethoxy) benzoyl	tert-butyloxy-2-methylpropanoate	577
210	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-methylpropanoic acid	521
211	4-(2-methyl-4-quinolinylmethoxy) benzoyl	methyl-2-methylpropanoate	535
212	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-(4-morpholinyl)-2-oxoethyl	562
213	4-(2-methyl-4-quinolinylmethoxy) benzoyl	2-(dimethylamino)-2-oxo	520

214	4-(2-methyl-4-quinolinylmethoxy)benzoyl	1,1-dimethyl-2-propenyl	503
215	4-(2-methyl-4-quinolinylmethoxy)benzoyl	tert-pentyl	505
216	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-propynyl	473
217	4-(2-methyl-4-quinolinylmethoxy)benzoyl	2-propenyl	475
218	4-(2-methyl-4-quinolinylmethoxy)benzoyl	1-methyl-2-propynyl	487
219	4-(2-methyl-4-quinolinylmethoxy)benzoyl	1-methyl-2-propenyl	489
220	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	466
221	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	449
222	4-(2-methyl-4-quinolinylmethoxy)benzoyl	----	449
223	4-(2-butynyloxy)benzoyl	isopropyl	374
224	4-(2-butynyloxy)benzoyl	H	332
225	4-[(2-methyl-3-pyridinyl)methoxy]benzoyl	(1,1-dimethyl-ethoxy) carbonyl	485
226	4-[(2-methyl-3-pyridinyl)methoxy]benzoyl	H	385
227	4-(2,5-dimethylbenzyl)oxy]benzoyl	(1,1-dimethyl-ethoxy) carbonyl	496
228	4-(2,5-dimethylbenzyl)oxy]benzoyl}	H	398
301	4-(2-methyl-4-quinolinylmethoxy)benzoyl	NH ₂	449
302	4-(2-methyl-4-quinolinylmethoxy)benzoyl	NHMe	463
303	4-(2-methyl-4-quinolinylmethoxy)benzoyl	NMe ₂	477

304	4-(2-methyl-4-quinolinylmethoxy)benzoyl	NH ₂	449
305	4-(2-methyl-4-quinolinylmethoxy)benzoyl	NMe ₂	477
306	4-(2-methyl-4-quinolinylmethoxy)benzoyl	NH- <i>i</i> -Pr	491
307	4-(2-methyl-4-quinolinylmethoxy)benzoyl	NHMe	463
308	4-(2-methyl-4-quinolinylmethoxy)benzoyl	OH	450
309	4-{[(2-methyl-4-quinolinyl)methyl]amino}benzoyl	--	419
310	4-{methyl[(2-methyl-4-quinolinyl)methyl]amino}benzoyl	--	433
311	4-(3-phenyl-4,5-dihydro-5-isoxazolyl)benzoyl	--	394
312	4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzoyl	--	395
313	4-[3-(3-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzoyl	--	395
314	4-[3-(2-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzoyl	--	395
315	4-[3-(4-quinolinyl)-4,5-dihydro-5-isoxazolyl]benzoyl	--	445
316	4-[3-(2,6-Dimethyl-4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzoyl	--	423
317	3-methoxy-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzoyl	--	425
318	4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzoyl	--	411

319	4-[5-(2-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzoyl	--	395
320	4-[5-(4-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzoyl	--	395
501	1-[(2-methyl-4-quinolinyl)methyl]-1H-indole-5-carbonyl	H	444
502	1-[(2-methyl-4-quinolinyl)methyl]-1H-indole-5-carbonyl	---	443
503	6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthoyl	H	485
504	6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthoyl	---	470
505	6-[(2-methyl-4-quinolinyl)methoxy]-2-naphthoyl	---	470
506	6-[(2-methyl-4-quinolinyl)methoxy]-1,2,3,4-tetrahydro-1-isoquinolinecarbonyl	---	475
507	1-[(2-methyl-4-quinolinyl)methyl]-1H-benzimidazole-5-carbonyl	---	444
508	1-[(2-methyl-4-quinolinyl)methyl]-1H-indole-4-carboxamide	---	443
701	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	448
702	4-(2-methyl-4-quinolinylmethoxy)benzoyl	---	463
703	4-(2-methyl-4-	---	463


	quinolinylmethoxy) benzoyl		
704	4-(2-methyl-4-quinolinylmethoxy) benzoyl	---	463
705	4-(2-methyl-4-quinolinylmethoxy) benzoyl	H	421
706	4-(2-methyl-4-quinolinylmethoxy) benzoyl	H	421
707	4-(2-methyl-4-quinolinylmethoxy) benzoyl	(1,1-dimethyl-ethoxy) carbonyl	521


The following tables contain representative examples of the present invention. Each entry in each table is intended to be paired with each formula at the start of the table.

For example, example 1 is intended to be paired with each of

5 formulae A-AG.

Table 2






Ex #	R ¹⁰
1	H
2	methyl
3	methoxy
4	1-methylethyl
5	1-methylethoxy
6	phenyl
7	[1,1'-biphenyl]-4-yl
8	phenoxy
9	2-phenylethyl
10	2-(3,5-dimethylphenyl)ethyl
11	1-(2,6-dimethylphenyl)ethyl
12	2-phenylethenyl
13	phenoxymethyl
14	(2-methylphenyl)methoxy
15	(3-methylphenyl)methoxy
16	3-methylphenoxy
17	2,6-dimethylphenoxy
18	(2,6-dimethylphenyl)methoxy
19	3,5-dimethylphenoxy
20	(3,5-dimethylphenyl)methoxy
21	2-(3,5-dimethylphenyl)ethyl
22	2-(3,5-dimethylphenyl)ethenyl

23	(3-amino-5-methylphenyl)methoxy
24	(2-amino-6-methylphenyl)methoxy
25	(3-cyano-5-methylphenyl)methoxy
26	(3-cyano-5-methylphenoxy)methyl
27	(3-cyano-5-nitrophenyl)methoxy
28	(3,5-diethoxyphenyl)methoxy
29	(3,5-dimethoxyphenyl)methoxy
30	3,5-dimethoxyphenoxy
31	2-(3,5-dimethoxyphenyl)ethyl
32	1-(3,5-dimethoxyphenyl)ethoxy
33	(3,5-dichlorophenyl)methoxy
34	(2,6-dichlorophenyl)methoxy
35	(3,5-dibromophenyl)methoxy
36	3,5-dibromophenoxy
37	(3-amino-5-cyanophenyl)methoxy
38	[2,6-bis(trifluoromethyl)phenyl]methoxy
39	2,6-bis(trifluoromethyl)phenoxy
40	(3-aminocarbonyl-5-methylphenyl)methoxy
41	([1,1'-biphenyl]-2-yl)methoxy
42	([1,1'-biphenyl]-3-yl)methoxy
43	[5-methyl-3-(methylsulfonyl)phenyl]methoxy
44	5-methyl-3-(methylsulfonyl)phenoxy
45	(2-pyridinyl)methoxy
46	(4-pyridinyl)methoxy
47	(2,6-dimethyl-4-pyridinyl)methoxy
48	2,6-dimethyl-4-pyridinyloxy
49	1-(2,6-dimethyl-4-pyridinyl)ethoxy
50	(3,5-dimethyl-4-pyridinyl)methoxy
51	(2,6-diethyl-4-pyridinyl)methoxy
52	(2,6-dichloro-4-pyridinyl)methoxy
53	(2,6-dimethoxy-4-pyridinyl)methoxy
54	(2-chloro-6-methyl-4-pyridinyl)methoxy
55	(2-chloro-6-methoxy-4-pyridinyl)methoxy
56	(2-methoxy-6-methyl-4-pyridinyl)methoxy

57	(1-naphthalenyl)methoxy
58	1-naphthalenyloxy
59	(2-naphthalenyl)methoxy
60	(2-methyl-1-naphthalenyl)methoxy
61	(4-methyl-2-naphthalenyl)methoxy
62	(4-quinolinyl)methoxy
63	1-(4-quinolinyl)ethoxy
64	4-quinolinylloxy
65	(4-quinolinylloxy)methyl
66	2-(4-quinolinyl)ethyl
67	(2-methyl-4-quinolinyl)methoxy
68	2-methyl-4-quinolinylloxy
69	(2-chloro-4-quinolinyl)methoxy
70	(2-methoxy-4-quinolinyl)methoxy
71	(2-hydroxy-4-quinolinyl)methoxy
72	(2-trifluoromethyl-4-quinolinyl)methoxy
73	(2-phenyl-4-quinolinyl)methoxy
74	(2,6-dimethyl-4-quinolinyl)methoxy
75	(2,7-dimethyl-4-quinolinyl)methoxy
76	(5-quinolinyl)methoxy
77	(7-methyl-5-quinolinyl)methoxy
78	(7-methoxy-5-quinolinyl)methoxy
79	(8-quinolinyl)methoxy
80	2-(1,2,3-benzotriazol-1-yl)ethyl
81	(2-benzimidazolyl)methoxy
82	(1,4-dimethyl-5-imidazolyl)methoxy
83	(3,5-dimethyl-4-isoxazolyl)methoxy
84	(4,5-dimethyl-2-oxazolyl)methoxy
85	(2,5-dimethyl-4-thiazolyl)methoxy
86	(3,5-dimethyl-1-pyrazolyl)ethyl
87	(1,3-benzodioxo-4-yl)methoxy
88	(1,3,5-trimethyl-4-pyrazolyl)methoxy
89	(2,6-dimethyl-4-pyrimidinyl)methoxy
90	(4,5-dimethyl-2-furanyl)methoxy

91	(4,5-dimethyl-2-thiazolyl)methoxy
92	2-(2-oxazolyl)ethyl
93	2-butynyloxy
94	4-hydroxy-2-butynyloxy
95	4-pyridyl
96	4-pyridoxy
97	(2-methyl-4-quinolinyl)methylamino
98	3-phenyl-4,5-dihydro-5-isoxazolyl
99	3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl
100	5-(4-pyridinyl)-4,5-dihydro-3-isoxazolyl

Table 3



Ex #	R ²
1	H
2	methyl
3	ethyl
4	1-methylethyl

5	cyclobutyl
6	n-butyl
7	2,2-dimethylpropyl
8	cyclopropylmethyl
9	2-methoxyethyl
10	2-hydroxyethyl
11	2-aminoethyl
12	2-dimethylaminoethyl
13	2-(4-morpholinyl)ethyl
14	2-(1-piperidinyl)ethyl
15	2-(1-piperizinyl)ethyl
16	phenyl
17	benzyl
18	3-picoyl
19	formyl
20	acetyl
21	pivaloyl
22	benzoyl
23	nicotinoyl
24	methanesulfonyl
25	benzenesulfonyl
26	t-butylsulfonyl
27	methoxycarbonyl
28	t-butoxycarbonyl
29	isopropylloxycarbonyl
30	Dimethylcarbamyl
31	4-morpholinecarbonyl
32	2-thiophenecarbonyl
33	2-fluoroethyl
34	2,2-difluoroethyl
35	2-(dimethylamino)-2-oxoethyl
36	2-oxo-2-(4-morpholinyl)ethyl
37	tert-butyl
38	1,1-dimethylpropyl

39	2-propenyl
40	1-methyl-2-propenyl
41	1,1-dimethyl-2-propenyl
42	2-propynyl
43	1-methyl-2-propynyl
44	1,1-dimethyl-2-propynyl
45	(2-pyrrolidinyl)methyl

UTILITY

The compounds of formula I are expected to possess matrix metalloprotease and/or aggrecanase and/or TNF- α inhibitory activity. The MMP inhibitory activity of the compounds of the present invention is demonstrated using
5 assays of MMP activity, for example, using the assay described below for assaying inhibitors of MMP activity. The compounds of the present invention are expected to be bioavailable in vivo as demonstrated, for example, using the
10 ex vivo assay described below. The compounds of formula I are expected to have the ability to suppress/inhibit cartilage degradation in vivo, for example, as demonstrated using the animal model of acute cartilage degradation described below.

15 The compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit MPs. These would be provided in commercial kits comprising a compound of this invention.

20 Metalloproteases have also been implicated in the degradation of basement membranes to allow infiltration of cancer cells into the circulation and subsequent penetration into other tissues leading to tumor metastasis (Stetler-Stevenson, Cancer and Metastasis Reviews, 9, 289-303, 1990).
25 The compounds of the present invention should be useful for the prevention and treatment of invasive tumors by inhibition of this aspect of metastasis.

The compounds of the present invention should also have utility for the prevention and treatment of osteopenia
30 associated with matrix metalloprotease-mediated breakdown of cartilage and bone that occurs in osteoporosis patients.

Compounds that inhibit the production or action of TNF and/or Aggrecanase and/or MMP's are potentially useful for the treatment or prophylaxis of various inflammatory,
35 infectious, immunological or malignant diseases or

conditions. Thus, the present invention relates to a method of treating various inflammatory, infectious, immunological or malignant diseases. These include acute infection, acute phase response, age related macular degeneration,

5 alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia (including cachexia resulting from cancer or HIV), calcium pyrophosphate dihydrate deposition disease, cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary

10 disease, coagulation, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy (including inflammatory bowel disease), Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host

15 disease, hemorrhage, HIV infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease,

20 periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pyoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis (including juvenile rheumatoid

25 arthritis and adult rheumatoid arthritis), sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases, spondylitis, stroke, systemic lupus erythematosus,

30 ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis.

Some compounds of the present invention have been shown to inhibit TNF production in lipopolysacharride stimulated mice, for example, using the assay for TNF induction in mice

35 and in human whole blood as described below.

Some compounds of the present invention have been shown to inhibit aggrecanase, a key enzyme in cartilage breakdown, as determined by the aggrecanase assay described below.

As used herein "µg" denotes microgram, "mg" denotes milligram, "g" denotes gram, "µL" denotes microliter, "mL" denotes milliliter, "L" denotes liter, "nM" denotes nanomolar, "µM" denotes micromolar, "mM" denotes millimolar, "M" denotes molar and "nm" denotes nanometer. "Sigma stands for the Sigma-Aldrich Corp. of St. Louis, MO.

A compound is considered to be active if it has an IC₅₀ or K_i value of less than about 10 µM for the inhibition of a desired MP. Preferred compounds of the present invention have K_i's or IC₅₀'s of ≤1 µM. More preferred compounds of the present invention have K_i's or IC₅₀'s of ≤0.1 µM. Even more preferred compounds of the present invention have K_i's or IC₅₀'s of ≤0.01 µM. Still more preferred compounds of the present invention have K_i's or IC₅₀'s of ≤0.001 µM.

Aggrecanase Enzymatic Assay

A novel enzymatic assay was developed to detect potential inhibitors of aggrecanase. The assay uses active aggrecanase accumulated in media from stimulated bovine nasal cartilage (BNC) or related cartilage sources and purified cartilage aggrecan monomer or a fragment thereof as a substrate.

The substrate concentration, amount of aggrecanases time of incubation and amount of product loaded for Western analysis were optimized for use of this assay in screening putative aggrecanase inhibitors. Aggrecanase is generated by stimulation of cartilage slices with interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α) or other stimuli. Matrix metalloproteases (MMPs) are secreted from cartilage in an inactive, zymogen form following stimulation, although active enzymes are present within the matrix. We have shown

that following depletion of the extracellular aggrecan matrix, active MMPs are released into the culture media (Tortorella, M.D. et. al. Trans. Ortho. Res. Soc. 20, 341, 1995). Therefore, in order to accumulate BNC aggrecanase in culture media, cartilage is first depleted of endogenous aggrecan by stimulation with 500 ng/ml human recombinant IL- β for 6 days with media changes every 2 days. Cartilage is then stimulated for an additional 8 days without media change to allow accumulation of soluble, active aggrecanase in the culture media. In order to decrease the amount of other matrix metalloproteases released into the media during aggrecanase accumulation, agents which inhibit MMP-1, -2, -3, and -9 biosynthesis are included during stimulation. This BNC conditioned media, containing aggrecanase activity is then used as the source of aggrecanase for the assay. Aggrecanase enzymatic activity is detected by monitoring production of aggrecan fragments produced exclusively by cleavage at the Glu373-Ala374 bond within the aggrecan core protein by Western analysis using the monoclonal antibody, BC-3 (Hughes, CE, et al., Biochem J 306:799-804, 1995). This antibody recognizes aggrecan fragments with the N-terminus, 374ARGSVIL, generated upon cleavage by aggrecanase. The BC-3 antibody recognizes this neopeptide only when it is at the N-terminus and not when it is present internally within aggrecan fragments or within the aggrecan protein core. Other proteases produced by cartilage in response to IL-1 do not cleave aggrecan at the Glu373-Ala374 aggrecanase site; therefore, only products produced upon cleavage by aggrecanase are detected. Kinetic studies using this assay yield a K_m of $1.5 \pm 0.35 \mu M$ for aggrecanase.

To evaluate inhibition of aggrecanase, compounds are prepared as 10 mM stocks in DMSO, water or other solvents and diluted to appropriate concentrations in water. Drug (50 μl) is added to 50 μl of aggrecanase-containing media and 50 μl of 2 mg/ml aggrecan substrate and brought to a

final volume of 200 ul in 0.2 M Tris, pH 7.6, containing 0.4 M NaCl and 40 mM CaCl₂. The assay is run for 4 hr at 37°C, quenched with 20 mM EDTA and analyzed for aggrecanase-generated products. A sample containing enzyme and substrate without drug is included as a positive control and enzyme incubated in the absence of substrate serves as a measure of background.

Removal of the glycosaminoglycan side chains from aggrecan is necessary for the BC-3 antibody to recognize the ARGSVIL epitope on the core protein. Therefore, for analysis of aggrecan fragments generated by cleavage at the Glu373-Ala374 site, proteoglycans and proteoglycan fragments are enzymatically deglycosylated with chondroitinase ABC (0.1 units/10 ug GAG) for 2 hr at 37°C and then with keratanase (0.1 units/10 ug GAG) and keratanase II (0.002 units/10 ug GAG) for 2 hr at 37°C in buffer containing 50 mM sodium acetate, 0.1 M Tris/HCl, pH 6.5. After digestion, aggrecan in the samples is precipitated with 5 volumes of acetone and resuspended in 30 ul of Tris glycine SDS sample buffer (Novex) containing 2.5% beta mercaptoethanol. Samples are loaded and then separated by SDS-PAGE under reducing conditions with 4-12% gradient gels, transferred to nitrocellulose and immunolabeled with 1:500 dilution of antibody BC3. Subsequently, membranes are incubated with a 1:5000 dilution of goat anti-mouse IgG alkaline phosphatase second antibody and aggrecan catabolites visualized by incubation with appropriate substrate for 10-30 minutes to achieve optimal color development. Blots are quantitated by scanning densitometry and inhibition of aggrecanase determined by comparing the amount of product produced in the presence versus absence of compound.

TNF PBMC ASSAY

Human peripheral blood mononuclear cells (PBMC) were obtained from normal donor blood by leukaphoresis and

isolated by Ficoll-Paque density separation. PBMCs were suspended in .5ml RPMI 1640 with no serum at 2×10^6 cells/ml in 96 well polystyrene plates. Cells were preincubated 10 minutes with compound, then stimulated with 1 μ g/ml LPS (Lipopolysaccharide, Salmonella typhimurium) to induce TNF production. After an incubation of 5 hours at 37°C in 95% air, 5% CO₂ environment, culture supernatants were removed and tested by standard sandwich ELISA for TNF production.

10 TNF Human Whole Blood Assay

Blood is drawn from normal donors into tubes containing 143 USP units of heparin/10ml. 225ul of blood is plated directly into sterile polypropylene tubes. Compounds are diluted in DMSO/serum free media and added to the blood samples so the final concentration of compounds are 50, 10, 5, 1, .5, .1, and .01 μ M. The final concentration of DMSO does not exceed .5%. Compounds are preincubated for 15 minutes before the addition of 100ng/ml LPS. Plates are incubated for 5 hours in an atmosphere of 5% CO₂ in air. At the end of 5 hours, 750ul of serum free media is added to each tube and the samples are spun at 1200RPM for 10 minutes. The supernatant is collected off the top and assayed for TNF-alpha production by a standard sandwich ELISA. The ability of compounds to inhibit TNF-alpha production by 50% compared to DMSO treated cultures is given by the IC50 value.

TNF Induction In Mice

Test compounds are administered to mice either I.P. or P.O. at time zero. Immediately following compound administration, mice receive an I.P. injection of 20 mg of D-galactosamine plus 10 μ g of lipopolysaccharide. One hour later, animals are anesthetized and bled by cardiac puncture. Blood plasma is evaluated for TNF levels by an ELISA specific for mouse TNF. Administration of

representative compounds of the present invention to mice results in a dose-dependent suppression of plasma TNF levels at one hour in the above assay.

5 MMP ASSAYS

The enzymatic activities of recombinant MMP-1, 2, 3, 7, 8, 9, 13, 14, 15, and 16 were measured at 25°C with a fluorometric assay (Copeland, R.A.; Lombardo, D.; Giannaras, J. and Decicco, C.P. *Bioorganic Med. Chem. Lett.* **1995**, *5*, 1947-1952). Final enzyme concentrations in the assay were between 0.05 and 10 nM depending on the enzyme and the potency of the inhibitor tested. The permissive peptide substrate, MCA-Pro-Leu-Gly-Leu-DPA-Ala-Arg-NH₂, was present at a final concentration of 10 μ M in all assays. Initial velocities, in the presence or absence of inhibitor, were measured as slopes of the linear portion of the product progress curves. IC₅₀ values were determined by plotting the inhibitor concentration dependence of the fractional velocity for each enzyme, and fitting the data by non-linear least squares methods to the standard isotherm equation (Copeland, R.A. *Enzymes: A practical Introduction to Structure, Mechanism and Data Analysis*, Wiley-VHC, New York, **1996**, pp 187-223). All of the compounds studied here were assumed to act as competitive inhibitors of the enzyme, binding to the active site Zn atom as previously demonstrated by crystallographic studies of MMP-3 complexed with related hydroxamic acids (Rockwell, A.; Melden, M.; Copeland, R.A.; Hardman, K.; Decicco, C.P. and DeGrado, W.F. *J. Am. Chem. Soc.* **1996**, *118*, 10337-10338). Based on the assumption of competitive inhibition, the IC₅₀ values were converted to K_i values as previously described.

Compounds tested in the above assay are considered to be active if they exhibit a K_i of ≤ 10 μ M. Preferred compounds of the present invention have K_i's of ≤ 1 μ M. More

preferred compounds of the present invention have K_i 's of $\leq 0.1 \mu\text{M}$. Even more preferred compounds of the present invention have K_i 's of $\leq 0.01 \mu\text{M}$. Still more preferred compounds of the present invention have K_i 's of $< 0.001 \mu\text{M}$.

5 Using the methodology described above, a number of compounds of the present invention were found to exhibit K_i 's of ≤ 10 μ M, thereby confirming the utility of the compounds of the present invention.

10 Dosage and Formulation

The compounds of the present invention can be administered orally using any pharmaceutically acceptable dosage form known in the art for such administration. The active ingredient can be supplied in solid dosage forms such as dry powders, granules, tablets or capsules, or in liquid dosage forms, such as syrups or aqueous suspensions. The active ingredient can be administered alone, but is generally administered with a pharmaceutical carrier. A valuable treatise with respect to pharmaceutical dosage forms is Remington's Pharmaceutical Sciences, Mack Publishing.

The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an antiinflammatory and antiarthritic agent.

The compounds of this invention can be administered by any means that produces contact of the active agent with the agent's site of action in the body of a mammal. They can be

administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but generally
5 administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage regimen for the compounds of the present invention will, of course, vary depending upon known
10 factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment;
15 the route of administration, the renal and hepatic function of the patient, and the effect desired. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

20 By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20
25 mg/kg/day. For a normal male adult human of approximately 70 kg of body weight, this translates into a dosage of 70 to 1400 mg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, compounds of the
30 present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

The compounds for the present invention can be administered in intranasal form via topical use of suitable
35 intranasal vehicles, or via transdermal routes, using those

forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent

5 throughout the dosage regimen.

In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers

10 (collectively referred to herein as carrier materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.

15 For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral
20 administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable
25 binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium
30 alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch,

methyl cellulose, agar, bentonite, xanthan gum, and the like.

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.

Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose

derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets.

Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of

5 medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain
10 coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral
15 administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also
20 used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in
25 Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field. Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

30 Capsules

Capsules are prepared by conventional procedures so that the dosage unit is 500 milligrams of active ingredient, 100 milligrams of cellulose and 10 milligrams of magnesium stearate.

A large number of unit capsules may also be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

Syrup

		<u>Wt. %</u>
	Active Ingredient	10
10	Liquid Sugar	50
	Sorbitol	20
	Glycerine	5
	Flavor, Colorant and Preservative	as required
15	Water	as required

The final volume is brought up to 100% by the addition of distilled water.

20 Aqueous Suspension

		<u>Wt. %</u>
	Active Ingredient	10
	Sodium Saccharin	0.01
	Keltrol® (Food Grade Xanthan Gum)	0.2
25	Liquid Sugar	5
	Flavor, Colorant and Preservative	as required
	Water	as required

30 Xanthan gum is slowly added into distilled water before adding the active ingredient and the rest of the formulation ingredients. The final suspension is passed through a homogenizer to assure the elegance of the final products.

35

Resuspendable Powder

		<u>Wt. %</u>
	Active Ingredient	50.0
5	Lactose	35.0
	Sugar	10.0
	Acacia	4.7
	Sodium Carboxymethylcellulose	0.3
10	Each ingredient is finely pulverized and then uniformly mixed together. Alternatively, the powder can be prepared as a suspension and then spray dried.	

Semi-Solid Gel

		<u>Wt. %</u>
15	Active Ingredient	10
	Sodium Saccharin	0.02
	Gelatin	2
	Flavor, Colorant and	as required
20	Preservative	
	Water	as required

25 Gelatin is prepared in hot water. The finely pulverized active ingredient is suspended in the gelatin solution and then the rest of the ingredients are mixed in. The suspension is filled into a suitable packaging container and cooled down to form the gel.

Semi-Solid Paste

		<u>Wt. %</u>
	Active Ingredient	10
	Gelcarin® (Carrageenin gum)	1
5	Sodium Saccharin	0.01
	Gelatin	2
	Flavor, Colorant and	as required
	Preservative	
	Water	as required

10

Gelcarin® is dissolved in hot water (around 80°C) and then the fine-powder active ingredient is suspended in this solution. Sodium saccharin and the rest of the formulation ingredients are added to the suspension while it is still warm. The suspension is homogenized and then filled into suitable containers.

15

Emulsifiable Paste

		<u>Wt. %</u>
20	Active Ingredient	30
	Tween® 80 and Span® 80	6
	Keltrol®	0.5
	Mineral Oil	63.5

25

All the ingredients are carefully mixed together to make a homogenous paste.

Soft Gelatin Capsules

A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.

35

Tablets

Tablets may be prepared by conventional procedures so that the dosage unit is 500 milligrams of active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose and 10 milligrams of magnesium stearate.

A large number of tablets may also be prepared by conventional procedures so that the dosage unit was 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

Injectable

A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

Suspension

An aqueous suspension is prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S.P., and 0.025 mL of vanillin.

The compounds of the present invention may be administered in combination with a second therapeutic agent, especially non-steroidal anti-inflammatory drugs (NSAID's). The compound of Formula I and such second therapeutic agent can be administered separately or as a physical combination in a single dosage unit, in any dosage form and by various routes of administration, as described above.

The compound of Formula I may be formulated together with the second therapeutic agent in a single dosage unit (that is, combined together in one capsule, tablet, powder, or liquid, etc.). When the compound of Formula I and the
5 second therapeutic agent are not formulated together in a single dosage unit, the compound of Formula I and the second therapeutic agent may be administered essentially at the same time, or in any order; for example the compound of Formula I may be administered first, followed by
10 administration of the second agent. When not administered at the same time, preferably the administration of the compound of Formula I and the second therapeutic agent occurs less than about one hour apart, more preferably less than about 5 to 30 minutes apart.

15 Preferably the route of administration of the compound of Formula I is oral. Although it is preferable that the compound of Formula I and the second therapeutic agent are both administered by the same route (that is, for example, both orally), if desired, they may each be administered by
20 different routes and in different dosage forms (that is, for example, one component of the combination product may be administered orally, and another component may be administered intravenously).

The dosage of the compound of Formula I when
25 administered alone or in combination with a second therapeutic agent may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the recipient, the nature and
30 extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described above.

Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the
35 combined active ingredients. For this reason, when the

compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced). For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low-viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.

These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.


The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of osteoarthritis or rheumatoid arthritis, which comprise one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I. Such kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.

In the present disclosure it should be understood that the specified materials and conditions are important in practicing the invention but that unspecified materials and conditions are not excluded so long as they do not prevent the benefits of the invention from being realized.

Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations. Various equivalents, changes and modifications may be made without departing from the spirit and scope of this invention, and it is understood that such equivalent embodiments are part of this invention.

WHAT IS CLAIMED IS:

1. A compound of formula I:



I

5 or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from $-\text{COR}^5$, $-\text{CO}_2\text{H}$, $\text{CH}_2\text{CO}_2\text{H}$, $-\text{CO}_2\text{R}^6$, $-\text{CONHOH}$,
 $-\text{CONHOR}^5$, $-\text{CONHOR}^6$, $-\text{N}(\text{OH})\text{COR}^5$, $-\text{N}(\text{OH})\text{CHO}$, $-\text{SH}$, $-\text{CH}_2\text{SH}$,
 10 $-\text{S}(\text{O})(=\text{NH})\text{R}^a$, $-\text{SN}_2\text{H}_2\text{R}^a$, $-\text{PO}(\text{OH})_2$, and $-\text{PO}(\text{OH})\text{NHR}^a$;

ring B is a 3-13 membered non-aromatic carbocyclic or
 heterocyclic ring comprising: carbon atoms, 0-3
 carbonyl groups, 0-4 double bonds, and from 0-2 ring
 15 heteroatoms selected from O, N, NR^2 , and $\text{S}(\text{O})_p$, provided
 that ring B contains other than a S-S, O-O, or S-O
 bond;

Z is absent or selected from a C_{3-13} carbocycle substituted
 20 with 0-5 R^b and a 5-14 membered heterocycle comprising:
 carbon atoms and 1-4 heteroatoms selected from the
 group consisting of N, O, and $\text{S}(\text{O})_p$ and substituted
 with 0-5 R^b ;

25 U^a is absent or is selected from: O, NR^{a1} , $\text{C}(\text{O})$, $\text{C}(\text{O})\text{O}$,
 $\text{OC}(\text{O})$, $\text{C}(\text{O})\text{NR}^{a1}$, $\text{NR}^{a1}\text{C}(\text{O})$, $\text{OC}(\text{O})\text{O}$, $\text{OC}(\text{O})\text{NR}^{a1}$, $\text{NR}^{a1}\text{C}(\text{O})\text{O}$,
 $\text{NR}^{a1}\text{C}(\text{O})\text{NR}^{a1}$, $\text{S}(\text{O})_p$, $\text{S}(\text{O})_p\text{NR}^{a1}$, $\text{NR}^{a1}\text{S}(\text{O})_p$, and $\text{NR}^{a1}\text{SO}_2\text{NR}^{a1}$;

X^a is absent or selected from C_{1-10} alkylene, C_{2-10}
 30 alkenylene, and C_{2-10} alkynylene;

Y^a is absent or selected from O, NR^{a1} , $S(O)_p$, and $C(O)$;

Z^a is selected from H, a C_{3-13} carbocycle substituted with
 5 0-5 R^c and a 5-14 membered heterocycle comprising:
 carbon atoms and 1-4 heteroatoms selected from the
 group consisting of N, O, and $S(O)_p$ and substituted
 with 0-5 R^c ;

10 provided that Z, U^a , Y^a , and Z^a do not combine to form a N-N,
 N-O, O-N, O-O, $S(O)_p$ -O, O- $S(O)_p$ or $S(O)_p$ - $S(O)_p$ group;

R^1 is selected from H, C_{1-4} alkyl, phenyl, and benzyl;

15 R^2 is selected from Q, Cl, F, C_{1-10} alkylene-Q substituted
 with 0-3 R^{b1} , C_{2-10} alkenylene-Q substituted with 0-3
 R^{b1} , C_{2-10} alkynylene-Q substituted with 0-3 R^{b1} ,
 $(CR^{a1}R^{a1})_rO(CR^{a1}R^{a1})_r-Q$, $(CR^{a1}R^{a1})_rNR^a(CR^{a1}R^{a1})_r-Q$,
 $(CR^{a1}R^{a1})_rC(O)(CR^{a1}R^{a1})_r-Q$, $(CR^{a1}R^{a1})_rC(O)O(CR^{a1}R^{a1})_r-Q$,
 20 $(CR^{a1}R^{a1})_rC(O)O-C_{2-5}$ alkenylene, $(CR^{a1}R^{a1})_rC(O)O-C_{2-5}$
 alkynylene, $(CR^{a1}R^{a1})_rOC(O)(CR^{a1}R^{a1})_r-Q$,
 $(CR^{a1}R^{a1})_rC(O)NR^{a1}$, $(CR^{a1}R^{a1})_rC(O)NR^a(CR^{a1}R^{a1})_r-Q$,
 $(CR^{a1}R^{a1})_rNR^aC(O)(CR^{a1}R^{a1})_r-Q$, $(CR^{a1}R^{a1})_rOC(O)O(CR^{a1}R^{a1})_r-Q$,
 $(CR^{a1}R^{a1})_rOC(O)NR^a(CR^{a1}R^{a1})_r-Q$,
 25 $(CR^{a1}R^{a1})_rNR^aC(O)O(CR^{a1}R^{a1})_r-Q$,
 $(CR^{a1}R^{a1})_rNR^aC(O)NR^a(CR^{a1}R^{a1})_r-Q$, $(CR^{a1}R^{a1})_rS(O)_p(CR^{a1}R^{a1})_r-Q$,
 $(CR^{a1}R^{a1})_rSO_2NR^a(CR^{a1}R^{a1})_r-Q$, $(CR^{a1}R^{a1})_rNR^aSO_2(CR^{a1}R^{a1})_r-Q$, and
 $(CR^{a1}R^{a1})_rNR^aSO_2NR^a(CR^{a1}R^{a1})_r-Q$;

30 R^{2a} is selected from H, C_{1-6} alkyl, OR^a , NR^{a1} , and $S(O)_pR^a$;

R^{2b} is H or C_{1-6} alkyl;

Q is selected from H, a C₃₋₁₃ carbocycle substituted with 0-5 R^d and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-5 R^d;

R³ is selected from Q¹, Cl, F, C₁₋₆ alkylene-Q¹, C₂₋₆ alkenylene-Q¹, C₂₋₆ alkynylene-Q¹, (CR^aR^a)_rO(CR^aR^a)_r-Q¹, (CR^aR^a)_rNR^a(CR^aR^a)_r-Q¹, (CR^aR^a)_rNR^aC(O)(CR^aR^a)_r-Q¹, (CR^aR^a)_rC(O)NR^a(CR^aR^a)_r-Q¹, (CR^aR^a)_rC(O)(CR^aR^a)_r-Q¹, (CR^aR^a)_rC(O)O(CR^aR^a)_r-Q¹, (CR^aR^a)₂rS(O)_p(CR^aR^a)_r-Q¹, and (CR^aR^a)_rSO₂NR^a(CR^aR^a)_r-Q¹;

Q¹ is selected from H, phenyl substituted with 0-3 R^d, naphthyl substituted with 0-3 R^d and a 5-10 membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^d;

R^a, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

R^a¹, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

alternatively, R^a and R^a¹ when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)_p;

R^{a2} , at each occurrence, is independently selected from C_{1-4} alkyl, phenyl and benzyl;

R^b , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , NR^aR^{a1} , $C(O)R^a$,
 5 $C(O)OR^a$, $C(O)NR^aR^{a1}$, $R^aNC(O)NR^aR^{a1}$, $OC(O)NR^aR^{a1}$, $R^aNC(O)O$,
 $S(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $NR^aS(O)_2NR^aR^{a1}$, $OS(O)_2NR^aR^{a1}$,
 $NR^aS(O)_2R^{a2}$, $S(O)_pR^{a2}$, CF_3 , and CF_2CF_3 ;

10 R^{b1} , at each occurrence, is independently selected from OR^a ,
 Cl, F, Br, I, =O, -CN, NO_2 , and NR^aR^{a1} ;

R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , NR^aR^{a1} , $C(O)R^a$,
 15 $C(O)OR^a$, $C(O)NR^aR^{a1}$, $R^aNC(O)NR^aR^{a1}$, $OC(O)NR^aR^{a1}$, $R^aNC(O)O$,
 $S(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $NR^aS(O)_2NR^aR^{a1}$, $OS(O)_2NR^aR^{a1}$,
 $NR^aS(O)_2R^{a2}$, $S(O)_pR^{a2}$, CF_3 , CF_2CF_3 , C_{3-10} carbocycle
 substituted with 0-3 R^{c1} and a 5-14 membered heterocycle
 comprising: carbon atoms and 1-4 heteroatoms selected
 20 from the group consisting of N, O, and $S(O)_p$ and
 substituted with 0-3 R^{c1} ;

R^{c1} , at each occurrence; is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , NR^aR^{a1} , $C(O)R^a$,
 25 $C(O)OR^a$, $C(O)NR^aR^{a1}$, $R^aNC(O)NR^aR^{a1}$, $OC(O)NR^aR^{a1}$, $R^aNC(O)O$,
 $S(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $NR^aS(O)_2NR^aR^{a1}$, $OS(O)_2NR^aR^{a1}$,
 $NR^aS(O)_2R^{a2}$, $S(O)_pR^{a2}$, CF_3 , and CF_2CF_3 ;

R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , NR^aR^{a1} , $C(O)R^a$,
 30 $C(O)OR^a$, $C(O)NR^aR^{a1}$, $R^aNC(O)NR^aR^{a1}$, $OC(O)NR^aR^{a1}$, $R^aNC(O)O$,
 $S(O)_2NR^aR^{a1}$, $NR^aS(O)_2R^{a2}$, $NR^aS(O)_2NR^aR^{a1}$, $OS(O)_2NR^aR^{a1}$,

$\text{NR}^{\text{a}}\text{S}(\text{O})_2\text{R}^{\text{a}^2}$, $\text{S}(\text{O})_p\text{R}^{\text{a}^2}$, CF_3 , CF_2CF_3 , C_{3-10} carbocycle and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, - and $\text{S}(\text{O})_p$;

5.

R^5 , at each occurrence, is selected from C_{1-10} alkyl substituted with 0-2 R^b , and C_{1-8} alkyl substituted with 0-2 R^e ;

10 R^e , at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b ;

R^6 , at each occurrence, is selected from phenyl, naphthyl, C_{1-10} alkyl-phenyl- C_{1-6} alkyl-, C_{3-11} cycloalkyl, C_{1-6} alkylcarbonyloxy- C_{1-3} alkyl-, C_{1-6} alkoxy carbonyloxy- C_{1-3} alkyl-, C_{2-10} alkoxy carbonyl, C_{3-6} cycloalkylcarbonyloxy- C_{1-3} alkyl-, C_{3-6} cycloalkoxy carbonyloxy- C_{1-3} alkyl-, C_{3-6} cycloalkoxy carbonyl, phenoxycarbonyl, phenyloxy carbonyloxy- C_{1-3} alkyl-, phenylcarbonyloxy- C_{1-3} alkyl-, C_{1-6} alkoxy- C_{1-6} alkylcarbonyloxy- C_{1-3} alkyl-, [5-(C_{1-5} alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl, [5-(R^{a})-1,3-dioxa-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, - C_{1-10} alkyl- $\text{NR}^7\text{R}^{\text{a}}$, $-\text{CH}(\text{R}^8)\text{OC}(=\text{O})\text{R}^9$, and $-\text{CH}(\text{R}^8)\text{OC}(=\text{O})\text{OR}^9$;

R^7 is selected from H and C_{1-10} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;

30 R^{a} is selected from H and C_{1-10} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;

R^8 is selected from H and C_{1-4} linear alkyl;

R^9 is selected from H, C_{1-8} alkyl substituted with 1-2 R^f ,
 C_{3-8} cycloalkyl substituted with 1-2 R^f , and phenyl
 substituted with 0-2 R^b ;

5


R^f , at each occurrence, is selected from C_{1-4} alkyl, C_{3-8}
 cycloalkyl, C_{1-5} alkoxy, and phenyl substituted with 0-2
 R^b ;

10 p , at each occurrence, is selected from 0, 1, and 2;

r , at each occurrence, is selected from 0, 1, 2, 3, and 4;
 and,

15 r^1 , at each occurrence, is selected from 0, 1, 2, 3, and 4.

2. A compound according to Claim 1, wherein the
 compound is of formula II:



20

II

or a stereoisomer or pharmaceutically acceptable salt form
 thereof, wherein;

25 A is selected from $-CO_2H$, CH_2CO_2H , $-CONHOH$, $-CONHOR^5$,
 $-CONHOR^6$, $-N(OH)COR^5$, $-N(OH)CHO$, $-SH$, and $-CH_2SH$;

ring B is a 4-7 membered non-aromatic carbocyclic or
 heterocyclic ring comprising: carbon atoms, 0-1
 30 carbonyl groups, 0-1 double bonds, and from 0-2 ring

heteroatoms selected from O, N, and NR^2 , provided that ring B contains other than a O-O bond;

5 Z is absent or selected from a C_{3-11} carbocycle substituted with 0-4 R^b and a 5-11 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $\text{S}(\text{O})_p$ and substituted with 0-3 R^b ;

10 U^a is absent or is selected from: O, NR^{a1} , $\text{C}(\text{O})$, $\text{C}(\text{O})\text{O}$, $\text{C}(\text{O})\text{NR}^{a1}$, $\text{NR}^{a1}\text{C}(\text{O})$, $\text{S}(\text{O})_p$, and $\text{S}(\text{O})_p\text{NR}^{a1}$;

X^a is absent or selected from C_{1-4} alkylene, C_{2-4} alkenylene, and C_{2-4} alkynylene;

15

Y^a is absent or selected from O and NR^{a1} ;

20 Z^a is selected from H, a C_{3-10} carbocycle substituted with 0-5 R^c and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $\text{S}(\text{O})_p$ and substituted with 0-5 R^c ;

25 provided that Z, U^a , Y^a , and Z^a do not combine to form a N-N, N-O, O-N, O-O, $\text{S}(\text{O})_p\text{-O}$, $\text{O-S}(\text{O})_p$ or $\text{S}(\text{O})_p\text{-S}(\text{O})_p$ group;

R^1 is selected from H, C_{1-4} alkyl, phenyl, and benzyl;

30 R^2 is selected from Q, C_{1-6} alkylene-Q, C_{2-6} alkenylene-Q, C_{2-6} alkynylene-Q, $(\text{CR}^a\text{R}^{a1})_r\text{O}(\text{CR}^a\text{R}^{a1})_r\text{-Q}$, $(\text{CR}^a\text{R}^{a1})_r\text{NR}^a(\text{CR}^a\text{R}^{a1})_r\text{-Q}$, $(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})(\text{CR}^a\text{R}^{a1})_r\text{-Q}$, $(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{O}(\text{CR}^a\text{R}^{a1})_r\text{-Q}$, $(\text{CR}^a\text{R}^{a1})_r\text{C}(\text{O})\text{NR}^a\text{R}^{a1}$,

$(\text{CR}^a\text{Ra}^1)_r\text{C}(\text{O})\text{NR}^a(\text{CR}^a\text{Ra}^1)_r\text{-Q}$, $(\text{CR}^a\text{Ra}^1)_r\text{S}(\text{O})_p(\text{CR}^a\text{Ra}^1)_r\text{-Q}$,
and $(\text{CR}^a\text{Ra}^1)_r\text{SO}_2\text{NR}^a(\text{CR}^a\text{Ra}^1)_r\text{-Q}$;

Q is selected from H, a C₃₋₆ carbocycle substituted with 0-5
5 R^d, and a 5-10 membered heterocycle comprising: carbon
atoms and 1-4 heteroatoms selected from the group
consisting of N, O, and S(O)_p and substituted with 0-5
R^d;

10 R^a, at each occurrence, is independently selected from H,
C₁₋₄ alkyl, phenyl and benzyl;

R^{a1}, at each occurrence, is independently selected from H and
C₁₋₄ alkyl;

15

alternatively, R^a and R^{a1} when attached to a nitrogen are
taken together with the nitrogen to which they are
attached to form a 5 or 6 membered ring comprising
carbon atoms and from 0-1 additional heteroatoms
20 selected from the group consisting of N, O, and S(O)_p;

R^{a2}, at each occurrence, is independently selected from C₁₋₄
alkyl, phenyl and benzyl;

25 R^b, at each occurrence, is independently selected from C₁₋₆
alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^{a1}, C(O)R^a, C(O)OR^a,
C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

R^c, at each occurrence, is independently selected from C₁₋₆
30 alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^{a1}, C(O)R^a, C(O)OR^a,
C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, CF₃, C₃₋₆ carbocycle
and a 5-6 membered heterocycle comprising: carbon

atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p;

R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, CF₃, C₃₋₆ carbocycle and a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p;

10

R⁵, at each occurrence, is selected from C₁₋₆ alkyl substituted with 0-2 R^b, and C₁₋₄ alkyl substituted with 0-2 R^e;

15 R^e, at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b;

R⁶, at each occurrence, is selected from phenyl, naphthyl, C₁₋₁₀ alkyl-phenyl-C₁₋₆ alkyl-, C₃₋₁₁ cycloalkyl, C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy carbonyloxy-C₁₋₃ alkyl-, C₂₋₁₀ alkoxy carbonyl, C₃₋₆ cycloalkylcarbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxy carbonyloxy-C₁₋₃ alkyl-, C₃₋₆ cycloalkoxy carbonyl, phenoxycarbonyl, phenyloxy carbonyloxy-C₁₋₃ alkyl-, phenylcarbonyloxy-C₁₋₃ alkyl-, C₁₋₆ alkoxy-C₁₋₆ alkylcarbonyloxy-C₁₋₃ alkyl-, [5-(C₁-C₅ alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl, [5-(R^a)-1,3-dioxa-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, -C₁₋₁₀ alkyl-NR⁷R^{7a}, -CH(R⁸)OC(=O)R⁹, and -CH(R⁸)OC(=O)OR⁹;

30

R⁷ is selected from H and C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl-, and phenyl-C₁₋₆ alkyl-;

R^{7a} is selected from H and C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;

5 R^8 is selected from H and C_{1-4} linear alkyl;

R^9 is selected from H, C_{1-6} alkyl substituted with 1-2 R^f , C_{3-6} cycloalkyl substituted with 1-2 R^f , and phenyl substituted with 0-2 R^b ;

10


R^f , at each occurrence, is selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-5} alkoxy, and phenyl substituted with 0-2 R^b ;

15 p , at each occurrence, is selected from 0, 1, and 2;

r , at each occurrence, is selected from 0, 1, 2, 3, and 4;
and,

20 r^1 , at each occurrence, is selected from 0, 1, 2, 3, and 4.

3. A compound according to Claim 2, wherein the compound is of formula IIIa or IIIb:



or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

30 A is selected from $-CO_2H$, CH_2CO_2H , $-CONHOH$, $-CONHOR^5$, $-N(OH)CHO$, and $-N(OH)COR^5$;

Z is absent or selected from a C₅₋₆ carbocycle substituted with 0-3 R^b and a 5-6 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^b;

U^a is absent or is selected from: O, NR^{a1}, C(O), C(O)NR^{a1}, S(O)_p, and S(O)_pNR^{a1};

X^a is absent or selected from C₁₋₄ alkylene, C₂₋₄ alkenylene, and C₂₋₄ alkynylene

Y^a is absent or selected from O and NR^{a1};

Z^a is selected from H, a C₅₋₆ carbocycle substituted with 0-3 R^c and a 5-10 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^c;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

R² is selected from Q, C₁₋₆ alkylene-Q, C₂₋₆ alkenylene-Q, C₂₋₆ alkynylene-Q, (CR^aR^{a1})_rC(O)(CR^aR^{a1})_r-Q, (CR^aR^{a1})_rC(O)O(CR^aR^{a1})_r-Q, (CR^aR^{a2})_rC(O)NR^aR^{a1}, (CR^aR^{a2})_rC(O)NR^a(CR^aR^{a1})_r-Q, and (CR^aR^{a1})_rS(O)_p(CR^aR^{a1})_r-Q;

Q is selected from H, a C₃₋₆ carbocycle substituted with 0-3 R^d and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^d;

R^a, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

10 R^{a1}, at each occurrence, is independently selected from H and C₁₋₄ alkyl;

R^{a2}, at each occurrence, is independently selected from C₁₋₄ alkyl, phenyl, and benzyl;

15

R^b, at each occurrence, is independently selected from C₁₋₄ alkyl, OR^a, Cl, F, =O, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

20 R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a1}, C(O)R^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

25 R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a1}, C(O)R^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, CF₃, and phenyl;

30 R⁵, at each occurrence, is selected from C₁₋₄ alkyl substituted with 0-2 R^b, and C₁₋₄ alkyl substituted with 0-2 R^e;

R^e, at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4;


5

r^1 , at each occurrence, is selected from 0, 1, 2, 3, and 4;
and,


s and s^1 combine to total 2, 3, or 4.

10

4. A compound according to Claim 3, wherein the compound is of formula IVa or IVb:



IVa



IVb

15

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

Z is absent or selected from phenyl substituted with 0-3 R^b
and pyridyl substituted with 0-3 R^b ;

20

U^a is absent or is O;

X^a is absent or is CH_2 or CH_2CH_2 ;

25

Y^a is absent or is O;

Z^a is selected from H, phenyl substituted with 0-3 R^c ,
pyridyl substituted with 0-3 R^c , and quinolinyl
substituted with 0-3 R^c ;

30

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, or O-O group;

R¹ is selected from H, CH₃, and CH₂CH₃;

5

R² is selected from Q, C₁₋₆ alkylene-Q, C₂₋₆ alkynylene-Q, C(O)(CR^aRA¹)_r-Q, C(O)O(CR^aRA¹)_r-Q, C(O)NR^a(CR^aRA¹)_r-Q, and S(O)_p(CR^aRA¹)_r-Q;

10 Q is selected from H, cyclopropyl substituted with 0-1 R^d, cyclobutyl substituted with 0-1 R^d, cyclopentyl substituted with 0-1 R^d, cyclohexyl substituted with 0-1 R^d, phenyl substituted with 0-2 R^d and a heteroaryl substituted with 0-3 R^d, wherein the heteroaryl is
15 selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl;

R^a, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

20

R^{a1}, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

25 R^{a2}, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

R^b, at each occurrence, is independently selected from C₁₋₄ alkyl, OR^a, Cl, F, =O, NR^aRA¹, C(O)R^a, C(O)OR^a, C(O)NR^aRA¹, S(O)₂NR^aRA¹, S(O)_pRA², and CF₃;

30

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aRA¹, C(O)R^a, C(O)NR^aRA¹, S(O)₂NR^aRA¹, S(O)_pRA², and CF₃;

R^d, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a1}, C(O)R^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, CF₃ and phenyl;

5

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, and 3;

10

r¹, at each occurrence, is selected from 0, 1, 2, and 3; and,

s and s¹ combine to total 2, 3, or 4.

15

5. A compound according to Claim 2, wherein;

A is selected from -CO₂H, CH₂CO₂H, -CONHOH, -CONHOR⁵, -N(OH)CHO, and -N(OH)COR⁵;

20

ring B is a 4-7 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, and NR², provided that ring B contains other than a O-O bond;

25

Z is absent or selected from a C₅₋₆ carbocycle substituted with 0-3 R^b and a 5-6 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted
30 with 0-3 R^b;

U^a is absent or is selected from: O, NR^{a1}, C(O), C(O)NR^{a1}, S(O)_p, and S(O)_pNR^{a1};

X^a is absent or selected from C₁₋₂ alkylene, C₂₋₄ alkenylene,
and C₂₋₄ alkynylene

Y^a is absent or selected from O and NR^{a1};

5

Z^a is selected from H, a C₅₋₆ carbocycle substituted with 0-3
R^c and a 5-10 membered heteroaryl comprising carbon
atoms and from 1-4 heteroatoms selected from the group
consisting of N, O, and S(O)_p and substituted with 0-3
10 R^c;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N,
N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

15 R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

R² is (CR^aRA¹)_rO(CR^aRA¹)_r-Q or (CR^aRA¹)_rNR^a(CR^aRA¹)_r-Q;

Q is selected from H, a C₃₋₆ carbocycle substituted with 0-3
20 R^d and a 5-10 membered heterocycle comprising: carbon
atoms and 1-4 heteroatoms selected from the group
consisting of N, O, and S(O)_p and substituted with 0-3
R^d;

25 R^a, at each occurrence, is independently selected from H,
C₁₋₄ alkyl, phenyl and benzyl;

R^{a1}, at each occurrence, is independently selected from H and
C₁₋₄ alkyl;

30

R^{a2}, at each occurrence, is independently selected from C₁₋₄
alkyl, phenyl and benzyl;

- R^b , at each occurrence, is independently selected from C_{1-4} alkyl, OR^a , Cl, F, =O, NR^aR^a , $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^a$, $S(O)_2NR^aR^a$, $S(O)_pR^a$, and CF_3 ;
- 5 R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, NR^aR^a , $C(O)R^a$, $C(O)NR^aR^a$, $S(O)_2NR^aR^a$, $S(O)_pR^a$, and CF_3 ;
- 10 R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, NR^aR^a , $C(O)R^a$, $C(O)NR^aR^a$, $S(O)_2NR^aR^a$, $S(O)_pR^a$, CF_3 and phenyl;
- R^5 , at each occurrence, is selected from C_{1-4} alkyl substituted with 0-2 R^b , and C_{1-4} alkyl substituted with
- 15 0-2 R^e ;
- R^e , at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b ;
- 20 p , at each occurrence, is selected from 0, 1, and 2;
- r , at each occurrence, is selected from 0, 1, 2, 3, and 4; and,
- 25 r^1 , at each occurrence, is selected from 0, 1, 2, 3, and 4.

6. A compound according to Claim 5, wherein;

30 A is -CONHOH;

ring B is a 5-6 membered non-aromatic carbocyclic or heterocyclic ring comprising: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring

heteroatoms selected from O, N, and NR^2 , provided that ring B contains other than a O-O bond;

5 Z is absent or selected from phenyl substituted with 0-3 R^b and pyridyl substituted with 0-3 R^b ;

U^a is absent or is O;

10 X^a is absent or is CH_2 or CH_2CH_2 ;

Y^a is absent or is O;

15 Z^a is selected from H, phenyl substituted with 0-3 R^c , pyridyl substituted with 0-3 R^c , and quinolinyl substituted with 0-3 R^c ;

provided that Z, U^a , Y^a , and Z^a do not combine to form a N-N, N-O, O-N, or O-O group;

20 R^1 is selected from H, CH_3 , and CH_2CH_3 ;

R^2 is $(\text{CR}^a\text{R}^a)^r\text{O}(\text{CR}^a\text{R}^a)^r\text{-Q}$ or $(\text{CR}^a\text{R}^a)^r\text{NR}^a(\text{CR}^a\text{R}^a)^r\text{-Q}$;

25 Q is selected from H, cyclopropyl substituted with 0-1 R^d , cyclobutyl substituted with 0-1 R^d , cyclopentyl substituted with 0-1 R^d , cyclohexyl substituted with 0-1 R^d , phenyl substituted with 0-2 R^d , and a heteroaryl substituted with 0-3 R^d , wherein the heteroaryl is selected from pyridyl, quinolinyl, thiazolyl, furanyl, 30 imidazolyl, and isoxazolyl;

R^a , at each occurrence, is independently selected from H, CH_3 , and CH_2CH_3 ;

R^{a1} , at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

5 R^{a2} , at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

10 R^b , at each occurrence, is independently selected from C₁₋₄ alkyl, OR^a, Cl, F, =O, NR^aR^{a1}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

15 R^c , at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a1}, C(O)R^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, and CF₃;

20 R^d , at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, NR^aR^{a1}, C(O)R^a, C(O)NR^aR^{a1}, S(O)₂NR^aR^{a1}, S(O)_pR^{a2}, CF₃ and phenyl;

p , at each occurrence, is selected from 0, 1, and 2;

20

r , at each occurrence, is selected from 0, 1, 2, and 3; and,

r^1 , at each occurrence, is selected from 0, 1, 2, and 3.

25

7. A compound according to Claim 1, wherein the compound is selected from the group:

30 N -{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-(trifluoromethyl)[1,1'-biphenyl]-4-carboxamide

N -{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[2-(trifluoromethyl)phenoxy]benzamide

35 N -{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(3-methyl-2-pyridinyl)benzamide

- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}[1,1'-biphenyl]-4-carboxamide
- 5 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-phenoxybenzamide
- 4-(benzyloxy)-*N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- 10 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-methoxy[1,1'-biphenyl]-4-carboxamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-2'-methyl[1,1'-biphenyl]-4-carboxamide
- 15 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(2-methoxyphenoxy)benzamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(2-methylphenoxy)benzamide
- 20 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(3-methylphenoxy)benzamide
- 25 4-(5,8-dihydro-4-quinolinyl)-*N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-3',5'-dimethyl[1,1'-biphenyl]-4-carboxamide
- 30 *N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-6-(2-methylphenyl)nicotinamide
- N*-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-6-(2-methoxyphenyl)nicotinamide
- 35 (3*S*,4*S*)-*N*-hydroxy-1-isopropyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 40 (3*S*,4*S*)-1-(2,2-dimethylpropanoyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 45 (3*S*,4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(methylsulfonyl)-3-pyrrolidinecarboxamide
- 50 (3*S*,4*S*)-*N*-hydroxy-1-methyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

- tert*-butyl (3*S*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 5 (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 10 *tert*-butyl 4-[*cis*-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)pyrrolidinyl]-1-piperidinecarboxylate
- 15 *cis*-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(4-piperidinyl)-3-pyrrolidinecarboxamide
- 20 *cis*-1-[3-[(1,1-dimethylethoxy)carbonyl]pyrrolidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 25 *cis*-*N*-hydroxy-1-[3-pyrrolidinyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- 30 *tert*-butyl (3*R*, 4*R*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- tert*-butyl (3*S*, 4*R*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 35 (3*S*, 4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 40 *tert*-butyl (3*R*, 4*S*)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 45 (3*R*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- N*-{(1*R*, 2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-(4-pyridinyl)benzamide
- 50 (3*S*, 4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

- 5 (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-3-pyrrolidinecarboxamide
- (3*S*, 4*S*)-1-allyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 10 (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propyl-3-pyrrolidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-1-(2-methyl-2-propenyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 20 (3*S*, 4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-3-pyrrolidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-1-isopentyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-neopentyl-3-pyrrolidinecarboxamide
- 35 (3*S*, 4*S*)-1-butyl-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 40 (3*S*, 4*S*)-1-(3-butenyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3*S*, 4*S*)-1-(2-butyryl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 45 (3*S*, 4*S*)-1-(2-furylmethyl)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 50 (3*S*, 4*S*)-*N*-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

- 5 (3R,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-furancarboxamide
- (3S,4R)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-furancarboxamide
- 10 (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(1,3-thiazol-2-ylmethyl)-3-pyrrolidinecarboxamide
- 15 (3S,4S)-1-acetyl-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 20 (3S,4S)-N-hydroxy-1-isobutyryl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 25 (3S,4S)-N-hydroxy-1-(3-methylbutanoyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3S,4S)-1-(cyclopropylcarbonyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 30 (3S,4S)-1-(cyclobutylcarbonyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 35 (3S,4S)-N-hydroxy-1-(methoxyacetyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 40 (3S,4S)-1-(2-furoyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- 45 (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-thienylcarbonyl)-3-pyrrolidinecarboxamide
- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propionyl-3-pyrrolidinecarboxamide
- 50 (3R,4S)-4-{[4-(2-butynyloxy)benzoyl]amino}-N-hydroxy-tetrahydro-3-furancarboxamide

- N-[(1R,2S)-2-[(hydroxyamino)carbonyl]-4-oxocyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 5 N-[(1R,2S,4R)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 10 N-[(1R,2S,4S)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 15 (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-tetrahydro-2H-pyran-4-yl-3-pyrrolidinecarboxamide
- 20 methyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 25 ethyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 30 propyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 35 allyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- isopropyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 2-propynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 40 2-butyryl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 45 3-butenyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- 50 benzyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate

- N-((1R,2S)-4-(dimethylamino)-2-
[(hydroxyamino)carbonyl]cyclopentyl)-4-[(2-methyl-4-
quinolinyl)methoxy]benzamide
- 5 (3S,4S)-4-[[4-(2-butynyloxy)benzoyl]amino]-N-hydroxy-1-
isopropyl-3-pyrrolidinecarboxamide
- N-((1R,2S)-4,4-difluoro-2-
[(hydroxyamino)carbonyl]cyclopentyl)-4-[(2-methyl-4-
10 quinolinyl)methoxy]benzamide
- (3S,4S)-N-hydroxy-1-isopropyl-4-[[4-(2-
methylphenoxy)benzoyl]amino]-3-pyrrolidinecarboxamide
- 15 *cis*-N-hydroxy-2-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-1-
cyclopentanecarboxamide
- trans*-N-hydroxy-2-[[[4-[(2-methyl-4-
20 quinolinyl)methoxy]phenyl]carbonyl]amino]-1-
cyclopentanecarboxamide
- (1S,2R)-N-hydroxy-2-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-1-
25 cyclopentanecarboxamide
- (1R,2S)-N-hydroxy-2-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-1-
cyclopentanecarboxamide
- 30 *cis*-N-hydroxy-2-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-1-
cyclohexanecarboxamide
- 35 *trans*-N-hydroxy-2-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]carbonyl]amino]-1-
cyclohexanecarboxamide
- 40 *trans*-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-3-[[[4-
[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-
4-pyrrolidinecarboxamide
- trans*-N-hydroxy-3-[[[4-[(2-methyl-4-
45 quinolinyl)methoxy]phenyl]carbonyl]amino]-4-
pyrrolidinecarboxamide
- cis*-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-3-[[[4-
[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-
4-pyrrolidinecarboxamide
- 50

cis-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide

- 5 (3*S*, 4*R*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 20 (3*S*, 4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 25 (3*S*, 4*R*)-1-[(butoxy)carbonyl]-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 30 (3*S*, 4*R*)-*N*-hydroxy-1-[[[(1-methylethyl)oxy]carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 35 (3*S*, 4*R*)-*N*-hydroxy-1-(methylsulfonyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 40 (3*S*, 4*R*)-*N*-hydroxy-1-(phenylsulfonyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 45 (3*S*, 4*R*)-1-acetyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 50 (3*S*, 4*R*)-1-benzoyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3*S*, 4*R*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

- (3*S*, 4*R*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 5 (3*S*, 4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-3-piperidinecarboxamide
- 10 (3*S*, 4*R*)-1-(dimethylcarbonyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 15 (3*S*, 4*R*)-*N*-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 20 (3*S*, 4*R*)-1-ethyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 25 (3*S*, 4*R*)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-3-piperidinecarboxamide
- 30 (3*S*, 4*R*)-*N*-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 35 (3*S*, 4*R*)-1-(cyclopropylmethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 40 (3*S*, 4*R*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 45 (3*S*, 4*S*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*R*, 4*S*)-1-[[[(1,1-dimethylethyl)oxy]carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-

- quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*R*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-1-[[[2-methylpropyl]oxy]carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-1-(methoxycarbonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-1-[(1-methylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-1-(methylsulfonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-1-(3,3-dimethylbutanoyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*, 4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-1-benzoyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-1-[(pyridin-3-yl)carbonyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiophenecarbonyl)-4-piperidinecarboxamide

- (3*S*,4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-4-piperidinecarboxamide
- 10 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[2-(2-thienyl)ethyl]carbamyl]-4-piperidinecarboxamide
- 15 (3*S*,4*S*)-1-[(1,1-dimethylethyl)carbamyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*S*,4*S*)-*N*-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*,4*S*)-1-ethyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-4-piperidinecarboxamide
- 30 (3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*,4*S*)-1-cyclobutyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*,4*S*)-1-butyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-methylpropyl)-4-piperidinecarboxamide
- 45 (3*S*,4*S*)-1-(cyclopropylmethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*S*,4*S*)-1-(2,2-dimethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

- (3*S*, 4*S*)-1-cyclopentyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropyranyl)-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-1-benzyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiazolylmethyl)-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-pyridinylmethyl)-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-pyridinylmethyl)-4-piperidinecarboxamide
- 25 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-pyridinylmethyl)-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*trans*-3-phenyl-2-propenyl)-4-piperidinecarboxamide
- 30 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-phenyl-4-piperidinecarboxamide
- 35 (3*R*, 4*S*)-1-(2,2-dimethylpropionyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*R*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-methyl-4-piperidinecarboxamide
- 45 (3*R*, 4*S*)-1-(dimethylcarbamyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*S*, 4*S*)-1-hexyl-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

- (3*S*,4*S*)-1-(2-fluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
5
- (3*S*,4*S*)-1-(2,2-difluoroethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 10 (3*S*,4*S*)-*N*-hydroxy-1-(1-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*,4*S*)-1-(1-ethylpropyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*S*,4*S*)-1-[1-[(1,1-dimethylethyl)oxy]carbonyl]-4-tetrahydropiperidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropiperidinyl)-4-piperidinecarboxamide
- 30 (3*S*,4*S*)-1-[1-[(1,1-dimethylethyl)oxy]carbonyl]-3-tetrahydropyrrolidinyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-tetrahydropyrrolidinyl)-4-piperidinecarboxamide
- 40 (3*S*,4*S*)-1-(1,1-dimethyl-2-propynyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-thiophenylmethyl)-4-piperidinecarboxamide
- 50 (3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide

- (3*S*,4*S*)-*N*-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide
- 5 (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide
- 10 (3*S*,4*S*)-1-[2-(*N,N*-dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 15 (3*S*,4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 20 (3*S*,4*S*)-1-(*t*-butylsulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 25 (3*S*,4*S*)-1-(benzenesulfonyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*,4*S*)-1-(*t*-butylsulfinyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 30 (3*S*,4*S*)-*N*-hydroxy-1-(2-hydroxyethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 35 (3*S*,4*S*)-1-[2-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 40 (3*S*,4*S*)-1-(2-aminoethyl)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 45 (3*S*,4*S*)-1-[2-(*N,N*-dimethylamino)ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 50 (3*S*,4*S*)-1-[(2*S*)-2-aminopropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

- (3*S*, 4*S*)-1-[(2*R*)-2-amino-3-hydroxypropyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[[2*R*)-2-pyrrolidinyl]methyl]-4-piperidinecarboxamide
- 10 (3*S*, 4*R*)-*N*-hydroxy-1-(2-hydroxyethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 15 (3*S*, 4*R*)-1-(2-aminoethyl)-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- 20 (3*S*, 4*R*)-1-cyclobutyl-*N*-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3*R*, 4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-2*H*-pyran-3-carboxamide
- 25 (3*S*, 4*S*)-1-tert-butyl-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 30 tert-butyl 2-[(3*S*, 4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate
- 35 2-[(3*S*, 4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoic acid
- 40 methyl 2-[(3*S*, 4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate
- (3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide
- 45 (3*S*, 4*S*)-1-[2-(dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide

- (3*S*, 4*S*)-1-(1,1-dimethyl-2-propenyl)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 5 (3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-4-piperidinecarboxamide
- 10 (3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-4-piperidinecarboxamide
- 15 (3*S*, 4*S*)-1-allyl-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 20 (3*S*, 4*S*)-*N*-hydroxy-1-(1-methyl-2-propynyl)-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- (3*S*, 4*S*)-*N*-hydroxy-1-(1-methyl-2-propenyl)-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 25 *N*-{(1*R*, 2*S*)-4,5-dihydroxy-2-[(hydroxyamino)carbonyl]cyclohexyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- 30 (5*S*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-piperidinecarboxamide
- 35 (3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-piperidinecarboxamide
- (3*S*, 4*S*)-3-{[4-(2-butynyloxy)benzoyl]amino}-*N*-hydroxy-1-isopropyl-4-piperidinecarboxamide
- 40 (3*S*, 4*S*)-3-{[4-(2-butynyloxy)benzoyl]amino}-*N*-hydroxy-4-piperidinecarboxamide
- 45 *tert*-butyl (3*S*, 4*S*)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-1-piperidinecarboxylate

- (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- 5 *tert*-butyl (3*S*,4*S*)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-4-[(hydroxyamino)carbonyl]-1-piperidinecarboxylate
- 10 (3*S*,4*S*)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-*N*-hydroxy-4-piperidinecarboxamide
- 15 (*cis,cis*)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 20 (*cis,cis*)-3-Methylamino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 25 (*cis,trans*)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(*N*-hydroxy)cyclohexylcarboxamide
- 30 (*cis,trans*)-3-Dimethylmino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 35 (*cis,trans*)-3-(1-Methyl-1-ethylmino)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 40 (*cis,cis*)-3-Hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(*N*-hydroxy)cyclohexylcarboxamide
- 45 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-{{(2-methyl-4-quinolinyl)methyl}amino}benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-{methyl[(2-methyl-4-quinolinyl)methyl]amino}benzamide

- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-(3-phenyl-4,5-dihydro-5-isoxazolyl)benzamide
- 5 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(3-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 10 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(2-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-quinolinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 15 4-[3-(2,6-Dimethyl-4-pyridinyl)-4,5-dihydro-5-isoxazolyl]-*N*-{*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-3-methoxy-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 20 3-Hydroxy-*N*-{*cis*-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- 25 *N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(2-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide
- N*-{*cis*-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(4-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide
- 30 *N*-{4-[(hydroxyamino)carbonyl]-3-pyrrolidinyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide
- N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-5-carboxamide
- 35 *N*-hydroxy-3-[(6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthoyl)amino]-4-piperidinecarboxamide
- 40 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthamide
- N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-2-naphthamide
- 45 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-6-[(2-methyl-4-quinolinyl)methoxy]-1,2,3,4-tetrahydro-1-isoquinolinecarboxamide
- 50 *N*-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-benzimidazole-5-carboxamide

N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1*H*-indole-4-carboxamide

5 (±)-*cis-N*-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide

10 (±)-*trans-N*-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-cycloheptanecarboxamide

15 (4*S*, 5*R*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxohexahydro-1*H*-azepine-4-carboxamide

(3*S*, 4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-4-carboxamide

20 (3*S*, 4*R*)-*N*-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-3-carboxamide

25 (4*S*, 5*R*)-*N*-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-7-oxohexahydro-1*H*-azepine-4-carboxamide

30 (2*S*, 3*R*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide

35 (2*R*, 3*R*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide, and

tert-butyl (2*S*, 3*R*)-2-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate

40

or a pharmaceutically acceptable salt form thereof.

8. A pharmaceutical composition, comprising: a
45 pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to one of Claims 1, 2, 3, 4, 5, 6, or 7 or a pharmaceutically acceptable salt form thereof.

9. A method of treating a condition or disease mediated by MMPs, TNF, aggrecanase, or a combination thereof
5 in a mammal, comprising: administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to one of Claims 1, 2, 3, 4, 5, 6, or 7 or a pharmaceutically acceptable salt form thereof.

10

10. A method of treating according to Claim 9, wherein the disease or condition is referred to as acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune
15 hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary disease, coagulation, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy,
20 Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, HIV infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent hydrarthrosis, Lyme disease,
25 meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic
30 arthritis, pyoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases,
35 spondylitis, stroke, systemic lupus erythematosus,

ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis.

5 11. A Compound according to one of Claims 1, 2, 3, 4, 5, 6, or 7 or a pharmaceutically acceptable salt form thereof for use in therapy.

10 12. Use of a compound according to one of Claims 1, 2, 3, 4, 5, 6, or 7 or a pharmaceutically acceptable salt form thereof for the manufacture of a medicament for the treatment of a condition or disease mediated by MMPs, TNF, aggrecanase, or a combination thereof.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70673 A3

(51) International Patent Classification⁷: **C07D 401/12**,
405/12, 307/24, 215/14, A61K 31/55, A61P 29/00, C07C
259/08

Foulkstone Road, Wilmington, DE 19803 (US). **VOSS, Matthew, E.**: 106 Westview Drive, Lincoln University, PA 19352 (US). **XUE, Chu-Biao**: 11 Rivendell Court, Hockessin, DE 19707 (US).

(21) International Application Number: PCT/US01/08334

(22) International Filing Date: 15 March 2001 (15.03.2001)

(74) Agent: **VANATTEN, Mary, K.**; Dupont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, HU, IN, JP, KR, LT, LU, LV, MX, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA.

(30) Priority Data:
60/190,182 17 March 2000 (17.03.2000) US
60/233,373 18 September 2000 (18.09.2000) US
60/255,539 14 December 2000 (14.12.2000) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(71) Applicant: **DUPONT PHARMACEUTICALS COMPANY** [US/US]; Chestnut Run Plaza, 974 Centre Road, Wilmington, DE 19805 (US).

Published:
— with international search report


(72) Inventors: **DUAN, Jingwu**: 17 Springbrook Lane, Newark, DE 19711 (US). **OTT, Gregory**: 2038 Locust Street, Philadelphia, PA 18193 (US). **CHEN, Linhua**: 402 Foulk Road, Apartment 2C1, Wilmington, DE 19803 (US). **LU, Zhonghui**: 3314 Old Capital Trail, Wilmington, DE 19808 (US). **MADUSKUIE, Thomas, P., Jr.**: 613

(88) Date of publication of the international search report:
14 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/70673 A3

(54) Title: CYCLIC β -AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF- α



(I)

(57) Abstract: The present application describes novel cyclic β -amino acid derivatives of formula (I) or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR^a, and S(O)_p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF- α inhibitors.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/08334

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/12 C07D405/12 C07D307/24 C07D215/14 A61K31/55
A61P29/00 C07C259/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MOHAMED, M. M. ET AL: "Studies on the cyclization of the products of Stobbe condensation with 2,4-dimethylacetophenone" REV. ROUM. CHIM. (1981), 26(3), 441-8 , XP001031461 Compound 5b	1
A	WO 98 08815 A (PROCTER & GAMBLE) 5 March 1998 (1998-03-05) abstract example 56	1,8,9,12
A	WO 99 19296 A (ONO PHARMACEUTICAL CO ;SUGIURA TSUNEYUKI (JP); TAKAHASHI KANJI (JP) 22 April 1999 (1999-04-22) abstract page 444 -page 446; example 56 -/-	1,8,9,12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

15 November 2001

Date of mailing of the international search report

30/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Diederer, J

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 01/08334

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 00 63197 A (NAKATSUKA MASASHI ;KAMIKAWA YUMIKO (JP); SAMIZO FUMIO (JP); SUMITO) 26 October 2000 (2000-10-26) abstract example 833 ---	1-6,8-12
P, X	WO 00 59865 A (ONO PHARMACEUTICAL CO ;SUGIURA TSUNEYUKI (JP); TAKAHASHI KANJI (JP) 12 October 2000 (2000-10-12) abstract Example 18(1) -----	1-6,8-12

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1-3 (partially), 5 (partially), 8-12 (partially)

Present claims 1-3, 5 and 8-12 relate to an extremely large number of possible compounds, compositions, methods and uses. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds, compositions, methods and uses claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely the compounds of claims 4 and 6 and the corresponding compositions, and uses thereof.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. onal Application No

PCT/US 01/08334

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9808815	A	05-03-1998	AU 4074197 A	19-03-1998
			BR 9713465 A	28-03-2000
			CN 1232451 A	20-10-1999
			CZ 9900631 A3	11-08-1999
			EP 0927161 A1	07-07-1999
			HU 0000478 A2	28-09-2000
			JP 2000516955 T	19-12-2000
			NO 990855 A	23-04-1999
			PL 331802 A1	02-08-1999
			SK 25099 A3	14-02-2000
			TR 9900431 T2	21-04-1999
			WO 9808815 A1	05-03-1998
WO 9919296	A	22-04-1999	AU 9458098 A	03-05-1999
			BR 9812807 A	17-10-2000
			CN 1282319 T	31-01-2001
			EP 1024134 A1	02-08-2000
			HU 0100579 A2	28-05-2001
			WO 9919296 A1	22-04-1999
			JP 2001172245 A	26-06-2001
			JP 3155536 B2	09-04-2001
			NO 20001813 A	09-06-2000
			TR 200001732 T2	22-01-2001
WO 0063197	A	26-10-2000	AU 4249700 A	02-11-2000
			WO 0063197 A1	26-10-2000
WO 0059865	A	12-10-2000	AU 3669700 A	23-10-2000
			WO 0059865 A1	12-10-2000